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The poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyse the 
transfer of ADP-ribose polymers onto acceptor proteins. The biology and biochemistry of 
PARP-1 has been extensively studied and, for many years, this was thought to be the sole 
protein responsible for poly(ADP-ribosyl)ation reactions. However, the functions of the 
remaining members of the PARP family remain unclear. PARP-2 is responsible for 10-
15% of the poly(ADP-ribosyl)ation reactions in the cell and, like PARP-1, is activated by 
damage to DNA. Recently, the biological importance of PARP-2 has been illustrated by 
studies using knockout mice and antisense RNA. The protein has been shown to have an 
important role in DNA repair, telomeric integrity, inflammation and cellular 
differentiation; but the picture is cloudy. There is currently a major requirement for 
isoform-selective inhibitors of PARP-2 to use as tools to study the functions of the 
enzyme. This work focuses upon the design and synthesis of these molecules and their 
biological evaluation. 
 
Three sets of target compounds were proposed, based on the structure of the murine 
PARP-2 active site with our lead compound 5-AIQ docked. An initial series of 5-
substituted 5-AIQs with carboxylic acids tethered were prepared by alkylation of 5-AIQ 
or Heck reaction with 5-iodoisoquinolin-1-one but these molecules did not show 
selectivity for PARP-2 over PARP-1. A further set of 5-acylaminoisoquinolin-1-ones 
were prepared by treating 5-AIQ with the appropriate acid chloride and were more 
promising. 5-benzamidoisoquinolinone displayed a 9-fold selectivity for PARP-2 over 
PARP-1 in our assays.  This was in contrast to the best literature compound which had a 
ca. 3-fold selectivity for PARP-2 in our system (reported 60-fold selectivity). 
 
3-substituted compounds were initially prepared using the established chemistry of the 
Hurtley reaction but two new routes were developed. The first of these involved an initial 
Friedel-Crafts reaction of 5-nitroisocoumarin and rearrangement followed by 
decarbonylation / decarboxylation. The second is likely to become the most efficient way 
to synthesise 3-aryl-5-nitroisoquinolin-1-ones and involves Suzuki reaction with 3-
chloro-1-methoxyisoquinoline as the key step. The 3-substituted compounds were 
generally highly potent against PARP-1/2 in comparison with 5-AIQ but were not 
selective. 
 
Several approaches were explored in the synthesis of 4-substituted isoquinolin-1-ones but 
by far the most successful were palladium-catalysed couplings with protected 4-bromo-5-
nitroisoquinolin-1-ones. The most promising 4-substituted compound was 5-amino-4-(4-
trifluromethyl)isoquinolin-1-one which was ca. 8-fold selective for PARP-2. 
 
A series of 3,5- and 4,5-disubstituted 5-AIQs was generated using previously developed 
chemistry. Biological evaluation showed these compounds were not significantly active 
against either PARP isoform. 
 
A new synthesis of our lead compound 5-AIQ was developed in which the only 
purification steps were filtration and recrystallisation. This has become by far the most 
efficient way to synthesise this important molecule. 
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1. Introduction 
 
1.1 The PARP superfamily 
 
The poly(ADP-ribosyl)ation of proteins involves the transfer of multiple ADP-ribose 
units onto glutamic acid residues of the targets, resulting in the formation of polymers.   
The formation of poly(ADP-ribose) (PAR) was first reported in 19631 and, since then, 
there has been an intense research focus into both the functions of the polymer and of the 




1.2.1 Molecular Structure 
   
The PARPs are found in most eukaryotes, with the notable exception of yeasts.2 The first 
isoform to be discovered and characterised was poly(ADP-ribose)polymerase-1 (PARP-
1).  The human gene for PARP-1 comprises 23 exons and is located on chromosome 1 at 
position q41-q42, contained within 43 Kb of DNA.3 Initial proteolytic studies of the 
enzyme revealed three main functional domains,4 which have been further subdivided 
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Figure 1. The domain structures of PARP-1 
Four domains from the six depicted have now been designated with a function. The 
DNA-binding domain (DBD) is found close to the N terminus and was originally thought 
to contain just two zinc-binding sites5 but a third zinc finger structure was reported in 
2008.6 The initially discovered zinc-binding domains are essential for DNA binding, 
unlike their newly discovered counterpart, which appears to have a role in protein-protein 
interactions and the DNA-dependant activation of PARP-1, although the role of this third 
zinc finger is still controversial. 
 
Domain B, the nuclear localisation signal (NLS), contains the PARP nuclear-homing 
sequence which is essential for nuclear translocation.7 Also present in the domain is a 
cleavage site for a number of apoptotic proteases.8 Amongst these, caspase-3 has been 
identified as being primarily responsible for the breakdown of PARP-1 during 
programmed cell death.9 
 
The Automodification domain, or domain D, contains a breast-cancer susceptibility 
sequence (BRCA1), C-terminus (BRCT) motif which is found in numerous proteins 
involved in cell-cycle control and DNA repair and recombination.10 It is known that 
proteins possessing the ca. 100-amino-acid motif can form heterodimers11 and, therefore, 
its presence in PARP-1 provides a platform for protein-protein interactions and for 
dimerisation.  In lower organisms, such as Drosophila, a leucine zipper has been found in 
domain D12 and it has been postulated that this motif is responsible for protein-protein 
interactions in such species.  Interestingly the leucine zipper is poorly conserved in 
vertebrates, suggesting that the presence of the BRCT domain has rendered it redundant. 
 
Close to the carboxy terminus lies domain F, the catalytic domain.  Alignment and 
comparison of the amino-acid sequences of PARP-1 from multiple species shows that 
domain F has been highly conserved throughout evolution.  Analysis of the crystal 
structure of the chicken PARP-1 catalytic fragment revealed common features with the 
active sites of some bacterial toxins, which are mono-ADP-ribosyl transferases,13 and 
random mutagenesis of residues in the active site has demonstrated that the conserved 
E988 is essential for elongation of the PAR chain.14 Scheme 1 shows the reactions 













































































































Scheme 1. PAR-generating reactions catalysed by PARPs. a) Generation of cyclic oxonium ion following 
weakening of the C–N bond. b) Initiation, the cation is quenched by a nucleophilic glutamate residue from 
an acceptor protein. c) Branching, via the 2’′-OH of the nicotinamide-ribose. d) Elongation, via the 2’′-OH 
of the adenine-ribose. 
 
The first step of the PARP-catalysed reaction is removal of the nicotinamide as a leaving 
group. This is facilitated by a trio of strong hydrogen bonds to the primary amide, which 
stretches and weakens the glycosidic C–N bond. This process generates the intermediate 
highly electrophilic oxonium ion (Scheme 1). The “Initiation” then involves the 
nucleophilic attack of the anionic γ-carboxylate of a glutamate residue from an acceptor 
protein at the α-face of the anomeric carbon of the cyclic oxonium ion. Elongation and 
branching rely on the same chemistry, quenching of the oxonium ion via an oxygen 
nucleophile but supplied by a 2’-hydroxy group of a ribose of the growing polymer. Each 
molecule of NAD+ contains two ribose units and these are identified as either the 
adenine-ribose or the nicotinamide-ribose, depending on their relative positions. If the 
adenine-ribose 2’-OH is utilised to quench the cyclic oxonium ion, elongation of the PAR 
chain occurs. Quenching by the nicotinamide-ribose 2’-hydroxy creates a branch-point in 
the chain, which occurs approximately once in every thirty-to-fifty ADP-ribose units 
polymerised.15  
Automodification of the enzymes themselves is the principal regulator of PARP activity, 
as the process ultimately leads to termination of catalytic activity due to electrostatic 
repulsion between the poly(ADP)ribosylated enzyme and DNA.   
The PAR polymer has a short biological half-life of less than one minute in vivo, owing 
to degradation by the enzyme poly(ADP-ribose) glycohydrolase (PARG). PARG 
hydrolyses the glycosidic (1” → 2’) linkages in linear and the (1” → 2”) linkages in 
branched PAR to produce ADP-ribose.16 Following the actions of PARG, one ADP-
ribose unit is left, linked through a carboxylate group on a glutamate residue to the 
acceptor protein.  ADP-ribose protein lyase is the enzyme responsible for the removal of 
this last residue via hydrolysis of the ester bond between the protein and the ADP-ribose 
monomer.17   
 
1.2.2 DNA Repair 
 
The major heterologous acceptors of PAR generated by PARP-1 are proteins involved in 
nuclear functions, including DNA repair and replication, transcription and chromatin-
structure modulation, suggesting that PARP-1 is involved in the regulation of these 
processes.  The poly(ADP-ribosyl)ation of histones is thought to be particularly important 
as the build up of anionic charge leads to a relaxation of chromatin structure, allowing 
components of the DNA-repair pathway access to the DNA.18  PARP-1 interacts directly 
(through the BRCT motif) with multiple components of the base excision repair (BER) 
and single-strand-break repair (SSBR) pathways.  
 
The crucial role of PARP-1 in DNA repair is also evidenced by the hypersensitivity of 
cells to DNA-damaging agents which have been treated with PARP-1 inhibitors19.  For 
example, Huet and Laval20 showed Chinese Hamster Ovary (CHO) cells had decreased 
DNA repair and decreased survival when treated with bleomycin in combination with 3-
aminobenzamide 1a, rather than with bleomycin alone.  Another group21 used X-rays as 
the DNA-damaging agent and showed that co-treatment with 1a resulted in diminished 
survival in V79-B310H cells. 
 
Until highly PARP-1-selective inhibitors are available, perhaps a better strategy to 
investigate the importance of PARP-1 alone in DNA repair is to use PARP-1 antisense 
mRNA.22 Stevnsner and co-workers23 used nitrogen mustard 2 (HN2) to damage DNA in 
HeLa S3 cells expressing PARP-1 antisense mRNA and showed that these cells displayed 
decreased gene specific repair and survival.  Similar observations were made by Ding et 
al.











Figure 2. The structure of the PARP inhibitor 3AB 1a. 
 
 
In addition, studies on PARP-1-knockout mice (which develop normally and are fertile) 
have shown markedly increased sensitivity to ionising radiation and alkylating agents.22 
When PARP-1-/- mice were exposed to γ-rays (8 Gy), the majority died within 4-6 days, 
whereas approximately 50% of the wild-type mice survived an identical exposure for 
three weeks.26 In a different experiment, using the alkylating agent N-methyl-N-
nitrosourea 4 (MNU), the authors reported that all PARP-1 deficient mice had died four 
weeks after intraperitoneal injection.  In contrast, 60% of the control mice survived and 
lived for over eight weeks post-injection.  Interestingly, it has been shown that PARP-1 
knockouts do not recruit the scaffold protein X-ray repair cross complementing I 
(XRCC1) to single strand breaks (SSB) and have delayed SSBR,15 suggesting a possible  











Figure 3. The structures of the alkylating agents HN2 2, MMS 3 and MNU 4. 
 
PARP-1 plays a major role in the initial stages of SSBR, which are outlined below. 
 
1) The SSBR pathway begins with the detection of SSBs and this is achieved 
by PARP-1 (and possibly other PARP isoforms19, 27) binding to the 
damaged site through its zinc fingers. 
2) The DNA-bound PARP-1 is activated resulting in PAR production and 
chromatin relaxation following histone poly(ADP-ribosyl)ation (note that 
this process is transient as the PAR polymers are rapidly degraded by 
PARG). 
3) With the chromatin in a relaxed state, PARP-1 interacts with and recruits 
XRCC1 to the site of damage. This protein acts as a molecular scaffold28 
and allows the assembly of the SSBR complex through interaction with 
the multiple components involved (most importantly DNA polymerase 
and DNA ligase).  
4) In order that the final two stages of SSBR can take place, the damaged 3’ 
and 5’ ‘ends’ of DNA must be restored to their original undamaged state. 
Multiple enzymes are involved in this process including XRCC1, PNKP 
and APTX. 
5) Gap filling is the penultimate stage of SSBR and involves the replacement 
of a single lost nucleotide (short-patch repair) or two or more nucleotides 
(long-patch repair). DNA polymerases perform this insertion and Pol β 
has been shown to be of particular importance.29 
6) The final stage of SSBR is ligation of the inserted nucleotide(s). Short-
patch repair sites are generally ligated by DNA ligase 3 whereas DNA 
ligase 1 is important in the ligation step of long-patch repair.  
 
PARP-2 is also implicated in these processes and this will be discussed in a later section.  
The role of PARP-1 in the repair of double-strand breaks (DSBs) is unclear.  The two 
major mechanisms for the repair of DSBs are homologous recombination (HR) and non-
homologous end joining (NHEJ) and there is evidence to suggest that PARP-1 is not 
required for the efficient running of these processes.30 However, Audebert et al.31 showed 
that DSB repair was slowed in PARP-1 deficient cells and in cells pre-treated with a 
PARP-1 inhibitor; suggesting that there may be a PARP-1 dependant DSB pathway.   
 
Ataxia telangiectasia mutated (ATM) is a protein kinase that is crucial in DSB repair, 
phosphorylating several key proteins in the pathway. Ku86 is part of the Ku hetero-
dimer32 which is thought to bind to damaged DNA ends and recruit essential factors in 
the DSB repair pathway.33 The fact that PARP-1/ATM and PARP-1/Ku86 double 
knockouts are not viable has been attributed to the loss of SSBR through loss of PARP-1 
activity and DSB repair through the loss of ATM or Ku86.  The above evidence points to 




The initial stages of mitosis involve chromosomal segregation and this occurs at a 
structure known as the spindle, which is based on microtubules.  Several PARPs localise 
to the spindle. The work of Chang et al.34 showed that PAR is enriched in the spindle and 
also required for its assembly and structure, as hydrolysis of PAR led to inhibition of the 
formation and maintenance of the spindles.  
 
The Aurora kinases were discovered in 199535 and are involved in the regulation of many 
processes involved in mitosis. Aurora-B is part of the chromosomal passenger complex 
(CPC) that plays an essential role in guiding the stage-to-stage progress through and 
completion of mitosis.  In order that duplicated DNA can be segregated in mitosis, the 
chromosomes must first be condensed. The key mediator in this process is histone 3.  
Aurora-B regulates the activity of histone 3 via phosphorylation at serines 10 and 2836 
and PARP-1 has been shown to interact specifically with Aurora-B through the BRCT 
domain.37 Damage to DNA during mitosis would result in poly(ADP-ribosylation) of the 
kinase, subsequent deactivation and a reduction in phosphorylation at serines 10 and 28 
on histone 3.  This is significant as the likely result is prevention of chromosomal 
condensation and a subsequent halting of progression of metaphase.  This suggests a 
regulatory role of PARP-1 in mitosis.  Additionally, PARP-1 has been found localised 
both to the centrosomes (the major microtubule organising centres) and the chromosomes 
in the interphase and cytokinesis (cell division) phases of mitosis.38   
 
1.2.4 Transcriptional regulation and NF-κB 
 
PARP-1 is involved in transcriptional regulation and acts either through direct 
interactions with transcription factors or by modifications of chromatin structure.  
Numerous transcription factors and co-factors are stimulated by PARP-1 including b-
Myb, transcription enhancer factor-1 (TEF-1), nuclear factor (NF)-κB,39 activator 




The term NF-κB covers a family of inducible transcription factors that are important in 
the regulation of various genes involved in inflammation and the immune response, the 
most studied form of NF-κB is a heterodimer consisting of two subunits, p50 and p65.  In 
order for NF-κB to promote the expression of genes, several co-factors are required and 
the two most important of these are the histone acetyltransferases p300 and cAMP 
response element-binding protein (CREB)-binding protein (CBP).  PARP-1 has also been 
shown to act as a co-factor for NF-κB,41 interacting with both subunits.  Hassa et al.39 
obtained some clues to the possible molecular mechanisms at work when they showed 
PARP-1 is acetylated by p300/CBP and that this was required for the association of 
PARP-1 with p50 and subsequent activation of NF-κB.  The potential importance of the 
PARP-1/p50 interaction was demonstrated by Tulin and Spradling42 who showed that 
Drosophila mutants with diminished levels of the protein displayed a similar phenotype, 
consisting of immune-system defects, as mice lacking the p50 gene.  This research also 
shows that the PARP-1 mediated regulation of NF-κB has been conserved throughout 
evolution.  
 
In DNA repair, the poly(ADP-ribosyl)ation of histones by PARP-1 results in a relaxation 
of chromatin structure and this may also occur in transcription.  Chromatin exists in a 
number of different structural states that have differing levels of transcriptional activity; 
for example, metaphase chromosomes are highly condensed whereas interphase 
chromosomes are much more disperse.  Kim et al.43 showed that PARP-1 binds to the 
functional unit of chromatin, the nucleosome, and that activation of the enzyme, followed 
by removal, was required for transcription to occur.  The group also showed that PARP-1 
was activated in the absence of DNA damage (by using nick-free, circular DNA 
templates) but the mechanism of this activation remains an open question.  Another group 
showed that poly(ADP-ribosyl)ation was required44 for the formation of long-term 
memory in Aplysia and postulated that a PARP-1-mediated decondensation of chromatin 
structure allowed the high level of transcription required (for the formation of long term 
memory), to take place. 
 
1.2.5 Inflammation and inflammatory diseases 
 
As mentioned above, PARP-1 is involved in the regulation of NF-κB45 and AP-1,46 
which are important transcription factors involved in controlling the expression of pro-
inflammatory mediators; therefore, the protein has a role in inflammation.  In addition, a 
key feature of inflammatory disease is oxidative stress. This is an imbalance of the 
antioxidant / pro-oxidant species in the cell, favouring oxidation. Once the normal 
cellular protective systems are exhausted (e.g. glutathione redox cycle) there is a build up 
of reactive oxygen and nitrogen species. These species damage DNA and therefore cause 
activation of PARP-1 and, when in excess, overactivation.  This overactivation can lead 
to cell death and this has been shown to be important in many disease states, which 
involve inflammation.  The role of PARP-1 in cell death can be explained by two 
mechanisms. Firstly, depletion of cellular NAD+ causes a depletion of ATP as the cell 
attempts to resynthesise and replenish stores of the lost NAD+.  The loss of ATP will lead 
to cellular death by necrosis.  The second pathway is mediated through apoptosis-
mediating factor (AIF).  Persistent poly-ADP-ribosylation reactions have been shown to 
cause the relocation of AIF from the mitochondria to the nucleus, where subsequent DNA 
fragmentation occurs; this leads to cell death by apoptosis.47 PARP-1 is a target of 
caspases 3 and 7 during apoptosis and these proteases break down PARP-1 into two 
fragments: p24 and p89.  This fragmentation inactivates PARP-1 and can be seen as a 




Activation of PARP-1 was directly linked to asthma by Boulares et al. in 2003.48 The 
group used a mouse model of asthma, which was induced by ovalbumin.  The detection 
of PAR was used as evidence of PARP-1 activation and 3-aminobenzamide 1a (3-AB) 
was used to inhibit PARP-1.  Administration of 3-AB diminished PAR to undetectable 
levels, reduced the expression of inducible nitric oxide (iNOS) and reduced cell 
migration.   In order to validate the results (3-AB is a weak and non-selective PARP 
inhibitor), PARP-1-/- mice were also investigated and the phenotype provided protection 
from the disease in the model.  A similar model (but in guinea pigs) was used by Suzuki 
et al.,49 who showed that administration of 3-AB or 5-aminoisoquinolin-1-one 5 (5-AIQ) 








Figure 4. The structure of 5-AIQ 5.  
 
 
These studies suggest that PARP-1 plays a crucial role in asthma but the results of 
experiments using knockout mice in asthma must be viewed with caution.  There are two 
stages to creating an animal model of asthma: sensitisation, which involves priming the 
animal with the antigen, and elicitation, where the inflammatory response is triggered in 
the presensitised animal.  As knockout mice will never possess a particular gene, both 
stages of the model will be influenced.  Therefore further studies are required using 
selective inhibitors of PARP-1 and, indeed, other PARP isoform-selective inhibitors to 
determine the role of PARP-1 and of the other PARP isoforms in asthma. 
 
1.2.7 Ischaemia-reperfusion injury 
 
Occlusion of blood vessels supplying oxygenated blood to tissues will result in those 
tissues becoming ischaemic.  Rapid reperfusion of these tissues with oxygenated blood 
results in the generation of free radicals (oxygen is an oxidising diradical ⋅O-O⋅) and 
other oxidants.  The generated species then cause SSBs in DNA and other cellular 
damage (such as modifications of lipids and proteins), resulting in activation of PARP-1.  
If the level of PARP-1 activation is great, then its substrate, NAD+, is consumed.  The 
cell will then attempt to resynthesise NAD+ from nicotinamide, utilising ATP.  The 
resultant cellular deficiency in NAD+ and ATP negatively impacts processes such as 
glycolysis, which ultimately leads to cell death by necrosis, unless the balance is 
redressed.  The rationale for the use of PARP-1 inhibitors in ischaemia-reperfusion injury 
is to prevent depletion of cellular NAD+ and, therefore, cell death, which ultimately 
results in protection of the organ concerned.    
 
Inhibitors of PARP-1 have been shown to be of excellent therapeutic benefit when 
administered in animal models of ischaemia-reperfusion injury of various organs 
including the kidney, liver and heart (i.e. myocardial infarction).  In a rat model of 
myocardial infarction which involved coronary artery occlusion followed by reperfusion, 
5-AIQ was shown to cause a significant, dose-related reduction in infarct size.50 The 
doses of 5-AIQ required in this study were low, ranging from 0.03-0.3 mg kg-1, this is in 
constrast to similar studies with the lipophilic PARP inhibitor 3-AB 1a which required a 
significantly higher dose (> 10 mg kg-1) to produce similar effects.51, 52    
 
Another study53 used a separate rat model of shock / resuscitation and assessed liver 
microcirculation and function both with and without pre-treatment with 5-AIQ.  The 
group found that the controls suffered from compromised liver function and that 5-AIQ 
ameliorated this effect. The dose of 5-AIQ used in this study was 3 mg kg-1 and lower 
dosing schedules were not attempted in this work. In order to assess the protective effects 
of 5-AIQ on renal injury caused by ischaemia-reperfusion, Chatterjee et al.54 used 
hydrogen peroxide to induce oxidative stress in rat renal proximal tubular cells and 
incubated the cells with varying concentrations of the PARP inhibitor.  In addition, the 
researchers tested the efficacy of 5-AIQ in vivo by subjecting rats to renal bilateral 
ischaemia-reperfusion both with and without treatment with 5-AIQ. 5-AIQ was found to 
significantly reduce cell injury and death caused by oxidative stress in the isolated tissue 
and also in the in vivo models. In the rat model 5-AIQ also showed extreme promise in 
protecting rats from multiple organ injury and dysfunction caused by haemorrhage and 
resuscitation.55 In this study, the i.v. dose of 5-AIQ required was 30 µg kg-1, some 330-
fold lower than that of the benchmark inhibitor at the time 3-AB 1a (10 mg kg-1). 
 
 
1.2.8 Inflammatory bowel diseases 
 
Although the precise aetiology of inflammatory bowel diseases is currently unknown, 
numerous animal and clinical studies have demonstrated the importance of the formation 
of reactive nitrogen species (RNS) and reactive oxygen species (ROS) in the 
development of the disorders.  For example, polymorphonuclear leukocytes (PMNs) 
derived from patients with ulcerative colitis have increased levels of oxygen free radicals, 
in comparison with those derived from healthy patients.56 As the generation of free 
radicals is linked to activation of PARP-1, the role of this enzyme has been examined in 
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Figure 5. Structure of TNBS 6 and DNBS 7. 
 
 
Zingarelli et al.57 induced colitis in PARP-1-/- and wild-type mice using 
trinitrobenzenesulfonic acid 6 (TNBS).  The group observed that whilst the wild-type 
mice displayed symptoms of ulceration and chronic erosion for up to seven days, the 
PARP-1 knockout mice were completely recovered within six days.  Symptoms of colitis 
were associated with an increase in intercellular adhesion molecule-1 (ICAM-1), 
infiltration by neutrophils, peroxidation of lipids and nitrosative damage, which were 
diminished in the mutant mice, indicating a role for PARP-1 in the activation of these 
processes.  Similar results were obtained in the work of Cuzzocrea et al.58 who examined 
the value of the PARP inhibitors 5-AIQ and 3-AB in a dinitrobenzene sulfonic acid 8 
(DNBS)-induced model of colitis.  Here, PARP-1 inhibition (evidenced by a reduction in 
PAR staining) caused a diminution in myeloperoxidase activity, ICAM-1 up-regulation 
and colon injury.   
 
It is, therefore, unsurprising that researchers have examined the role of PARP-1 and other 
isoforms in such disorders and several groups have established a link between increased 





The chronic inflammation in rheumatoid arthritis has been linked to superoxide anions 
which would suggest a potential role for PARP-1 in the disease. Additionally, 
autoantibodies against PARP-1 have been found to be present in patients with rheumatoid 
arthritis and other autoimmune diseases.62, 63 Peroxynitrite (ONOO-) is the cytotoxic 
product formed when superoxide reacts with nitric oxide and (mainly due to its capability 
to cross cell membranes and long half-life) is thought to be the primary mediator of DNA 
damage in inflammatory diseases, in vivo.64 The work of Pacher et al.65 demonstrated that 
a reduction in PARP activity by pre-treatment with an inhibitor or by introducing the 
PARP-1-/- phenotype, protected fibroblasts from peroxynitrite-induced injury. The 
authors also found that oral treatment with a PARP inhibitor resulted in delayed clinical 
signs of arthritis and improved histological status (a sign of reduced tyrosine nitration) in 
a collagen-induced model of arthritis in mice. These data point to a possible clinical 





1.3.1 Molecular Structure 
 
The PARP-2 gene encodes for a 62 kDa protein and is localised at chromosome 14 at 
position q11.2 in humans and C1 in mouse.66 The mouse protein consists of three 









Figure 6. The domain structure of PARP-2. 
 
Figure 7. Domain structure of PARP-2 
The DNA-binding domain (Figure 6, residues 1-64) of PARP-2 is distinct from the 
corresponding PARP-1 domain and, interestingly, lacks the zinc fingers that are essential 
for binding to DNA by this latter isoform of the enzyme. This domain is, however, rich in 
basic amino-acids (ca. 25% Lys or Arg)66 and these residues probably play a major role 
in binding to DNA.  The differences in structure of the DNA domains of PARPs 1 and 2 
may also reflect the differences in the DNA structures which the two enzymes recognize 
and the fact that PARP-2 binds to SSBs less efficiently than does PARP-1.  The PARP-2 
DBD contains both a NLS and a nucleolar localisation Signal (NoLS).  Lying between 
the DBD and domain E, there is a DNRD (AspAsnArgAsp) caspase-3/7 cleavage site.67 
Domain E is the site responsible for the protein-protein interactions that PARP-2 shares 
with various partners which include PARP-1, XRCC1 and DNA ligase 3.15 In addition, 
this domain acts as the automodification domain in PARP-2. Domain F, or the catalytic 
domain, of mouse and human PARP-2 are highly conserved and both show high 
homology with the human PARP-1 catalytic domain domain (69% in the case of human 
PARP-266). 
 
1.3.2 PARP-2 targets, partners and functions 
 
PARP-2 is significantly less active in terms of catalytic activity, compared with PARP-1, 
and accounts for approximately 5-10% of the total cellular PARP activity.15   The enzyme 
has been shown to heterodimerise with PARP-1 and shares many of its functions and 
targets; however, it has emerged that PARP-2 has some different protein targets and 
potential functions to PARP-1.   
 
1.3.3 DNA Repair 
 
PARP-2, like PARP-1, is activated by DNA damage and is considered to be a sensor of 
DNA strand breaks.  The two proteins heterodimerise and homodimerise in vivo in 
addition to poly(ADP-ribosyl)ating each other.  However, the major heterologous target 
of PAR synthesised by PARP-2 is the core histone, H2B, rather than H1, but the 
significance of this difference has not yet been elucidated.  The precise role of PARP-2 in 
SSBR and BER is not yet clear.  The protein interacts through its E domain with several 
key players in BER, including XRCC1, DNA pol B and DNA ligase III, which would 
suggest that it is somehow involved in the process of BER. In addition to accepting PAR 
synthesised by PARP-2, XRCC1 is also a negative regulator of the activity of the enzyme 
(as it is with PARP-168). The mechanism of this negative regulation is to reduce the rate 
of automodificaiton of the enzymes by binding to the automodification domain. This 
results in the PARP isoforms remaining at the DNA lesion rather than becoming detached 
and available for further rounds of DNA repair. It is likely that this negative feedback 
loop is in place to prevent excessive XRCC1 recruitment by PARPs 1 and 2. 
 
Schreiber et al.15 showed that PARP-2-/- mouse embryonic fibroblasts (MEFs) display a 
delay in the repair of alkylated bases following treatment with N-methyl-N-nitrosourea 
(MNU) and the importance of PARP-1 in BER has been outlined above.  Interestingly, 
the authors noted that the loss of PARP-2 had a similar impact to the loss of PARP-1, 
even though PARP-1 is expressed in increased levels, suggesting that perhaps it is the 
PARP-1/2 heterodimer that is important for efficient BER.   
 
Somewhat contradictory results were obtained by Fisher et al.69 who used hydrogen 
peroxide to induce SSBRs in human A549 cells and depleted PARP-1 and PARP-2 using 
siRNA.  Although the authors found that a reduction in PARP-1 significantly reduced the 
rate of SSBR, a reduction in PARP-2 had only a minor effect, even when PARP-1 was 
also knocked down.  A possible explanation for this unexpected result is an incomplete 
knock down of the proteins but further studies are required to clarify the role of PARP-2 
in SSBR and selective inhibitors of PARP-2 would be valuable tools for this purpose. 
 
1.3.4 Telomeric integrity 
 
Telomeres are the complexes of protein and DNA found at the ends of the chromosomes, 
which contain multiple duplex T2AG3 repeats.  Telomeres have a protective role, 
preventing the progressive loss of the chromosome ends with each round of replication 
and also preventing the ends from being processed as DSBs, which would lead to non-
homologous end-joining or homologous recombination. The classical view of telomeres 
was that they were arranged as linear double-stranded repeats but Griffith et al.70 showed 
that the telomeric DNA loops back on itself, forming a lasso structure termed a t-loop 
(telomere-loop). This process requires a single-strand 3’ overhang and is mediated by 
telomeric repeat binding factor-2 (TRF2) which also has a role in telomere protection 
through association with various DNA-repair and damage signalling factors.71, 72 PARP-2 
has been shown to interact with TRF273 and affects its ability to bind DNA through both 
a non-covalent interaction of PAR with the DNA binding domain of TRF2 and a covalent 
modification at the dimerisation domain. These interactions and modifications would 
open up the t-loop structure and, much in the same way PARP-1 facilitates the repair of 
DNA, allow access of the DNA-repair enzymes to the site of damage. An alternative 
telomeric structure was proposed by de Lange,74 in which the DNA forms dimers and 
tetramers involving G-quadruplexes; it is possible that both structures co-exist.    
 
Dantzer et al.73 showed that PARP-2-/- mouse embryonic fibroblasts (MEFs) displayed 
normal telomere length and telomerase activity when compared to wild-type cells. 
However, these cells showed increased numbers of chromatid and chromosome breaks 
and of chromosome ends that lacked detectable T2AG3 repeats. These results from 
knockout mice suggest that PARP-2 has a functional role in the maintenance of telomeres 
but further work using selelective inhibitors of this isoform are required to gain insights 




As mentioned above, PARP-1 is implicated in inflammation due to its regulation of 
NF-κB and the fact that its over-activation by pro-inflammatory mediators leads to cell 
death by necrosis.  It is unlikely that the over-activation of PARP-2 alone will deplete 
cellular NAD+ levels, as it accounts for only ca. 10% of the total PARP activity in the 
cell.  At present, little is known about the role of PARP-2 in the regulation of genes 
involved in inflammation but some lines of evidence suggest a possible role.  Firstly, 
administration of the PARP-2 antisense oligonucleotide (ISIS 110251) in the interleukin-
10-deficient mouse (an animal model of colitis) resulted in a marked improvement in 
colonic inflammatory disease in this model and, in addition, a subsequent normalisation 
of colonic function was observed.75 
 
Secondly, PARP-2-knockout mice were also protected from focal cerebral ischaemia 
relative to wild-type controls. In global ischaemic insult, the mutants had worse outcomes 
than PARP-1-/- mice (which showed neuroprotection) in the hippocampus but with no 
effect in the cortex.76 Further studies are required to deduce the molecular mechanisms 
involved in these responses and the precise role that PARP-2 plays in inflammation, 
highlighting the immediate requirement for isoform-selective inhibitors of PARP-2.  
 
1.3.6 Cellular differentiation 
 
The study of PARP-2 knockout mice has provided evidence for specific roles of the 
isoform (i.e. PARP-1 independent) in cellular differentiation, which include the 
development of T lymphocytes,77 germ cells15 (specifically spermatogenesis) and 
adipocytes (adipogenesis).78 
 
1.3.7 T Lymphocytes 
 
Yelamos et al.77 reported that the deletion of PARP-2 but not of PARP-1 led to a 
significant diminution in CD4+CD8+ double-positive (DP) thymocytes, which was 
associated with a decrease in DP cell survival.   The authors also noted an increased 
expression of the pro-apoptotic protein, Noxa, in the PARP-2-/- thymocytes, which also 
showed a reduced expression of T-cell receptor (TCR).  These results suggest that PARP-
2 has a role in survival of T-cells during the process of thymopoiesis and may regulate 
the programmed cell death (apoptosis) of thymocytes.  Elucidation of the precise 
molecular mechanisms at work will require more studies and the use of PARP-2-selective 
inhibitors.   
 
1.3.8 Germ Cells 
 
PARP-2 is widely expressed in the seminiferous epithelium and is evenly distributed 
across the seminiferous tubules, this is in contrast to PARP-1 where expression is limited 
to the peripheral cell layer which contains rapidly deviding spermatogonia.15 This 
differening expression pattern for the two isoforms suggests distinct roles in 
spermatogenesis and perhaps a more prominent role for PARP-2. 
 
The multistage process of spermatogenesis involves one round of mitosis and two rounds 
of meiosis and results in the formation of haploid gametes from diploid spermatogonium. 
PARP-2-knockout mice display a phenotype which suggests an important role of the 
protein in the development of sperm cells. The mice display hypofertility and 
irregularities at numerous stages in the progression of spermatogenesis.79 Firstly, X- and 
Y- linked genes are upregulated, as meiotic chromosome deactivation is not fully 
effective.  Secondly, nuclear elongation is delayed, which adversely affects 
spermatogenesis.  Finally, chromosome mis-segregation at metaphase 1 is observed, 
associated with a loss of centromeric heterochromatin integrity. Interestingly, PARP-1-
knockout mice do not display hypofertility. These data would suggest a crucial role for 
PARP-2 but not PARP-1, in the development of sperm cells and it is possible that defects 




PARP-2 knockout mice display lipodystrophy, with decreased weight of white adipose 
tissue (WAT) and disorders in the differentiation of preadipocytes to adipocytes, when 
compared with wild-type mice.78 A proposed mechanism for this phenotype is that 
PARP-2 regulates the expression of peroxisome proliferator activated receptor-γ (PPARγ) 
as part of the RXR-PPARγ transcription complex.  Evidence for this theory was provided 
by Bai et al.78 who showed that PARP-2 siRNA diminished ligand-dependant activation 
and the basal activity of PPARγ. The group also showed, by chromatin 
immunoprecipitation, that PARP-2 interacted with the PPARγ/RXR complex, forming a 
heterodimer. PPARγ plays a vital part in the function of WAT by controlling the 
expression of several WAT proteins. These interesting results require further 
investigation, pointing to a role of PARP-2 in obesity and a potential role for PARP-2 




The gene for human PARP-3 is located on chromosome 3 at position p21.1-p22.280.  The 
protein contains 540 amino acids and consists of three domains.  The N-terminal domain 
is unique to PARP-3 and contains a concise targeting motif in exon 1, responsible for its 
function of localising the enzyme to the centrioles.  The centrioles reside within the 
centrosome, a structure that forms near the nucleus during interphase and is important in 
the processing of microtubules.  PARP-3 preferentially locates to the daughter centriole81 
and a splicing variant lacking the targetting motif leads to accumulation in the nucleus.  
An E domain is present in PARP-3, the function of which has not been elucidated.  The 
489-amino-acid catalytic domain shares ca. 35% sequence similarity with the other 












Figure 7. The molecular structure of PARP-3. 
 
Although no automodification domain is present, the protein is capable of 
automodification in the presence of biotinylated NAD+, as illustrated by Western blot 
analysis.82 Currently, the functions of PARP-3 are unclear but it has been reported that 
over-expression of the protein interferes with the G1/S cell cycle progression but not with 
centrosomal duplication or amplification81.  PARP-3 may, therefore, function in the 
maturation of the preferred daughter centriole until the G1-S restriction point (the cell-
cycle checkpoint between G1 and S phase).  The crystal structure of the human PARP-3 
catalytic domain has recently become available,82 allowing the rational design of 
selective PARP-3 inhibitors.  This will aid in the elucidation of any specific functions.  
The catalytic domains of PARPs 1 and 3 contain some key differences, which could 
potentially be exploited in the quest for selective inhibitors.  In PARP-3, the pocket 
between the donor site and the N-terminal α-helix bundle is slightly opened in 
comparison to PARP-1 as the D-loop is four amino acids shorter.  Additional differences 






PARP-4 or vault PARP (V-PARP) is the largest member of the PARP family with a 
molecular weight of 192.6 kDa.  It is found located in the vault complex in the cytoplasm 
and also in the nucleus and at the mitotic spindle (not associated with the vault 
complex).83 The gene for PARP-4 is located on chromosome 13q11, with 34 exons 
coding for its 1724 amino acids.  In mammals, vault particles are barrel-shaped 
ribonucleoprotein complexes found in the cytoplasm, consisting of PARP-4, major vault 
protein (MVP), telomerase associated protein (TEP-1) and an untranslated vault RNA 
(VRNA). 
 
The functions of the vault particles are currently unknown but they are highly conserved 
throughout evolution, suggesting a fundamental role in cellular survival. A role in cellular 
transport was proposed by Kickhoefer et al.84 in 1996. MVP is over-expressed in 
numerous non-P-glycoprotein-expressing tumour cell lines and it has been linked to 
multidrug resistance.85  
 
Unusually, the catalytic domain of PARP-4 is found at the N-terminus rather than at the 
C-terminus as with the other PARPs discovered so far.  The presence of a BRCT domain 
points to a possible role of the protein in DNA repair and, supporting this theory, PARP-
4-knockout mice show an increased susceptibility to both N,N-dimethylhydrazine-
induced colon tumourigenesis and urethane-induced lung tumourigenesis (although to a 
lesser extent).86 
 
1.6 PARP-5 and 6, the tankyrases 
 
PARP-5 or TRF1-interacting, ankyrin-related ADP-ribose (tankyrase-1) was discovered 
as a partner of the human telomeric repeat binding factor 1 (TRF-1) in a two-hybrid 
screen carried out by Smith et al.87 in 1998.  The 142 kDa protein consists of four 
domains.  At the N-terminus lies the HPS domain, named after the continuous repeats of 
histidine, proline and serine; the function of this domain is currently unknown.  The 
ankyrin (ANK) domain spans 842 amino-acids and contains 24 repeats of the ANK motif, 
important in protein-protein interactions and placing PARP-5 into the ANK family.  The 
ANK family of proteins have a structural role and link membrane based proteins to those 
found in the cytoplasm.88 Uniquely to PARP-5 the ANK domain is further divided into 
five ARC (ANK repeat cluster) subunits, stevewhich each act as a TRF-1 binding site.  A 
sterile alpha module (SAM) is responsible for the reversible polymerisation of PARP-5 
(i.e. to form a polyprotein)89 and is found adjacent to the catalytic domain.  
 
PARP-6 or tankyrase-2 is closely related to PARP-5.  The 127 kDa protein lacks the HPS 
domain but the other three domains are present and show high homology with PARP-5. It 
is of interest to note that PARP-5 or PARP-6a single-knockouts are viable but the double 
knockout is embryonic lethal.90 This indicates, similarly to PARPs -1 and –2, that the 
enzymes share redundant functions but that tankyrase activity is absolutely required for 
normal development. 
 
The telomeres were introduced above, in relation to PARP-2.  Telomeres are not 
completely replicated and gradually shorten over time, however, they are resynthesised 
by the enzyme telomerase. This is a ribonucleoprotein reverse transcriptase consisting of 
two subunits, the human telomerase RNA component (hTERC) and the human 
telomerase reverse transcriptase (hTERT) catalytic portion.  TRF-1 acts as a negative 
regulator of telomerase activity through the recognition of specific DNA sequences in 
telomeres.  The tankyrases poly(ADP-ribosyl)ate TRF-1 and the build up of negative 
charge is likely to block the binding of TRF-1 to telomeric DNA (as has been shown in 
vitro
91).  Therefore activation of the tankyrases will lead to elongation of telomeres; the 
mechanism of activation is currently unknown but Cook et al. showed that tankyrase-1 is 
not activated by DNA damage.92   
 
In normal cells, the level of telomerase activity is low but most cancer cells have high 
levels,92 which probably contributes to their immortality. It is possible to indirectly 
inhibit telomerase by stabilising the telomeric DNA in a G-quadruplex structure thus 
preventing the initial elongation step by the enzyme.93 Alternatively, the hTERT94 or 
hTERC95 subunits can be directly inhibited. Regardless of the mechanism, inhibition of 
telomerase leads to the shortening of telomeres and cellular senescence or apoptosis, 
which suggests that specific inhibitors may be of value in cancer therapy.   
 
One problem associated with the direct inhibition of telomerase is that shorter telomeres 
have fewer TRF-1-binding sites and, therefore, fewer molecules of TRF-1, enhancing the 
apparent activity of any non-inhibited telomerase.  Alternative approaches would be the 
direct inhibition of TRF-1 or the use of selective inhibitors of the tankyrases, which 
would decrease the access of telomerase to its substrate by blocking the poly(ADP-
ribosyl)ation of TRF-1. TRF-2, another telomeric binding protein involved in telomere 
protection, was introduced in relation to PARP-2. Currently, it is not known if there is 
any interaction between the tankyrases and TRF-2 but it would seem that PARP-2 has a 
more prominent role in its regulation. Again, selective inhibition of the relevant PARP 
isoform is required to help to answer the many open questions in this area. Until these 
tools are available, the generation of PARP-2/PARP-5 and PARP-2/PARP-6 double 
knockouts would, if viable, give further insights into the biological roles of these 
isoforms.   
 
1.7 PARP-7, PARP-12 and PARP-13 
 
PARP-12, PARP-13 and PARP-7 (ti-PARP) all have a similar domain structures 
containing CCCH (CysCysCysHis) zinc fingers close to the N-terminus, a central WWE 
(TrpTrpGlu) domain and a catalytic F domain.96  The WWE domain is probably a site for 
protein-protein interactions, whilst the zinc fingers differ in structure to those found in 
PARPs 1 and 2 and may bind to RNA rather than DNA.  The transcription of PARP-12 is 
induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and this is controlled by the 
dioxin-bound aryl hydrocarbon receptor (AHR).97 
 
Interestingly one isoform of PARP-13 was initially identified as ZAP,98 a protein found 
in rats associated with resistance to retroviral infection, which binds to viral RNA.  It is 
not currently known if the PARP-13 isoform containing the F domain also has a role in 
viral immunity.   
 
1.8 PARP-9, PARP-14 and PARP-15 
 
PARPs 9, 14 and 15 all share common structural features with one to three macro 
domains being linked to a catalytic PARP domain.96 The macro domain was first 
discovered in macroH2A (a histone variant) and is important in chromosomal 
inactivation and transcriptional repression.99 The macro domain of PARP-9 can bind to 
PAR100 and may have phosphoesterase activity, which suggests the protein may function 




PARP-10 contains an RNA-recognition motif (RRM) near to the N-terminus, then a 
glycine-rich domain before the catalytic domain.101 The isoform is known to interact with 
c-Myc, an important regulator of transcription, controlling cell proliferation.  Both the 
RRM and the glycine-rich domain present in PARP-10 have been found to be of 
importance in RNA-binding nucleolin, a partner of c-Myc.  PARP-10 has been shown to 
inhibit the cellular transformation caused by c-Myc and Ha-Ras. The protein also 
poly(ADP-ribosyl)ates histone H2A, suggesting a role in the regulation of chromatin 
structure. 
 
1.10 Other PARPs 
 
Very little is currently known about the remaining PARPs - PARP-6, 8, 11 and 16.  Other 
than a WWE sequence in PARP-11,96 no domains of note have been discovered in these 






The PARGs are responsible for breaking down PAR into free ADP-ribose molecules and 
possess both endo- and exoglycosidase activity.  Mammalian PARG genes encode a 
minimum of four isoforms.  PARGs-102, 99 and 59/60 are found in high abundance in 
the cytoplasm, whilst PARG-110/111 is found in low abundance in the nucleus.  
Unsurprisingly, PARG-110/111 contains two nuclear localisation signals in exon 1, the 
other PARG isoforms lack exon 1 and this probably explains their differing primary 
locations.  Mice with deletions of exons 2 and 3, resulting in a loss of PARG-110, 102 
and 99, have normal phenotypes but have an increased susceptibility to streptozotocin-
induced diabetes.102 The mice are also more susceptible to alkylating agents and ionising 
radiation than are wild type mice.  The deletion of all four PARG isoforms is embryonic-
lethal and fibroblast cells lacking PARG activity are also hypersensitive to cytotoxic 
DNA-damaging agents.  
 
1.12 Inhibitors of PARPs  
In the early years of research into inhibitors of the PARPs, it was assumed there was only 
a single isoform of the enzyme which is now known as PARP-1.  
1.12.1 Early PARP inhibitors 
 It was rationalised that the nicotinamide portion of NAD+ was required for ‘PARP’ 
inhibition and the first competitive inhibitors were 5-methylnicotinamide 8a and 
nicotinamide103 8b. However, it was soon shown that these molecules were not specific 
(for example, nicotinamide is also an inhibitor of adenosine 3’,5’-cyclic monophosphate 
phosphodiesterase, mono(ADP-ribosyl)transferases104 and SIRT-1). Additionally, the 
presence of the ring nitrogen meant that these compounds were substrates for NAD-
metabolising enzymes. This problem was circumvented in 1975 when Shall first reported 
benzamide 1b as an inhibitor of PARP105 but the hydrophobic nature and low solubility 

















Figure 8. The structures of 5-methylnicotinamide 8a, nicotinamide 8b and benzamide 1b. 
 
1.12.2 Benzamides 
Purnell and Whish106 examined a series of 3-substituted benzamides, amongst other 
compounds, in 1980. It was rationalised that the introduction of polar substituents would 
improve water-solubility compared with the parent compound. The compounds were 
assessed for activity against PARP by measuring percentage inhibition at a concentration 
of 50 µM and also by measuring the amount of NAD+ incorporated into an acid insoluble 
fraction. The authors found that all the benzamides were more potent than nicotinamide 
in their system and that the most potent benzamides were the unsubstituted compound 1b 
and 3-methoxybenzamide 1c.  Percentage inhibition (at 50 µM) was above 90%, except 















1c R = OMe
1d R = NO2
1e R = Me
1f R = Cl
 
Figure 9. A selection of the benzamides reported by Purnell and Whish106 and Banasik.107 
 
In a comprehensive study of over one hundred and thirty compounds, Banasik reported 
the IC50 values of a series of substituted benzamides.
107 From the values reported, it was 
clear that 3-substitution was well tolerated; 3-aminobenzamide 1a (IC50 = 33 µM), 3-
methylbenzamide 1e ((IC50 = 19 µM) and 3-chlorobenzamide 1f (IC50 = 22 µM) were 
examples of potent 3-substituted benzamide inhibitors. Substitution in the 2- or 4-
positions caused a drop in potency; the 2-Cl 1g (IC50 = 1000 µM) and 4-Cl 1h (IC50 = 
300 µM) analogues were relatively weak inhibitors. Disubstitution was not favoured; the 
difluoro- 1i (IC50 = 180 µM) was moderate but disubstitution with larger groups in 1j 





















Figure 10. The disubstituted benzamides 1i, 1j, and 1k. 
 
 The importance of the carboxamide with at least one amide proton for PARP inhibitory 
activity was demonstrated early on as thioamides108 and N-alkylated109 derivatives 
suffered from a dramatic loss of activity.   
More potent inhibitors were discovered by Suto110 and by Banasik104 who reported the 
3,4-dihydroisoquinolinones in which the carboxamide is fixed in conformation by the 




Figure 11. The structure of the 3,4-dihydroisoquinolin-1-one 9. 
 
 
These compounds were found to be several times more potent than conformationally free 
PARP inhibitors, with the 3,4-dihydroisoquinolin-1-one 9 proving to be over 50-fold 
more potent than 3-AB 1a. The authors concluded that maintenance of the carboxamide 
in the anti conformation was crucial for potent activity. 
 
Many different classes of PARP inhibitors have since been synthesised in which the 
carboxamide function is held in the required conformation as part of a heterocyclic ring, 
e.g. isoquinolin-1-ones, tricyclic benzimidazoles, quinazolin-4-ones. 
 
1.12.3 Benzimidazole-4-carboxamides and benzoxazole-4-carboxamides 
An interesting approach was developed by a group at the University of Newcastle who 
used an intramolecular hydrogen bond to hold the carboxamide in the active 













10a X = NH
11a X = O
10b X = NH R = H
10c X = NH R = F















Figure 12. Structures of some benzimidazole-4-carboxamides, benzoxazole-4-carboxamides and tricyclic 
PARP inhibitors. 
This strategy proved successful and the compounds generally had potencies far superior 
to similar molecules lacking the hydrogen bond.  The compounds were tested in a cell-
based assay and the most potent examples were found to be the 2-phenyl compounds. In 
general the benzimidazoles e.g. 10b (EC50 = 990 nM) performed better than the 
corresponding benzoxazoles  e.g. 11b (EC50 = 2100 nM). Particulary potent in their assay 
system was the 4-fluorophenyl derivative 10c (EC50 = 60 nM). Several groups have 
trapped the amide bond in the required confirmation by means of a covalent bond, in a 
tricyclic system.112, 113 Again, in general, the 2-phenyl-substituted compounds showed 
increased potency; for example, Agouron found that whilst the parent compound 12a had 
a Ki of 38 nM, the 4-fluorophenyl derivative 12b was several times more potent with a ki 
of 4 nM.  Substitution at other positions of the molecule such as the lactam ring in 
general did not lead to increased potency in this series. 
 
1.12.4 Quinazolinones and phthalazin-1-ones 
 
Banasik104 reported that quinazolin-4-one 13a had IC50 = 9.5 µM but sustitution at the 2-
position  increased potency, for example 13b and 13c have IC50 values of ca. 200 nM.
113 
8-substituted analogues have also been investigated and hydroxy or methyl groups are 










13a R = H
13b R = Me
13c R = Ph
14a R = H







Figure 13. Some simple quinazolin-1-ones and phthalazin-1-ones. 
 
 
Phthalazin-1-one 14a was also reported as an inhibitor by Banasik.104 Its IC50 was 
moderate and it was not until Kudos Pharmaceuticals began substituting in the 4-position 
of this heterocycle that potency began to improve significantly. The simple 4-
benzylphthalazin-1-one 14b had IC50 = 770 nM in their assay but, when the benzene ring 
was meta-substituted, potency increased and the N-phenylpropionamide 14c was 
particularly potent (IC50 = 20 nM) but was not a suitable drug candidate, owing to 
concerns over pharmacokinetics.114 PF50 was used as a measure of cellular potency and 
this potentiation factor was calculated as the ratio of the IC50 growth curve of HeLa B 
cells treated with MMS divided by the IC50 of the growth curve of cells treated with both 
MMS and PARP inhibitor. In the cell based assays, test compounds were used at a fixed 
concentration of 200 nM. In order to increase metabolic stability, the group modified the 
anilide group to a lactam ring in 14d (IC50 = 120 nM) but this also resulted in a drop in 
potency. This drop was reversed by the introduction of a second carbonyl group to the 
lactam in 14e (IC50 = 13 nM) but cellular potency was poor (PF50 = 1.94). Both PARP-1 
inhibitory potency and cellular potency were increased by the introduction of a fluorine 
atom in the para position of the benzyl moiety in 14f (IC50 = 5 nM, PF50 = 5.62). 
Interestingly, 14f was also tested against other PARP isoforms and showed a similar level 









Figure 14. A selection of phthalazin-1-ones developed by Kudos Pharmaceuticals.  
 
Indeed the introduction of a p-fluoro substituent seemed to generally increase general 
potency in the 4-benzyl series. A further increase in cellular activity was noted with 14g 
(IC50 = 3.8 nM, PF50 = 18.2) in which a methyl group was introduced α to the imide 
carbonyl. It was proposed that this increase was possibly due to enhanced cellular 
penetration due to increasing lipophilicity but when a geminal dimethyl functionality was 










14i R = H
14j R = Me
14k R = Et
 
Figure 15. The homopiperazine derivatives 14i, 14j and 14k 
 
 
Other structural modifications at the m-position of the benzyl moiety, such as introducing 
a homopiperazine ring, also gave rise to highly potent PARP-1 inhibitors.  For example, 













































Figure 16. The structure of the clinical candidate 14l developed by Kudos Pharmaceuticals 
 
 
However, it was found that the acylpiperazine 14l was not only a highly potent inhibitor 
(IC50 = 5 nM) but also possessed the best pharmacokinetic profile, was orally active and 
active in vivo in an SW620 colorectal cancer xenograft model. Due to these factors 14l 
was selected for clinical development for the treatment of BRCA1- and BRCA2-deficient 
cancers.116  
 



















15a R = H
 
Figure 17. Isoindoline PARP inhibitors. 
 
 
The unsubstituted isoindoline 15a is a relatively poor inhibitor of PARP-1, as are the 
simple 5-substituted analogues (EC50 > 10 µM) in a cell-protection assay.  However, 
more complex substitution at the 5-position, for example an adenosine group attached via 
an alkyl chain 15b, significantly improves potency. It should be noted that many classes 
of inhibitor are not potent in this type of assay, due to poor uptake across the cell 
membrane and not necessarily poor inibition of PARP. 
 
 1.12.6 Dihydroisoquinolinones and Isoquinolinones 
 
This research centres on the isoquinolinones and structure-activity relationships (SAR) 
will be discussed in more detail below but a brief introduction is given here.  Following 
the initial report of isoquinolin-1-one as an inhibitor of PARP (IC50 = 6.2 µM) by 
Banasik,104 Suto110 investigated the SAR of various 5-substituted analogues.  Elaboration 
at this position proved successful, with the 5-hydroxy analogues proving to be most 
potent with IC50s of 140 nM and 100 nM for the 3,4-unsaturated 17 and 3,4-saturated 18 























Figure 18. Structures of the isoquinolin-1-one PARP inhibitors 16, 17 and 18. 
 
Suto110 also reported 5-AIQ 5 as a PARP inhibitor for the first time with an IC50 of 260 
nM. This was notable as, upon conversion to its HCl salt, the compound became highly 
water-soluble. Although Suto did not investigate the compound further, the fact that he 
had synthesised a water-soluble PARP inhibitor was highly significant as the in vivo 
potency of the compound would be greatly increased by this modification (see above for 
comparisons with lipophillic PARP inhibitors in in vivo models of disease). It us 
unsurprising that the vast majority of inhibitors up to this point were not water-soluble as 
the required planar benzamide pharmacophore is also a molecular signature for 
lipophilicity.  The huge promise shown by 5-AIQ and the lack of 3- and 4-substituted 
analogues in the literature led us to select it as our lead compound for this research (see 
















1.12.7 Clinical trial development of PARP inhibitors 
 
Recently, a group at Abbott Laboratories117 have has identified a series of substituted 
pyrazolo[1,5-a]quinazolin-5(4H)-ones as potent inhibitors of PARP-1, with their lead 
pre-clinical candidate 19 showing excellent enzymatic and cellular potency and cross-
species oral bioavailability.  The PARP inhibitor AG-014699118 12c has recently 
completed a Phase 2 clinical trial in combination with temozolomide in patients with 
metastatic malignant melanoma; of the 40 evaluable patients, seven partial responses 
were seen. The compound developed by Kudos Pharmaceuticals 14l KU-
0059436/AZD2281 was shown to selectively inhibit BRCA1-119 and BRCA2-deficient120 
mammary cell growth, in combination with platinum drugs and as stand alone therapy.116 
The compound has entered Phase 2 clinical trials as monotherapy in BRCA-deficient 
ovarian or breast cancer patients and in combination with a variety of cytotoxic drugs for 
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1.12.8 PARP-2 inhibitors reported in the literature 
There are very few selective PARP-1 or PARP-2 inhibitors reported in the literature at 
present. Perkins et al.121 developed an assay for PARPs 1 and 2, based on the observation 
that heterologous expression of either isoform in cells of the yeast Saccharomyces 
cerevisiae resulted in growth inhibition; therefore, the endpoint of the assay was reversal 
of this inhibition. The authors used this assay to identify the compounds ICX56290675 
20 and ICX56258231 21 with eight-fold selectivity for PARP-1 and three-fold selectivity 
for PARP-2 respectively (note that 21 is possibly a hydrolytically activated prodrug for 
the corresponding phthalazinone 14b). Iwashita et al.122 discovered an inhibitor 
FR261529 22 with five-fold selectivity for PARP-2 over PARP-1; these discoveries were 
made through random screening of compound libraries or by chance in the search for 

















































Scheme 2. Structures of selective PARP-1 and PARP-2 inhibitors discovered by random screening. 
 
In 2004, the crystal structure of the catalytic fragment of murine PARP-2 was solved123 at 
2.8 Å resolution, seven years after the data for the chicken PARP-1 catalytic fragment 
were made available.13 The high degree of homology of the PARP catalytic domain 
between different species means PARP inhibitors are unlikely to show a wide species-
difference in their inhibitory activity between chicken, mouse and human PARPs, 
although any differences in important residues must be noted. 
 
The key residues involved in PARP-1 inhibitor binding were deduced by Ruf et al.124 
who studied the co-crystals of PARP-1 chicken catalytic fragment with the inhibitors 20, 
4ANI 23, 3MBA 1c and NU1025 13d bound. The authors identified hydrogen bonding 
between Gly863-NH, Gly863-O, and Ser904-OH and the lactam or amide group of the 
bound inhibitors; additionally, hydrophobic interactions were identified between 
PD128763 and Tyr907. The two key hydrogen-bonding residues in chicken PARP-1 are 



















Figure 21. Structures of the PARP inhibitors 23, 1c and 13d. 
 Ishida et al.125 attempted to rationalise the selectivity of the quinazolinone 13e for PARP-
1 (10-fold over PARP-2) and 22 for PARP-2 (5-fold over PARP-1 see above) by a 
combination of X-ray structural study via PARP-1 co-crystals and homology modelling 









Figure 22. The PARP-1 selective quinazolinone 13e 
 
The expected three hydrogen bonds between the lactam/carboxamide function of the 
inhibitors and Gly863/Ser904 in PARP-1 and Gly405/Ser446 in PARP-2 were seen. 
Additionally, a pi-pi interaction between the heterocyclic aromatic core of 13e and 
Tyr907/Tyr869 in PARP-1 and Tyr449/438 in PARP-2 was observed. The 4-phenyltetra-
hydropyridine moiety of 13e lay in a hydrophobic pocket lined by the residues Leu769, 
Ile879 and Pro881 in PARP-1.  In PARP-2, Leu769 is replaced by Gly314 and this single 
amino-acid difference resulted in a loss of hydrophobicity in the pocket and, hence, a loss 
of potency of 13e against PARP-2.  
The non-hydrogen-bonded nitrogen of the quinoxaline ring in 22 formed favourable 
contacts with the carboxylate of Glu988 in PARP-1; this residue is conserved in PARP-2 
(Glu534), suggesting that the binding mode was also conserved. The authors speculated 
that the replacement of Asp766 and Glu763 in human PARP-1 with Glu311 and Gln308 
in human PARP-2 resulted in more favourable interactions with the chlorophenyl moiety 
of 22 and therefore the observed increase in potency.  
The small changes in the amino-acid sequence between the murine PARP-2 catalytic 
fragment and the chicken PARP-1 active site make the design of selective inhibitors 
feasible as the above authors have suggested. On initial inspection of the two structures 
two key differences can be noted, firstly the hydrophobic binding pocket is larger in 
PARP-2 (and maybe lacking hydrophobicity around Gly314 – see above) suggesting that 
more three dimensional bulk will be tolerated in this area. The second key difference is 
the replacement of the neutral polar Gln308 in chicken PARP-1 with the basic Lys308 in 
murine PARP-2, which could be exploited by building an acidic function to an inhibitor 


























2. Research aims and objectives 
The functions of PARP-2 remain unclear, although tools such as knockout mice and 
antisense RNA offer some clues. Additionally, the effects of PARP-2 (and PARP-1) are 
mediated via two mechanisms, the catalytic activity of the enzyme and also through 
protein-protein interactions. As PARP-2-knockout mice would never express the protein, 
both mechanisms are knocked out, whereas, with a pharmacological inhibitor, only the 
enzymatic activity would be lost.  
There is currently a major need for potent and selective inhibitors of PARP-2 to study the 
function of the enzyme and the effect of inhibiting catalytic activity alone. The inhibitors 
discovered thus far have been found by random screening of PARP-1 inhibitor libraries 
and the current selectivity is modest; by using rational drug design significant 
improvements should be possible in terms of potency and selectivity.  
5-AIQ is a potent inhibitor of PARP-1 with excellent in vivo activity in animal models of 
disease and will serve as a template for our designed inhibitors.  
The major aim of this research is to develop isoform-selective inhibitors of PARP-2. In 
order to exploit the differences between the catalytic sites of PARP-1 and PARP-2, a 
bulky aromatic substituent will be introduced at the 3- or 4-position of the 5-AIQ to fit 
into the larger hydrophobic pocket in PARP-2. Therefore sets of 3- and 4-substituted 5-
AIQs will be prepared.  
An acidic function will be introduced at the 5-position of the molecule; this will be either 
tethered to the exocyclic 5-amine of 5-AIQ through CH2 units or directly attached at the 
5-position of isoquinolin-1-one. Other synthetic modifications at the 5-position will be 
considered, if appropriate. 
All synthesised inhibitors will be evaluated for PARP-1 and PARP-2 inhibitory activity 
by KuDOS Pharmaceuticals and IC50 values will be generated where possible. 
 
The key objective of the work is to design and synthesise inihibitors of PARP-2 with a 
higher degree of isoform-selectivity than any published compound. Obtaining samples of 
literature compounds and assessing them in our assays will measure this.   














3. Results and Discussion 
3.1 Molecular modelling 
Using the crystal structures of PARP-1 (PDB code 4PAX, chicken PARP I with NU1025 
13d (inhibitor, Ruf et al.124) and PARP-2 (PDB code 1GSO, murine PARP-2, Oliver et 
al.123) as starting structures, the binding pocket was established (by eye) and compared. 
This was achieved by uploading the relevant PDB files in UCSF Chimera (Version 1) and 

























Figure 23. Observed interactions and distances between 13d and the PARP-1 active site; all distances are 
in Ångstroms. 
 
Initial studies with PARP-1 involved measuring and mapping the binding pocket, 
together with key interactions between the bound NU1025 13d inhibitor and the pocket. 
Comparisons were also made to PARP-1 without an inhibitor present by uploading the 
PDB file 2PAW (corresponding to the catalytic fragment of chicken PARP-1 with no 
inhibitor bound) into UCSF Chimera. This was to establish and confirm previous 
observations that the receptor binding pocket is relatively rigid and does not change 
conformation upon binding the substrate or an inhibitor ligand. The observed significant 
interactions and distances in the PARP-1 model are shown in Figure 23, these distances 
would be used when docking 5-AIQ into PARP-2. Comparison of the binding pocket 
with and without a bound inhibitor showed little significant difference. 
The distances observed in the PARP-1 study (Figure 23) were then used to dock a 
minimised and charged (Gastieger + Hückel) 5-AIQ into the binding pocket of PARP-2. 
This was achieved by transferring the protein structures from UCSF Chimera into 
Hyperchem (Version 7.5). Once docked (by eye), the structure was transferred back into 
UCSF Chimera and restraints were added (as observed in the PARP-1 model) and the 
ligand was subjected to molecular dynamics (300 K for 5 ps, the last 1 ps was then 
averaged) and then re-minimised. The binding pocket and ligand (5.0 Å from ligand) 
were then subjected to molecular dynamics (300 K for 5 ps, the last 1 ps was then 
averaged) and the complete complex (enzyme and 5-AIQ) was minimised to give the 
final model. 
 
 Figure 24. Model of the catalytic fragment of PARP-2 with 13d docked and Lys308 shown in green.  
 
In this model, Lys308 sat relatively close in space (3.08 Å) to the 5-amino function in 5-
AIQ. The side chain of this residue was mobile but a stronger interaction between the 
acidic function and the lysine occurs when the two groups are close in space. Therefore, 
our CH2 tether was short (1-2 units from the amine or 1-3 units if attached directly to the 


















It was observed that the hydrophobic pocket in PARP-2 had a larger volume than the 
corresponding space in PARP-1, in our model.  The pocket lies south of the 3- and 4- 
positions in the docked 5-AIQ core and this difference will be exploited by 
functionalising these positions with bulky substituents. 
 
3.2 PARP-1 Assay 
 
There are numerous PARP-1 assays reported in the literature and many of them rely on 
the use of radiolabelled substrate, either 3H- or 32P-labelled NAD+.126 The assay 
developed by Purnell and Whish106 used nuclei isolated from the thymus of a freshly 
slaughtered pig, rather than pure enzyme. The authors calculated percentage inhibition of 
PARP activity by measuring the amount of [3H]adenosine-NAD+  incorporated into an 
acid-insoluble fraction, following initiation of the PARP reaction, when no inhibitor was 
present.  This was then compared with the value when an inhibitor was present. 
 
The assay reported by Cheung and Zhang127 involves the use of biotinylated NAD+ in 
addition to 3H-NAD+.  The PAR polymers produced bind to avidin-SPA beads also 
present in the reaction mixture, resulting in excitation of the scintillant and amplification 
of the signal. The signal produced from the free [3H]adenosine-NAD+ dissipates in 
aqueous solution, therefore the free ligands and complexes do not need to be separated, 
which greatly increases throughput.   
 
Figure 25. Structures of isoquinolin-1-ones with 
carboxylic acids tethered to the 5-position. a) n = 1-2; b) n 
=  1-3. 
 
An alternative ELISA-based assay was developed by Decker et al.127 PARP activity is 
measured using UV absorption and no radioisotopes are required. The assay is highly 
sensitive but the frequent washing steps required in ELISA assays decreases throughput 
and renders them prone to operator error.  
 
Another assay bypassing the use of radioisotopes has been reported by Trevigen Inc. and 
is commercially available. The assay uses biotinylated NAD+ in wells coated with histone 
acceptor proteins. The extent of incorporation of biotin into the PAR polymers and, 
therefore, activity of the enzyme is measured using a conjugated streptavidin detection 
system which gives a colorimetric readout. A similar minaturised assay, based on the 
same principles, has been developed by Lee et al.128 
 
KuDOS Pharmaceuticals Ltd. kindly agreed to screen the compounds for PARP-1 
activity though an established collaboration. This company has developed a FlashPlate 
scintillation proximity assay129 for the high-throughput screening of compound libraries.  
The principles of the assay briefly follow. PARP-1 is purified from HeLa nuclear extracts 
in-house and 96-well FlashPlates (NEN) are coated with scintillant. After the incubation 
of the inhibitor with PARP-1, the reagents (NAD+, 3H-NAD+ and DNA) are added to the 
wells to initiate the PARP-catalysed reaction. Column 11 is a positive control which does 
not contain test compound and column 12 is a negative control lacking DNA.  As a result 
of the PARP reaction, PARP-1 will automodify itself and the resulting structures will 
contain 3H-labelled adenine. Following termination of the reaction (cold AcOH), the 
PARP-1-3H-ADP-ribose complexes will come into close proximity with the FlashPlate 
walls which leads to signal amplification. Unreacted 3H-NAD+ will remain free in 
solution and therefore less likely to come close enough to the well walls to be amplified.  
The assay plates are read on a TopCount scintillation counter. 
 
In order to obtain IC50 values, eight different concentrations of inhibitor were used in a 
range surrounding the expected value. The recorded counts for TopCount are then 
transferred to the program ActivityBase which calculates the mean positive and negative 
counts per minute (cpm) from columns 11 and 12.  The percentage inhibition is 
calculated using the following equation: 
 
% Inhibition = 100 – [ (cpm of well – mean -ve cpm)/ mean +ve cpm –                          
mean –ve cpm) × 100 ]  
 
Percentage inhibition can then be plotted against enzyme concentration and the IC50 of 
the inhibitor can be calculated. 
 
3.3 PARP-2 Assay 
 
To date, there are very few assays of PARP-2 activity reported in the literature.  Perkins 
et al.
121 developed a novel cell based screen in yeast.  The assay relies on the fact that 
PARP-2 enzymatic activity causes growth inhibition in the organism; therefore reversal 
of this effect is a measure of PARP-2 inhibitory activity. 
 
KuDOS Pharmaceuticals Ltd. evaluated the compounds for inhibition of PARP-2 
catalytic using their ELISA based assay, developed in-house. The principles of the assay 
are as follows. 96-Well plates (Fisher Scientific) are coated with rabbit anti-PARP-2 
polyclonal antibody (Abcam Nunc-Immuno MaxiSorp) to which murine PARP-2 (Alexis 
Biochemicals) is bound. Column 11 of the plates is a positive control containing no test 
inhibitor and column 12 is a negative control containing no PARP-2 protein. Following 
incubation with test inhibitors, the plates are washed and scintillation fluid is added; they 
can then be read on a TopCount scintillation counter.  
 
The mean counts per minute (cpm) for all wells can then be obtained using the program 
ActivityBase.  From these values, percentage inhibition can be calculated using the 
following equation:  
 
% Inhibition = 100 – [ (cpm of well – mean -ve cpm)/ mean +ve cpm –                          
mean –ve cpm) x 100 ]  
 Percentage inhibition can then be plotted against enzyme concentration and the IC50 of 




3.4 5-Substituted Isoquinolinones 
 
The initial synthetic targets were the secondary amines with the general structure 25 
which could be feasibly synthesised from 5-AIQ and suitable two- or three-carbon 
electrophiles carrying a (masked) ω-carboxylic acid.  It was envisaged that alkylations at 
the nucleophilic amino group would proceed smoothly and this was the case when a weak 
base was used in combination with ethylbromoacetate.   
 
3.4.1 Synthesis of 5-AIQ 
 
Three different routes to 5-AIQ have been reported in the literature.  Wenkert at al.130 
first reported the synthesis of 5-AIQ in 1964. This route starts from the complete 
isoquinoline core already carrying a nitrogen substituent at the 5- position and is simply a 
series of adjustments of the oxidation levels. Commercially available 50 was N-oxidised 
to 51 in good yield. Polonowski rearrangement of this N-oxide with acetic anhydride 
















Scheme 3. Reported synthesis of 5-AIQ via Polonowski rearrangement of 51. (i) AcOH, H2O2; (ii) Ac2O, 
heat; (iii) Pd/C, H2. 
 
In our laboratory, the rearrangement step has been found to be low yielding and 
unreliable131 and this led us to examine other routes. 
 
An alternative novel synthesis was recently developed by Woon et al.132 In this route, the 
3-carbon and the ring-nitrogen are introduced as nucleophilic cyanide. Radical 
bromination of the Ar-Me group of the ester 52 led to the mono-brominated product 53.  
Nucleophilic displacement of bromide with cyanide gave the nitrile 54. Interestingly, this 
step could only be achieved with the expensive tetraethylammonium cyanide but not with 
simple alkali metal cyanides, even in the presence of phase-transfer catalysts. Selective 
reduction of 54 with DIBAL-H at -78°C furnished the imine, which cyclised in situ to the 
key intermediate 38. This was again converted to 5-AIQ by reduction of the nitro group.  
Unfortunately the yields of the displacement and reductive cyclisation steps were low, 

















Scheme 4. Synthesis of 5-nitroisoquinolin-1-one via radical bromination of 52. (i) Br2, (PhCO2)2, CCl4, hv, 
reflux; (ii) Et4NCN, MeCN; (iii) DIBAL-H. 
 
The final route reported55 also involved introduction of the 3-carbon. This was achieved 
through formation of the enamine 55 via condensation of 52 with dimethylformamide 
dimethyl acetal (DMFDMA).  Immediate passage of the crude reaction mixture of 55 
down a silica gel chromatography column provided enough acidity to protonate the basic 
enamine nitrogen, catalysing the hydrolysis of 55 to an intermediate aldehyde. The enol 
form of this aldehyde cyclised in situ. This cyclisation meant that 5-nitroisocoumarin 56 














Scheme 5. Synthesis of 5-nitroisocoumarin via enamine formation. (i) DMFDMA, DMF, reflux; (ii) SiO2. 
 
 
Saturation of a solution of 56 in 2-methoxyethanol with ammonia and boiling under 
reflux, followed by palladium-catalysed hydrogenation of the nitro group yielded 5 in an 
overall yield of 17%.  Although this yield was not ideal, it was nearly double that of the 
only other reliable published synthesis (via radical bromination of 52) and could be 
performed on scales of up to 8 g.  This method was therefore chosen to obtain starting 
























Scheme 6. Preferred route to 5-AIQ. (i) MeOH, H+, reflux, 84%; (ii) DMFDMA, DMF, reflux, SiO2, 42%; 
(iii) NH3, 2-methoxyethanol, reflux, 71%; (iv) H2, 10% Pd/C, EtOH, H





3.4.2 Alkylations of 5-AIQ 
 
The one-carbon CH2 tether was introduced by alkylating the exocyclic amino-nitrogen of 
5-AIQ with ethyl bromoacetate, using N,N-diisopropylethylamine as base.  The function 
of the base was to free the amine from its salt; as a weak base was chosen, lactam proton 
abstraction would not occur.  The yield obtained for this step to form 58 was somewhat 
disappointing (19%) but, as only a small amount of compound was required for 
biological testing, the reaction conditions were not optimised. Hydrolysis with aqueous 
hydrochloric acid gave the first target 59 as the hydrochloride salt in good yield in a final 
convenient step. An attempt to grow crystals of 59, in order to confirm its structure by X-
ray crystallography, resulted in formation of the methyl ester due to the use of methanol 















Scheme 7. Synthesis of 59 via an alkylation of 5-AIQ. (i) diisopropylethylamine, ethyl bromoacetate, 19%; 
(ii) aq. HCl, 87%. 
 
 
In order to attach a two-carbon tether, it was assumed the amino group of 5-AIQ would 
act as a Michael donor when reacted with the Michael acceptor, methyl propenoate.  
Sodium hydride was used to catalyse the reaction and, upon initial inspection of the NMR 
spectrum of 60, it was assumed the desired ester 61 had been formed in 67% yield.  Some 
doubt was cast upon this assumption by the chemical shift of the protons adjacent to the 
amine nitrogen, at 4.09ppm.  This value appears somewhat downfield for -CH2NAr 
protons and would be more appropriate for protons adjacent to a lactam.  It was feasible 
that the strong base, sodium hydride had removed the lactam proton in addition to 
forming the free amine at the 5-position.  The resultant anion would be more nucleophilic 
than the aromatic amino group and, therefore, more likely to react with methyl 
propenoate forming methyl 3-(5-amino-1-oxoisoquinolin-2(1H)-yl)propanoate 60 rather 
than the expected ester 61.  Upon acid-hydrolysis, the resultant carboxylic acid 62 was 
subject to analysis using Heteronuclear Multiple Quantum Correlation (HMQC) and 
Heteronuclear Multiple Bond Connectivity (HMBC) NMR experiments. HMQC 
experiments show strong proton-carbon couplings and therefore which protons are 
directly connected to particular carbons.  HMBC experiments inform about weaker 
proton-carbon couplings and therefore which protons are separated from the carbons in 
question by two to three bonds. The partial HMBC spectrum of 62 is shown below, along 
with assignments (full assignment of 62 can be found in the experimental section). Two 
key lines of evidence for the proposed structure are strong three-bond HMBC couplings 
between the 1-C and the NCH2 alkyl protons and also between the 3-C and the same 
protons.  If the alkylation had taken place at the 5-amino position, these protons would be 
























Figure 26. Partial HMBC spectrum of 62.  
 
 
Therefore, treatment of 5-AIQ with sodium hydride and methyl propenoate did not give 
























Scheme 8. Attempted synthesis of 60 which gave 61, hydrolysis yielded 62. (i) NaH, methyl propenoate 
67%; (ii) aq. HCl, 85%. 
 
3.4.3 Synthesis and Heck reaction of 5-iodoisoquinolin-1-one 
 
The next targets were the acids 28, 63 and 27, with the carboxylic acid or carbon tether 














Figure 27. The carboxylic acid targets 28, 63 and 27. 
 
To attach a two-carbon tether directly to the aromatic ring, it was planned to use 
palladium-catalysed chemistry and the Heck reaction of either 5-bromoisoquinolin-1-one 
64 or 5-iodoisoquinolin-1-one 65.  Initially discovered in the 1970s, the Heck reaction 
was independently reported by both Heck133and Mizoroki134 and involves the 
palladium(0)-catalysed arylation or alkenylation of alkenes by aryl or alkenyl halides (or 
pseudo-halides) in the presence of base.  The mechanism of the Heck reaction is not fully 
understood but is best represented by a catalytic cycle; the reaction involves four key 
steps. 
 
• Oxidative addition 
• Migratory insertion (carbopalladation) 
• β−hydride elimination 
• Reductive elimination 
 
Before the Heck reaction could be attempted, the starting aryl halide was required and 
this was either 5-bromoisoquinolin-1-one 64 or 5-iodoisoquinolin-1-one 65. Berry et 
al.
135 reported the synthesis of 5-bromoisoquinoline via a one-pot Curtius rearrangement 
of 3-(2-bromophenyl)propenoyl azide and trans→cis isomerism and cyclisation of the 
intermediate isocyanate at high temperature. The starting acyl azide was prepared in two 
steps from 2-bromoiodobenzene 69, using an iodine-selective Heck coupling reaction 
described by Plevyak et al.136 but using propanenitrile rather than acetonitrile as solvent; 
the higher boiling solvent allowed the avoidance of the use of a sealed tube to perform 
the reaction at 100oC to form E-2’-bromocinnamic acid 70. This was readily converted to 
the acyl chloride 71 by reaction with thionyl chloride. The acyl azide 72 was formed by 
reaction with sodium azide in water. However, the thermal Curtius rearrangement / 
isomerisation / cyclisation in tetraglyme proved troublesome, with little or none of the 
desired isoquinolin-1-one 64 formed (by TLC and/or MS analysis). In contrast to Curtius 
reactions which usually occur at <120oC,137, 138 trans→cis isomerisms require much 
higher temperatures to take place. The difficulties encountered in this synthesis of 64 
were therefore probably due to problems maintaining the very high temperature (260oC) 
required for the isomerisation / cyclisation step to occur. Similar attempts to cyclise 3-(2-




















Scheme 9. Attempted synthesis of 5-iodoisoquinolin-1-one via Curtius rearrangement of 72. (i) EtCN, 
Pd(OAc)2, propenoic acid, Et3N; (ii) SOCl2; (iii) NaN3, H2O; (iv) Heat, (MeOCH2CH2OCH2CH2)2O. 
 
An alternative approach was therefore investigated. The preferred starting material was 
the 5-iodo compound 65 as iodine is a better leaving group than bromine therefore aryl 
iodides tend to perform better in palladium-catalysed couplings. It was envisaged that the 
5-iodo function could be introduced via diazotisation of the amino group in 5-
aminoisocoumarin 74 or 5-aminoisoquinolin-1-one 5, followed by displacement with 
iodide ion. The isocoumarin 56 was made as usual and palladium-catalysed reduction of 
the nitro group furnished the corresponding amine. Close monitoring of this reaction by 
TLC was essential, as a slower reduction of the 3,4-double bond was also possible under 
the conditions. The diazotisation step was achieved with sodium nitrite and hydrochloric 
acid in water and subsequent nucleophilic displacement with potassium iodide (KI) gave 
5-iodoisocoumarin 75 in moderate yield. The established procedure (a number of 
alternatives are reported in the literature but this is by far the most straightforward and 
efficient) of saturation with ammonia and reflux in 2-methoxyethanol was used to convert 
75 to the isoquinolin-1-one 65.     
 
The method of Watson et al.131 was then employed for the Heck reaction, using 
propanenitrile as solvent, triethylamine as base and palladium(II) acetate as catalyst or, 
more accurately, precatalyst. This gave 26 in excellent yield and palladium-catalysed 
hydrogenation of the alkene, in methanol, also went smoothly to form the target 




























Scheme 10.  Synthesis of the targets 27 and 26 via Heck reaction of 5-iodoisoquinolin-1-one. (i) Pd/C, H2, 
89%; (ii) NaNO2, HCl, KI, 58%; (iii) NH3, 2-methoxyethanol, 62%; (iv) Propenoic acid, Et3N, Pd(II) 
acetate, 97%; (v) Pd/C, H2, 66%.    
 
3.4.4 Synthesis of 1-Oxo-1,2-dihydroisoquinoline-5-carboxylic acid 
 
1-Oxo-1,2-dihydroisoquinoline-5-carboxylic acid 28 is a known compound and is 
accessible by hydrolysis of 5-cyanoisoquinolin-1-one 76.131 Compound 76 was originally 
synthesised in low yield by Wenkert et al.130 by condensation of 2,6-dicyanotoluene 41 
with ethyl formate under basic conditions, then acidic workup.  When this procedure was 













41 76 77  
 Scheme 11.  Synthesis of 1-oxoisoquinoline-5-carboxylic acid 28. (i) KOBut, ethyl formate, 76 14%, 77 
13%; (ii) KOH, EtOH, 83%. 
 
An alternative synthetic method was developed by Watson et al.131 and this method was 
also followed. Thus, the enamine 78 was formed, following condensation of 2,6-
dicyanotoluene 41 with DMFDMA, as originally reported by Ponticello and Baldwin.139 










41 78 76  
 
Scheme 12.  Synthesis of 5-cyanoisoquinolin-1-one 76 via Pinner-type reaction of 41. (i) DMFDMA, 3 d, 
71%; (ii) MeOH, HCl, 55%.  
 
 
The Pinner reaction140 involves the treatment of nitriles e.g. 79 with anhydrous 
hydrochloric acid in the presence of alcohols resulting in a condensation to form imino 
ether hydrochloride salts 80.  These salts are unstable and there are a number of possible 
products depending upon the workup conditions, for example treatment with weak base 
would result in the formation of the imino ether 81 whereas using aqueous acid would 




















Scheme 13. General outcomes of the Pinner reation . 
 
 
The planned Pinner-type reaction of the enamine 78 involved treatment of the starting 
material, in an excess of anhydrous methanol, with dry hydrogen chloride gas followed 
by aqueous workup.  If the reaction was to follow a typical Pinner pathway, the formation 
of one or two products could be expected, depending on whether one or two of the cyano 
groups was converted to the methyl ester.  If a single cyano group reacted, one would 
expect the intermediate ester 84 to cyclise to form 5-cyanoisocoumarin 77.  Therfore, 
conversion of both cyano groups would give the intermediate ester 85 which would lead 















































Scheme 14. Expected pathways when 78 is subjected to Pinner conditions. 
 
However, Watson et al.131 reported that the only isolable product from Pinner reaction of 
78 was 5-cyanoisoquinolin-1-one 76.  The formation of this product could be rationalised 
by an intramolecular attack of the nitrogen lone pair of the imino ether on to the dimethyl 
iminium ion in 87, which could be formed by protonation and rearrangement of 88. The 
loss of dimethylamine from 89 would give 76.  This would take place in anhydrous 




























Scheme 15.  Proposed mechanism for the formation of 76 from 78. 
 
The overall yield of this second route was much better than the previous synthesis but a 
major disadvantage was the prolonged reaction times (>3 d) required to form the 
enamine. As only a small amount of 28 was needed for biological evaluation, the 
prolonged reaction times required to form the enamine in the second route were avoided 
and Wenkert’s more expedient but less efficient synthesis was chosen. With 76 in hand, 
the last remaining step was hydrolysis of the cyano group. The published vigorous base-
catalysed hydrolysis gave the target compound 28 in good yield.     
 
3.4.5 Novel synthesis of 5-bromoisoquinolin-1-one 64 
 
Several methods were considered in order to introduce a single CH2 unit, followed by a 
carboxylic acid, to the isoquinolin-1-one core. All the approaches relied upon the use of a 
5-haloisocoumarin or 5-haloisoquinolin-1-one as starting material. A more efficient route 
to these compounds was required, as the current multistep approach was low yielding 
(16% overall yield from the starting 2-methyl-3-nitrobenzioc acid) and time consuming.   
 
 
Isoquinolin-1-ones could be accessed by hydrolysis of 1-chloroisoquinolines; there are 
examples of such conversions (or similar) in the literature.141-143 Therefore, 5-bromo-1-
chloroisoquinoline is a simple functional group interconversion (FGI) away from the 
required 5-bromoisoquinolin-1-one 64 and the aim was to synthesise this precursor. The 
key step in a short synthesis would be the installation of bromine in the 5-position of the 
isoquinoline core. Gordon and Pearson144 reported that isoquinoline could be brominated 
selectively in the 5-position using a technique they termed the “swamping catalyst 
method” in which gaseous bromine was added to a mixture of molten aluminium chloride 
and isoquinoline over a sintered condenser.  Some years later, Braye et al.145 used the 
same technique to brominate the commercially available 1-chloroisoquinoline 90 
selectively in the 5-position to give 91 which was exactly the conversion required in the 
present work.  This chemistry was found to be both high yielding (ca. 65%) and 
reproducible, with the added bonus of avoiding column chromatography. As predicted, 
conversion to 5-bromoisoquinolin-1-one was straightforward and was achieved in a 
mixture of acetic acid and water at 100oC.  This new route to 64 required fewer steps and 













Scheme 16.  New, higher-yielding synthesis of 5-bromoisoquinolin-1-one 64. (i) Br2, 65%; (ii) AcOH/H2O, 
70%. 
 
3.4.6 Attempted synthesis of 2-(1-oxo-1,2-dihydroisoquinolin-5-yl)acetic acid 63 
 
The next step was to attempt direct attachment of a CH2CO2Et unit at the 5-position of 
the isoquinolin-1-one and the first approach was a palladium-catalysed coupling reaction 
of 5-bromoisoquinolin-1-one 64 and the enolate of ethyl acetoacetate 92 in the presence 



















Scheme 17.  Attempted synthesis of the ester 93 via palladium-catalysed coupling of 64 and ethyl 
acetoacetate. (i) Pd(OAc)2, P
tBu3, K3PO4, toluene. 
 
 
Paluki and Buchwald developed this type of chemistry and originally reported the 
palladium(II) catalysed α-arylation of ketones in 1997146 using aryl halides and ketones 
in the presence of base, catalyst and ligand. The authors suggested that the reaction 
proceeded by the in situ generation of palladium as the coordinatively unsaturated and 
reactive 14 electron oxidation state (usually coordinated to two ligands but represented as 
Pd(0)Ln) and oxidative addition with the aryl halide.  Substitution of the halide with the 
enolate of the ketone and reductive elimination would furnish the α-aryl ketone and 
regenerate the catalyst. The authors were keen to extend this protocol to esters, as many 
important drug molecules (e.g. Non-Steroidal Anti-Inflammatory drugs (NSAIDs)) are 
derivatives of α-aryl esters.  The same group reported the successful palladium-catalysed 
α-arylation of esters in 2001,147 which, in the case of the more readily enolised β-keto 
esters, were deacylated under the reaction conditions. Unfortunately, the protocol could 
not be extended to 5-haloisoquinolin-1-ones and, despite prolonged efforts with a range 
of reaction conditions including variation of solvent, catalyst, ligand and base,148 only 
starting material was recovered from the reaction mixture. Seeking an explanation for this 
unexpected lack of reactivity, it was speculated that the use of 5-haloisoquinolin-1-ones 
was perhaps an issue, as these compounds have limited solubility in many organic 
solvents and can also co-ordinate to palladium, possibly diminishing the catalytic activity 
of the metal. The reaction was therefore repeated using the isocoumarin 75 but again only 
starting material was recovered. Finally, the catalyst was varied, switching to a copper(I) 








64 R = NH X = Br
75 R = O X = I








Özdemir et al.150 have reported the successful synthesis of arylacetic acid derivatives 
from diethyl malonate 95 and various aryl halides catalysed by a palladium(1,3-
dialkylimidazolidin-2-ylidene) species formed in situ.  The group noted that the 
arylations in their study generally required milder reaction conditions than had previously 
been reported.151 In the present work, this reaction was investigated using the starting 5-
bromoisoquinolin-1-one 64 or 5-iodoisocoumarin 75 under a variety of conditions but the 
only isolable products were the starting aryl halide with traces of dehalogenated starting 
materials. The formation of the latter indicates that there is some formation of the aryl-Pd 
species but that this fails to react with the enolate. 
 
The earlier success of the Heck reaction led us back to more conventional palladium-
catalysed chemistry and the Stille reaction. In 1978, Kerdesky and Stille152 first used 
palladium-catalysed reactions of organotin compounds and acid chlorides to synthesise 
ketones. Stille developed this chemistry153, 154 and the Pd(0)-catalysed coupling of an 
alkyl, aryl or alkenyl halide and an organostannane is now known as the Stille cross-
coupling.  It was planned to couple allyltributylstannane with 75, anticipating the 
formation of 96, as allyl groups are known to be transmetallated selectively from 
allyltrialkylstannanes in preference to the alkyl groups. This approach introduces a three-
carbon unit but the terminal carbon could be cleaved oxidatively by ozonolysis (or 
osmium tetroxide / sodium periodate), followed by oxidation of the intermediate 
aldehyde 97 to give 98.  The Stille reaction gave a complex mixture of products and mass 
spectrometric analysis showed that none of the desired 5-allylisocoumarin had been 



















Scheme 19.  Proposed synthesis of 98 via Stille reaction to form 96. (i) Pd2(dba)3, SPhos, trimethylallyl tin, 
toluene; (ii) O3; (iii) PCC. 
 
 
As none of these approaches were successful, the synthetic efforts were paused in favour 
of obtaining biological data to guide future synthesis. The benchmark inhibitor 5-AIQ 
was tested to serve as a reference point for potency and selectivity.   
 
3.4.8 Initial SAR of 5-substituted isoquinolin-1-ones 
 
Ideally, compounds would be tested using the same assay for each PARP isoform but 
Kudos were unable to extend the protocol used in their Flashplate PARP-1 assay to 
PARP-2. The initial IC50 values of the early targets, obtained using the assays developed 





Table 1. Inhibition of the activities of PARP-1 and PARP-2 by 5- and 2-(ω-carboxyalkyl)isoquinolin-1-
ones; data for 5-AIQ 5  are shown for comparison. 
Cpd. 
No. 













































8.45 2.96 2.85 
 
 
As expected, 5-AIQ did not discriminate between the two PARP isoforms to a significant 
extent and had an IC50 of ca. 1 µM for each. The secondary amine 59 was slightly PARP-
2 selective (2.85 fold) whilst remaining moderately potent for each isoform.  When the 
amine function is replaced with a CH2 in 27, activity against both isoforms is reduced by 
approximately 6-fold. A possible explanation for this reduction in potency is that the 
amine NH in 59 forms favourable contacts with residues in the active sites of both 
isoforms and these are lost in 27. Interestingly, it has been proposed that a water-
mediated hydrogen bond between the amino group of 5-AIQ and the Glu988 carboxylate 
contributes to the increased potency of the inhibitor.155 The more rigid alkene 26 showed 
a minor increase in potency for PARP-1 and was slightly less potent towards PARP-2 
than its saturated counterpart.  However the differences observed are too small to suggest 
that free rotation about the alkane plays a significant role in activity against either 
isoform.    
 
The propanioc acid 62 retained activity for both isoforms and was slightly PARP-1 
selective. In fact, 62 was the most potent PARP-1 inhibitor of the series evaluated.  This 
result was somewhat unexpected given that the vast majority of SAR studies with PARP-
1 inhibitors show that one amide proton is absolutely required, in order that the three key 
hydrogen bonds with Gly863 and Ser904 in the PARP-1 catalytic site are formed.  It is 
feasible that 62 could bind to the active sites of PARP-1 (and -2) in two different ways.  
/Firstly, the amide carbonyl could form two hydrogen bonds, one with the Gly863 NH 
and a second with the Ser904, in the traditional way.  The third contact could be achieved 
thanks to the flexibility of the propanoic acid side chain, with the carboxylic acid 
hydroxy replacing the amide hydrogen. However it is likely that the acid would be 


























Figure 28. Possible binding modes of 62 in the PARP-1 active site. 
 
 
Alternatively, the compound could fit into the PARP-1 active site in a different manner. 
The carboxylate carbonyl could form two hydrogen bonds with Gly863 and Ser904 and 
an amine proton could participate in the final bond.  These two possible binding modes 
are shown in Figure 28. 
 Interestingly, Eltze et. al.156 have recently reported a selection of imidazoquinolinone, 
imidazopyridine and isoquinolindione compounds which lack an amide NH but possess 
other binding motifs. Many of these were potent PARP-1/2 inhibitors.   
 
It was surprising that the carboxylic acid 28 showed an apparent lack of activity as 
Watson et al.131 had shown this compound was a moderately potent PARP inhibitor, 
inhibiting PARP activity by 79% at a concentration of 13.2 µM, in comparison with a 
control. This result illustrates that caution must be exercised when comparing compounds 
tested in different assays as very different results can be obtained. 
 
3.4.9 Further modifications at the 5-position of 5-AIQ 
 
The modest selectivity and potency of the initial targets led us to consider other 
modifications at the 5-position of 5-AIQ. Interestingly, while these modifications were 
being considered, Pellicciari et al.157 published a paper reporting the synthesis and 
biological evaluation of a series of 5-benzoyloxyisoquinolin-1-ones and also some 
saturated (i.e. 3,4-dihydro) analogues. Initially, the group screened the compounds at a 
concentration of 10 µM against bovine PARP-1 and murine PARP-2 and calculated 
percentage activity, compared to control. The more promising compounds (in terms of 
apparent selectivity) were taken forward for further biological characterisation. The 
methods developed by Banasik et al.107 were then used to assay the compounds, again 
using bovine PARP-1 and murine PARP-2. Thus PARP activity was assessed by 
measuring the radioactivity of [3H]adenosine-NAD+ incorporated into acid insoluble 
material, following the PARP reaction. The group reported that 5-benzoyloxyisoquinolin-
1-one 99 showed a 60-fold selectivity for PARP-2 over PARP-1 using this assay. In 
addition, 99 and the potent PARP-1 (and 2) inhibitor PJ34 100 were tested in whole cells 
using fibroblasts derived from PARP-1 knockout mice or wild-type controls.  The vast 
majority of the PARP-catalytic activity in the PARP-1-/- cells would be due to PARP-2, 
whereas, in the wild-type cells, PARP-1 would account for 85-90% and PARP-2 10-15%.  
It was shown that PJ34 caused a 76% drop in PARP(1 + 2) activity (when compared with 
control) in the wild-type cells whereas 99 only caused a 9% drop. In the PARP-1-/- cells, 
PJ34 100 caused a 76% reduction in PARP(-2) activity whilst treatment with 99 resulted 
in a  90% drop.  The authors claim that these data show PJ34 inhibits PARPs 1 and 2 but 

















Figure 29. The PARP-2 selective ester 99 and proposed amide 101, and the unselective PJ34 100 
 
A potential problem with use of the the Pellicciari compound 99 is the presence of a 
phenyl ester group, which one would expect to be easily hydrolysed under physiological 
conditions, therefore limiting its usefulness in in vivo experiments.  With this in mind, it 
was planned to synthesise a series of benzamides, with the general structure shown in 
Scheme 20, in which the tethering amide bond would be much more stable in vivo than 
the isosteric ester in Pellicciari’s series.    
 
In order to generate the series, 5-AIQ was treated with various commercially available 
acid chlorides using pyridine as solvent. The functions of the pyridine were twofold, 
firstly to act as a base to quench the HCl formed in the reaction and secondly to act a 
nucleophilic catalyst, activating the acid chloride. In general, the acylations worked well 
and the isolation of products was achieved by evaporation of solvent and 





















Scheme 20.  Acylation of 5-AIQ with various acid chlorides. (i) Pyridine, 90°C, 16 h, 55-86%. 
 
3.4.10 Further SAR of 5-substituted isoquinolin-1-ones 
 
Table 2 shows the relevant yields and IC50 values of the compounds in this series.  
Additionally, the IC50 values of Pellicciari’s
157 compound 99 and the quinoxaline 22 
(claimed by Iwashita et al122 to be 5-fold selective for PARP-2) obtained in the assays are 
shown as small amounts were available to us for testing. Before comparing the results 
obtained in this study with other studies, it should be noted that the species from which 
the enzymes are isolated from or accessed by recombinant DNA technology, may vary. 
Pellicciari compared bovine PARP-1 with murine PARP-2, Iwashita did not disclose the 




Table 2. Inhibition of the activities of PARP-1 and PARP-2 by 5-amidoisoquinolin-1-ones; data for 5-AIQ 





















- 0.94 1.05 0.89 - 
101 PhCONH- 86% 13.9 1.5 9.3 - 
102 4-
BrPhCONH 
81% 33.2 25 1.3  
103 4-Me-
PhCONH- 
82% 13.4 6.5 2.1 - 
104 4-I-
PhCONH- 
76% 7.6 1.3 5.8 - 
105 4-O2N-
PhCONH- 
71% 3.0 1.6 1.9 - 
106 4-F3C-
PhCONH- 
72% 10.7 3.3 3.2 - 
107 4-F-
PhCONH- 





11.2 3.9 2.9 - 
109 2-I-
PhCONH- 
61% 4.5 3.2 1.4 - 
110 2-Me-
PhCONH- 
63% 31.6 5.6 5.6 - 
111 (thiophen-3-
yl)CONH- 
61% 22.4 7.0 3.2 - 
112 cHex-
CONH- 
68% >80 27.9 >2.9 - 




59% >50 19.9 >2.5 - 





 0.03 0.09 0.33 4.71122 
 
In general, better yields were achieved with aromatic (61-86%) over aliphatic acid 
chlorides (59-69%).  Substitution of the aromatic ring led to lower yields. Electron-
neutral substituents in the para-position were better tolerated than electron-withdrawing 
groups and, as expected, ortho-substitution caused a significant reduction in yield.   
 
In terms of selectivity, the most promising compound was N-(1-oxo-1,2-dihydro-
isoquinolin-5-yl)benzamide 101, which was 9.3-fold selective for PARP-2 over PARP-1.  
Substitution of the benzene ring in the acyl group generally reduced potency towards 
both isoforms but the effect on PARP-2 activity was generally more pronounced, so the 
compounds became less selective. However, the most potent inhibitor of PARP-2 was 4-
iodo-N-(1-oxo-1,2-dihydroisoquinolin-5-yl)benzamide 104 with an IC50 value of 1.3 µM; 
unfortunately, this compound also showed an increased potency towards PARP-1 and as 
a consequence, was only 5.8-fold selective. A bulkier electron-withdrawing group 
increased potency towards PARP-1, as illustrated by 106 (IC50 = 10.7 µM) and the most 
potent PARP-1 inhibitor 105 (IC50 = 3.0 µM); PARP-2 activity was only moderately 
affected.  A smaller electron-withdrawing group decreased PARP-1 activity and 4-fluoro-
N-(1-oxo-1,2-dihydroisoquinolin-5-yl)benzamide 107 had an IC50 value of 18.0 µM. 
Switching to the corresponding thiophene-2-carboxamide 111 led to a ca. 2-fold drop in 
PARP-1 activity but a ca. 5-fold drop in PARP-2 activity and therefore a drop in 
selectivity.  The alkyl carboxamides 112 and 113 suffered from a dramatic loss in PARP-
1/2 activity but again the effect was more pronounced for PARP-2 so the compounds 
became less selective for this isoform. The same was true for 114 which was synthesised 
to test the effect of steric bulk with aromaticity.  
 
With these promising data in hand, the next stage in the research would be the synthesis 
of a series of 3- and 4-subsituted isoquinolin-1-ones and evaluation of these molecules as 
inhibitors of PARP-1/2. The purpose of the preparation of these compound sets would be 
to test if structural modifications in the 3- and 4- positions had a similar impact on PARP-
1/2 inhibitory activity, as modifications in the 5-position. It was hoped that a bulky 
subsitituent in one of these positions would lead to an increased inhibitory potency 
against PARP-2 over PARP-1, owing to the larger hydrophobic-binding pocket (in 
conparrison with PARP-1) in this isoform. 
 
3.5 3-Substituted isoquinolin-1-ones 
 
The strategy to synthesise the series of 3-substituted isoquinolin-1-ones was to follow 








33 R = H
115 R = Cl
116 R = CF3
117 R = OMe
118 R = Me
119 R = Me
120 R = Et
121 R = Pentyl
 
 
Figure 30.  Target 3-aryl and 3-alkylisoquinolin-1-ones. 
 
The first eight compounds required were the 3-arylisoquinolin-1-ones 33 and 115-118 
and the 3-alkylisoquinolin-1-ones 119, 120 and 121. Three of these examples were 
chosen to test the effect of varying alkyl chain length (119-121) on PARP inhibitory 
activity. The other five molecules were designed to test the effect of varying the 
electronics of the 3-phenyl ring: 117 is highly electron-rich, 118 is electron-rich to a 
lesser extent, 116 is electron-deficient and 33 and 115 are electron neutral. 
 
There are currently a number of routes to 3-arylisoquinolin-1-ones in the literature 
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Scheme 21. Hg2+-catalysed cyclisation of methyl 3-nitro-2-phenylethynylbenzoate 30 to give 5-nitro-3-
phenylisocoumarin 31 which can be converted into the corresponding isoquinolin-1-one 32 by reaction 
with ammonia. (i) (Ph3P)PdCl2, CuI, ethynylbenzene; (ii) HgSO4, H2SO4, acetone; (ii) 2-methozyethanol, 
NH3; (iv) Pd/C, H2. 
Other routes include Hurtley reaction of 2-bromo-3-nitrobenzoic acid 34 with β-



























31 R = H






Scheme 22. Hurtley reation of 2-bromo-3-nitrobenzoic acid with β-diketones (left to right) and reaction of 
methyl 2-iodo-3-nitrobenzoate with arylethynes under Castro-Stevens conditions (right to left), to give 3-
aryl-5-nitroisocoumarins, precursors to isoquinolin-1-ones. (i) NaOEt, Cu; (ii) Pyridine, heat; (iii) 2-
methoxyethanol, NH3; (iv) Pd/C, H2. 
 
The mercury catalysed cyclisation could only be applied to methyl 3-nitro-2-phenyl-
ethynylbenzoate and not other arylethynes; this meant it was only useful for the synthesis 
of 5-nitro-3-phenylisocoumarin 31. The second literature route was limited to phenyl, 4-
methylphenyl and 4-methoxyphenyl arylethynes and therefore the corresponding 3-
arylisocoumarins. Far more versatile was the final route utilising the Hurtley reaction, as 
a range of 3-aryl and 3-alkylisocoumarins could be accessed and this pathway was 







3.5.1 Hurtley reaction 
 
Hurtley159 first reported the condensation of 2-bromobenzoic acid 122 with a range of β-
diketones with either copper (II) acetate or copper powder as catalyst and in the presence 
of ethanolic sodium ethoxide. Further investigations by Cirrigotis et al.160 showed that the 
carboxylic acid was essential and switching to analogues such as esters caused the 
reaction to fail.  The group also showed that the reaction proceeded with 2-iodobenzoic- 
acid, albeit in much lower yield and that a source of copper was essential. Two years 
later, Ames et al.161 reported the formation of the isocoumarin 123 by Hurtley coupling of 
2-bromo-3-nitrobenzoic acid 34 with pentane-2,4-dione 124, followed by deacylation of 












34 R = NO2
122 R = H
124
123 R = NO2125 R = NO2
 
 
Scheme 23.  Formation of 3-arylisocoumarins by Hurtley reaction of 34 or 122, followed by deacylation. (i) 
Cu, KOBut, 2-methylpropan-2-ol; (ii) NaCl, 170°C. 
 
The work of Woon162 significantly extended the scope of the use of the Hurtley reaction 
to form 5-nitro-3-substituted isocoumarins from 2-bromo-3-nitrobenzioic acid and β-
diketones.  The main findings of the research are summarised below. 
 
• It was possible to form 5-nitro-3-substituted isocoumarins in a single step using 
Hurtley’s original conditions but β-diketone cleavage side products were also 
formed.  
• The use of a potassium t-butoxide/t-butanol system abolished the formation of β-
diketone cleavage side products. 
• Copper powder was an effective catalyst. 
• The use of unsymmetrical β-diketones lead to the formation of two products. 
 
As quantities of 33, 117, 120 and 121 were available from a previous project, these 
compounds were evaluated directly. In the meantime, the method of Woon162 was 
followed in synthesising 2-bromo-3-nitrobenzoic acid and the β-diketones required as 
starting materials for the Hurtley reaction. The ortho-bromo acid 34 was prepared from 3-
nitrophthalic acid 126 in good yield (74%) by regioselective mercuration / 
















Scheme 24.  Synthesis of 34 by mercuration followed by bromination. (i) NaOH, Hg(OAc)2, AcOH, (ii) 
AcOH, Br2, NaBr, 74% (overall). 
 
Heptane-2,4-dione 124 was commercially available and the remaining β-diketones 128-
130 were synthesised by acylating the corresponding acetophenones 131-133 with acetic 








R131 R = Cl
132 R = CF3
133 R = Me
128 R = Cl
129 R = CF3
130 R = Me
128a R = Cl
129a R = CF3
130a R = Me
 
 
Scheme 25.  Synthesis of β-diketones via Claisen-condensation-type reactions. (i) BF3.(AcOH)2, 68-84% 
 
 
The desired products were obtained in moderate to good yields (68-84%) and in each 
case there was evidence of the presence of both the keto and enol form in the 1H NMR 
spectrum.  For example, the signals at δ 6.13 and 16.09 in the 1H NMR spectrum of 1-(4-
chlorophenyl)butane-1,3-dione 128 are characteristic of enol alkene and hydroxy protons 
respectively,  whereas the signal at δ 4.07 is due to the keto CH2 protons.   
 













Scheme 26. The different tautomers of 128 evidenced by 1H NMR. The intramolecular hydrogen bonds 
offer increased stability. 
 
The most prevalent tautomer was the enol form (generally >90%); this is unsurprising as 
intramolecular hydrogen bonding leads to the formation of a stable six membered ring in 
this form.   
 
With the starting materials in hand, the Hurtley reactions could be attempted. As 
expected, Hurtley reaction of the unsymmetrical β-diketones led to two products. The 
major product was the required 3-arylisocoumarin (e.g. 135) and was probably formed by 
deacetylation of the Hurtley intermediate (e.g. 136), whilst the minor product 3-methyl-5-





















Scheme 27. Two possible products are possible depending upon whether the Hurtley intermediate 136 
undergoes debenzoylation or decaylation. 
  
It is interesting that the 3-arylisocoumarin is the major product as electronically 
debenzoylation is favoured over deacylation due to the fact that benzoyl carbonyl carbons 
are less electrophillic than their acetyl counterparts. This suggests that steric effects 
dominate and the smaller acetyl group is preferentially lost. In line with the reported 
synthesis, the yields were low, ranging from 12% to 33%, but optimisation was not 





















135 R = Cl
137 R = CF3
138 R = Me
139 R = Cl
140 R = CF3
141 R = Me
115 R = Cl
116 R = CF3






Scheme 28.  Synthesis of 3-substituted isoquinolin-1-ones via Hurtley reaction. (i) Cu, KOBut, 2-
methylpropan-2-ol, 12-33%; (ii) NH3, 2-methoxyethanol, 24-80%; (iii) Pd/H2, HCl, 42-79%.   
 
With the synthesis of the 5-nitro-3-arylisocoumarins achieved, all that remained was to 
convert these to the corresponding isoquinoline-1-ones and then reduce the nitro function. 
These steps were achieved in good yields using the established procedures of saturation 
with ammonia and reflux in 2-methoxyethanol followed by palladium-catalysed 





3.5.2 Friedel-Crafts reaction 
Attention was then turned to the synthesis of 4-substituted isoquinolin-1-ones. It was 
rationalised that the most nucleophilic carbon of isoquinolin-1-ones is at the 4-position 









142 143  
Scheme 29.  Resonance forms of the lactams 142 and 143.  
The first strategy to exploit this electronic difference was electrophilic substitution via 
Friedel-Crafts alkylation or acylation. These reactions involve the Lewis-acid catalysed 
introduction of a keto or alkyl group on to an aromatic by reaction with an alkyl halide 
(or alkene) or acyl halide (or anhydride), respectively. The presence of the nucleophilic 
amino group on 5-AIQ meant it was not feasible to attempt Friedel-Crafts acylation 
reactions directly on this molecule as this would result in acylation of the amine. In 
addition the amine would act as an o-/p-directing group in the Friedel-Crafts alkylation, 
activating the carbocyclic ring and causing substitution in the 6- and 8-positions.  In order 
avoid this issue, 5-nitroisoquinolin-1-one 38 was chosen as the starting material; although 
the nitro group in this molecule is sterically larger than the amino function in 5-AIQ, 
possibly hindering substitution in the neighbouring 4-position, it deactivates the 




























Benzoyl chloride was chosen as both reactant and solvent; its high boiling point allowed 
that a range of temperatures could be studied and an excess of electrophile was unlikely 
to affect the path of the reaction. The strong Lewis acid, aluminium chloride (AlCl3) was 
used as a catalyst for the first series of experiments, which involved gradually increasing 
the temperature from room temperature until product was formed (as shown by TLC 
analysis). No reaction occurred until the temperature reached 150°C and a product 
significantly less polar than the starting material was formed in low yield after 3 days. 
Unfortunately, upon analysis by 1H and 13C NMR, this molecule was not the desired 4-
benzoyl-5-nitroisoquinolin-1-one but the N-substituted 2-benzoyl-5-nitroisoquinolin-1-
one 145, in low yield (26%).  It is likely that steric crowding at the 4-position led to the 
formation of this product.   
A Friedel-Crafts alkylation was attempted with benzyl chloride in nitrobenzene, again 
using AlCl3 as catalyst, but no reaction occurred even at temperatures up to 180°C. 

















Scheme 31.  Friedel-Crafts acylations of 38. (i) Ac2O, H
+, 36%; (ii) PhCOCl, AlCl3, 26%. 
 
For the next experiments, a less sterically demanding electrophile was chosen, formed 
from acetic anhydride under Brønsted acid-catalysis. A range of temperatures was again 
investigated. The desired product, 4-acetyl-5-nitroisoquinolin-1(2H)-one 146 formed at 
100°C and the reaction went to completion after 22 h. Interestingly, none of the N-sub-
stituted product was formed under these conditions, probably due to the change in 
catalyst from a Lewis to a Brønsted acid affecting the nucleophilicity at this position. A 
Lewis acid is likely to form a complex here whereas a Brønsted acid would simply 
protonate the attacking electrophile rendering it more reactive. The IR spectrum of 146 
was interesting in that the ketone carbonyl absorption 1761 cm-1 is unusually high for an 
aryl ketone.  The probable cause of this is that the ketone is forced out of plane and 
orthogonal to the isoquinolin-1-one by the peri nitro group. The resultant loss of 
conjugation would cause the change in IR absorption. Initial attempts to reduce the 
ketone with sodium borohydride resulted in a complex mixture. In a further attempt to 
introduce a benzoyl group to the 4-position, benzoic anhydride was used as the 
electrophile under Brønsted acid catalysis but no reaction occurred, even under forcing 
conditions. 
Following the failure of the attempts to benzoylate the 4-position of 38, focus was turned 
to the more reactive 5-nitroisocoumarin 56, as the switch to the lactone would prevent 
substitution occurring at the 2-position. Initially, 56 was treated with benzoyl chloride in 
a range of solvents, gradually increasing the temperature and using AlCl3 as catalyst. The 
reaction proceeded slowly (Table 3 entry B) at 100°C with nitromethane as solvent; a 
single product was formed in poor yield, as shown by TLC. Preliminary analysis of this 
product by 1H NMR showed the characteristic doublet, triplet, doublet coupling pattern of 
the 6-H, 7-H and 8-H of the isocoumarin and also the presence of a phenyl group, 
pointing to formation of the expected 4-benzoyl-5-nitroisocoumarin. However, further 
analysis by 13C NMR revealed that only one carbonyl group was present with a signal at 
δ 160.3, corresponding to the lactone carbonyl in isocoumarins. This observation was 
confirmed by IR, as only one carbonyl absorption at 1739 cm-1 was present in the IR 
spectrum of the product. The MS also showed the MW to be 28 Da lower than that of the 
intended product. Further characterisation of the product by HMBC and HMQC NMR 
experiments revealed the product to be 5-nitro-3-phenylisocoumarin 31 and this was 
confirmed by comparison of the NMR spectrum and melting point with an authentic 
sample and by co-elution by TLC.   
The chemistry of this new reaction was interesting and a series of experiments was 
designed to test the effects of solvent, Lewis acid and temperature on it.  A strong Lewis 
acid such as AlCl3 or SnCl4 (entries C and F) was essential and no reaction occurred with 
the weaker Lewis acids ZnCl2 and Zn(OTf)2 (entries H and I), even under forcing 
conditions for extended reaction times. The effect of temperature is compared in Entries 
C, D and E (100°C, 150°C and 180°C). The reaction rate was increased at 150°C; this 
temperature also gave the greatest yield (42%); increasing the temperature to 180°C led 
to a lower yield, probably owing to degradation of reactants or intermediates. 
The greatest yields and shortest reaction time were achieved with nitrobenzene as 
solvent. Comparison with use of nitromethane (Entries C and J) at 100°C suggested that 
the nature of the solvent had only a minor effect and the reaction temperature was 
paramount. However nitromethane and nitrobenzene are oxidising agents, so an 
experiment was conducted in the non-oxidising, high-boiling solvent pentachloroethane 
(Entry K); some product 31 was formed but in poor yield.  Having optimised the 
conditions (Entry D), the generality of this new reaction was tested by using a range of 
acid chlorides. The presence of an electron-donating group in the aromatic acid chloride 
Table 3. Outcomes of reactions of acyl chlorides with 5-nitroisocoumarin 56 under various 
Friedel-Crafts conditions.  










A PhCOCl AlCl3 DCM 40 7 SM
a 0 
B PhCOCl AlCl3 MeNO2 80 7 SM
a 0 
C PhCOCl SnCl4 PhNO2 100 7 31 21 
D PhCOCl SnCl4 PhNO2 150 3 31 42 
E PhCOCl SnCl4 PhNO2 180 3 31 27 
F PhCOCl AlCl3 PhNO2 150 3 31 38 
G PhCOCl Sn(OTf)2 PhNO2 150 3 31 19 
H PhCOCl ZnCl2 PhNO2 150 3 SM
a 0 
I PhCOCl Zn(OTf)2 PhNO2 150 3 SM
a 0 
J PhCOCl SnCl4 MeNO2 100 5 31 17 
K PhCOCl SnCl4 C2HCl5 150 3 31 13 
L Ph13COCl SnCl4 PhNO2 150 3 27 39 
M 4-O2NC6H4COCl SnCl4 PhNO2 150 3 34 10 
N 4-F3CC6H4COCl SnCl4 PhNO2 150 3 35 11 
O 4-EtOC6H4COCl SnCl4 PhNO2 150 3 SM
a 0 
P 4-ClC6H4COCl SnCl4 PhNO2 150 3 36 29 
Q 4-MeC6H4COCl SnCl4 PhNO2 150 3 37 23 
R 3-MeC6H4COCl SnCl4 PhNO2 150 3 38 21 
S 4-FC6H4CH2COCl SnCl4 PhNO2 150 3 
b
 0 
T Me(CH2)4COCl SnCl4 PhNO2 150 3 
b
 0 
a Only 56 recovered. b Mixture of decomposition products 
(Entry O) prevented any reaction but the 3-arylisocoumarin products were formed when 
electron-withdrawing groups were present (Entries M and N), although the yield was 
adversely affected. Groups with little electronic effect gave the expected products in 
satisfactory yields (Entries P, Q and R). The reaction did not proceed with aliphatic acid 
chlorides and only mixtures of decomposition products were obtained. 
Our initial investigations into this reaction gave some clues as to the possible mechanism 
by which the 3-aryl products were formed. The strong Lewis acidity and forcing 
conditions required suggested that the primary step might be the formation of the Friedel-
Crafts 4-acylated product and the poor yield with the non-oxidising pentachloroethane 
indicated that an oxidation step was possibly involved. In order to gain further insights 
into the mechanism, a 13C labelling study using 13C-carbonyl-labelled benzoyl chloride 
















56 147 148  
 
Scheme 32.  
13C-Labelling study. 
 
The 1H NMR spectrum of 148 contained a broad doublet at δ 7.87 ppm with a coupling 
constant of 5.5 Hz, corresponding to 4-H. In the unlabelled product 31, the corresponding 
signal is a broad singlet. These data confirm that the 13C from the labelled acid chloride 
has been incorporated into the product at position 8a, 5, 4a or 3, as the coupling constant 
is only consistent with 2JC-H or 
3
JC-H but not 
1
JC-H which would be much greater (>100 
Hz). The exact location of the 13C was proved by 13C NMR spectrum, primarily by the 
greatly enhanced peak at δ 156.8 which had previously been assigned as corresponding to 
3-C following HMBC and HMQC experiments. This was supported by the observation of 
one-bond carbon-carbon couplings between the 3-C and adjacent carbons with 1JC-C = 68 
Hz between 3-C and 1’-C and 1JC-C = 75 Hz between 3-C and 4-C. Additionally, longer 
range two- and three-bond couplings were observed with J values between 0 and 5 Hz 










































31 R = 4-H
135 R = 4-Cl
137 R = 4-CF3
138 R = 4-Me
154 R = 4-NO2








Scheme 33.  Proposed mechanism for the formation of 31 following Friedel-Crafts reaction of 5-
nitroisocoumarin 56. 
 
Having proved that the carbon framework of the benzoyl group was incorporated intact 
rather than the carbonyl detaching from the phenyl group, it was possible to propose a 
mechanism for the reaction path, following our previous observations. The initial Friedel-
Crafts product 149 is formed as shown by the requirement for forcing conditions and 
strong Lewis acidity. Next, a nucleophile in the reaction mixture, which could be a 
triflate or a chloride ion, attacks the ester carbonyl of the isocoumarin giving rise to the 
enol 150 which can tautomerise to the enol 151. After cyclisation, the product 31 could 
be formed either by direct decarbonylation of 152 or by oxidation to the corresponding 
carboxylic acid 153 and decarboxylation. In view of the literature reports that 6,8-
dihydroxy-4-formyl-3-methylisocoumarin is stable in hot aqueous formic acid163 and that 
decarboxylations of isocoumarin-4-carboxylic acids have been used synthetically to 
obtain isocoumarins,164, 165 a direct decarbonylation is unlikely and initial oxidation then 
loss of the carboxylic acid unit is more likely. This view is supported by the low yield 
obtained with the non-oxidising solvent, pentachloroethane (Entry K). 
 
Although serendipity had played a part in the discovery of this novel route to 5-nitro-3-
arylisocoumarins it was, nevertheless, synthetically useful despite moderate yields. The 
table below compares the yields obtained with this new reaction with those obtained 
using the Hurtley route.  
 
Table 4. Comparrison of the chemical yields obtained when various isocoumarins are synthesised by either 
the Hurtley route or the Friedel-Crafts route. 
3-Substiuent and compound 
number 
Yield  (% Hurtley from 34) Yield (% Friedel-Crafts 
from 56) 
Ph 31 78 42 
4-MePh 138 20 37 
4-F3CPh 137 12 11 
4-ClPh 135 33 29 
4-NO2Ph 154 0 10 
4-MeOPh 156 60 0 
3-Me 123 23 0 
  
In general, the two routes have similar yields from the starting bromobenzoic acid or 
isocoumarin but differences exist in the substituents which are tolerated; for example it is 
not possible to synthesise 5-nitro-3-(4-nitrophenyl)isocoumarin 154 using the Hurtley 
route but the Friedel-Crafts route allows this. Conversely, the Hurtley route tolerates 
alkyl substituents and electron-rich aromatics whereas the new route does not.  
 
3.5.3 Initial SAR with 3-substituted isoquinolin-1-ones 
 
The IC50 values of the first series of 3-substituted isoquinolin-1-ones tested are shown in 
the table below along with the values obtained for 5-AIQ for comparison. 
 
 
Table 5. Inhibition of the activities of PARP-1 and PARP-2 by 3,5-disubstituted isoquinolin-1-ones and 
isocoumarins; data for 5-AIQ 5  are shown for comparison 
Cpd. 
No. 
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The first point to note is that the 3-substituted compounds were generally some 10-fold 
more potent against both PARPs -1 and -2 than the 5-substituted series and also 2-10-fold 
more potent than 5-AIQ, except in the case of 5-amino-3-pentylisoquinolin-1-one 122, 
where all activity was lost. The most potent compound was the 3-(4-methylphenyl)-
substituted 118 which was slightly PARP-1 selective and ca. 10-fold more potent than the 
3-phenyl 33.  Adjusting the electronic configuration of the phenyl ring did not have a 
significant impact on potency and electron-neutral substituents were preferred. The 
electron-deficient 116 was slightly more potent than the electron-rich 117 but the 3-(4-
chlorophenyl)-substituted 115 showed the greatest potency of the three. It is tempting to 
speculate that the 3-arylisoquinolin-1-ones show increased potency over 5-AIQ thanks to 
the bulky aryl substituent occupying a lipophilic-binding pocket in the PARP1/2 active 
sites. However, the smaller 3-alkyl substituted compounds (3-Me and 3-Et) show a 
similar level of activity and this casts doubt on the requirement for a sterically large 
hydrophobic group in this position. 
 
Unfortunately, the series showed very little selectivity for either isoform; however, the 
significant increase in potency was promising. It was decided that some further examples 
would be examined; as potent non-isoform-selective PARP inhibitors are useful 
molecules in their own right and it was plausible that selectivity could be gained by 
subsequent modifications in other positions. 
 
The most potent PARP-1/2 inhibitor synthesised thus far was 5-amino-3-(4-
methylphenyl)isoquinolin-1-one 118. In order to ascertain if the position of the methyl 
group on the aromatic ring had any effect on potency or selectivity, the o- 157 and m- 158 
analogues were prepared.  In addition, 5-nitro-3-(4-iodophenyl)isocoumarin 159 and the 
corresponding isoquinolin-1-ones 160 and 161  would be synthesised; the iodo-phenyl 











157 X = NH2 R = NH
162 X = NO2R = NH
163 X = NO2R = O
158 X = NH2 R = NH
164 X = NO2R = NH
155 X = NO2R = O
159 X = NO2R = O
160 X = NO2R = NH
161 X = NH2 R = NH  
 
Figure 31. The secondary 3-substituted targets. 
 
The now established Friedel-Crafts-like procedure was used to prepare the next set of 
isocoumarins. Reaction with ammonia in the usual way gave the isoquinolin-1-ones. 
Pd/C mediated hydrogenation was used to reduce the nitro group in 162 and 164. In order 
to prevent any reductive de-iodination of 160, tin (II) chloride in EtOH was used as the 


























25 46 56 3 
 
158 
21 59 62 4 
I     
161 
34 55 51 5 
 
The new compounds were sent for biological evaluation and attention was turned to 
developing a more efficient route to 3-arylisoquinolin-1-ones as the overall yields for the 
current routes were poor.  
 
3.5.4 A novel route to 5-amino-3-arylisoquinolin-1-ones 
 
From earlier work, it was known that 1-chloroisoquinolines were precursors to 
isoquinolin-1-ones. Therefore, compounds with the general structure of 166 would be 
only two (functional group interconvcersions) FGIs away from the target 3-aryl 5-AIQs 
167. These compounds would be accessible by palladium-catalysed couplings and 
disconnection of the aryl group would give the dihalide 168. However, this could present 
a problem; palladium-catalysed coupling onto this compound may give the disubstituted 
product 169, as both halogens are activated by being adjacent to the ring nitrogen. In fact, 
the two chlorines in 1,3-dichloroisoquinolines show an inherent difference in reactivity 
and it is reported to be possible to perform selective Suzuki couplings on such 
molecules166 to give 1-aryl-3-chloroisoquinolines 170. Of course, this is opposite to the 























































This difference in coupling reactivity was highly likely to remain in 5-nitro-1,3-
dichloroisoquinolines however; it may be expected to translate into differences in 
electrophilic reactivity and thus could be exploited to protect selectively the 1-chloro 
position as the methoxy lactim 171. The final disconnection would be the 5-nitro group 
and we were encouraged by reports that nitration of 1-chloroisoquinoline gave 1-chloro-
5-nitroisoquinoline as the sole product in very good yield that selective nitration in the 5-
position would be possible.167, 168 Therefore, the forward synthesis was attempted. 
Classical nitration of 172 with concentrated nitric and sulfuric acids, ensuring that the 
isoquinoline was fully protonated in the reaction mixture to deactivate the heterocyclic 
ring, gave a single product 168, in excellent yield. The double-doublet, triplet, double-
doublet coupling pattern in the 1H NMR spectrum of the product provided evidence that 
nitration had occurred in either the 8- or 5-positions. The absence of a Nuclear 
Overhauser Enhancement Spectroscopy (NOESY) interaction between the 4-H and any 
other protons pointed to the absence of a proton in the 5-position and that electrophilic 
































Scheme 35. Synthesis of 158 via Suzuki coupling with 171. (i) HNO3/H2SO4, 91%; (ii) MeOH, Na, 92%; 




Pleasingly, reaction with sodium methoxide, formed in situ in methanol, displaced only 
the 1-Cl and gave 3-chloro-1-methoxy-5-nitroisoquinoline 171 as the sole product in 
good yield; none of the unwanted 1,3-dimethoxy-5-nitroisoquinoline or 1-chloro-3-
methoxy-5-nitroisoquinoline  were formed. This protected 3-chloro-5-nitroisoquinolin-1-
one was a suitable substrate upon which to perform palladium-catalysed couplings. An 
initial Stille coupling with tetramethyltin and tetrakis(triphenylphosphine) palladium in 
DMF failed and attentions were turned to the Suzuki-coupling.  
 
In order to evaluate this new route in comparison with the previously developed Friedel-
Crafts-type synthesis, it was decided that 158 would be synthesised and the overall yields 
would be compared. Compound 171 was treated with 3-methylphenylboronic acid in 
refluxing toluene using a Pd2(dba)3/SPhos catalyst system with K3PO4 as base. The sole 
product was 173, which was obtained in 67% yield. Aqueous hydrobromic acid was 
chosen to deprotect the lactim to furnish the isoquinolin-1-one, as a literature report had 
outlined a similar demethylation using this reagent.169 The deprotection was achieved in 
excellent yield and the remaining nitro-reduction had been performed previously. The 
overall yield for the synthesis of 158 from commercially available starting material was 
33%, an eight-fold improvement on the Friedel-Crafts-type route. Therefore, a second 
novel and efficient route has been developed for the synthesis of 3-arylisoquinolin-1-ones 
in this work. Both routes introduce diversity at a relatively late stage in the synthesis, 
which is important as the number of repetitive steps is reduced when producing libraries 
of compounds. It is likely that the route based on the Suzuki coupling will tolerate a 
wider range of functionality than all other routes (for example, electron-rich, electron-
deficient and sterically hindered boronic acids), such is the versatility of this reaction.  
 
3.4.10 Further SAR with 3-arylisoquinolin-1-ones 
 
The biological data for the 3-arylisoquinolin-1-ones 157, 158 and 161 are shown in Table 
7, along with 118 and 5-AIQ for comparison.  
 
Table 7. Inhibition of the activities of PARP-1 and PARP-2 by isomeric 3-(methylphenyl)-5-AIQs and by 
3-(4-iodophenyl)-5-AIQ; data for 5-AIQ 5 are shown for comparison 
Cpd. 
No. 





































1.14 0.37 3.09 
 
 
Somewhat unexpectedly, the position of the methyl group on the 3-phenyl ring had a 
dramatic effect on potency and the o- and m- derivatives 157 and 158 were some 100-
fold less potent against PARP-1 than was 118. The p-iodophenyl 161 showed a similar 
level of activity against PARP-1 as 5-AIQ but increased potency against PARP-2 
rendering it ca. 3-fold selective. When compared to the p-chlorophenyl derivative 115, 
the larger halogen causes a near 6-fold drop in PARP-1 activity and only a 2-fold drop in 
PARP-2 activity. This suggests that increase bulk in the p-phenyl group in the 3-position 
may be better tolerated in PARP-2. However the 3-p-methoxyphenyl 117 and 3-p-
methylphenyl 118 analogues are slightly PARP-1 selective which contradicts this 
proposal. A possible explanation for the drop in activity in 157 and 158 is that the 
lipophilic binding pocket in PARP-1/2 is long and narrow and will therefore tolerate p-
phenyl-substituents but not o- or m-. 
 
Due to the lack of selectivity of the 3-substituted isoquinolin-1-ones it was decided that 






3.6 4-Substituted isoquinolin-1-ones 
 
Various strategies were employed to attempt to introduce bulky lipophilic substituents to 
the 4-position of 5-AIQ.  The first of these, electrophilic substitution via the Friedel-
Crafts reaction, was unsuccessful and has been discussed above. 
 
3.6.1 Alkylations and condensations of 2,6-dicyanotoluene 
 
The two literature routes to 5-cyanoisoquinolin-1-one 76 have been discussed above; 
both of these involve condensations of 2,6-dicyanotoluene 41 and could feasibly be 
modified, by extension of the methyl group of the substrate, to give 4-alkyl-5-cyano-
isoquinolin-1-ones.  The first route to be examined was condensation of 41 with ethyl 
formate and it was postulated that substitution at the benzylic position of the starting 
dicyano compound, and subsequent reaction under the same conditions, would give the 
desired products. The methyl group of 41, which is activated by the flanking nitriles, was 
deprotonated with lithium bis(trimethylsilyl)amide; this anion was methylated with 
iodomethane, based on a procedure by Mao and Boekelheide.170 This process proceeded 
smoothly in excellent yield; however, the resulting 2,6-dicyanoethylbenzene 174 failed to 
























































The second synthesis of 76 involved condensation of 41 with DMFDMA to form an 
intermediate enamine 78. It was attempted to cause the ethyl analogue 174 to react with 
DMF/DMA under the same conditions, anticipating the formation of enamine 175; 
however, NMR and TLC analysis showed that, despite prolonged reaction times, the 
starting material remained unchanged. In order to increase the electrophilicity of the 
“carbonyl” carbon in DMFDMA, a catalytic amount of acid was added to the reaction 
and the mixture was stirred for a further two days. Separation and analysis of the 
resulting complex mixture of products by chromatography revealed that, although none 
of the expected enamine 175 was formed, the corresponding aldehyde 176 was obtained, 
but in very low yield (12%).  
Scheme 36. Synthesis of 5-cyano-4-methylisocoumarin 177, 5-cyanoisoquinolin-1-one 178 and 5-cyano-
isocoumarin 177 from 2,6-dicyanotoluene 41. (i) KOBut, ethyl formate, 76 14%, 77 13%; (ii) DMFDMA, 71%; 
(iii) MeOH, HCl, 55%; (iv) LHMDS, MeI, 94%; (v) KOBut, ethyl formate, 0%; (vi) DMFDMA, 0%; (vii) 
DMFDMA, TsOH, 12%; (viii) diisopropylamine, 13%. 
It is likely that the aldehyde is formed from the intermediate enamine by hydrolysis on 
the slightly acidic silica. This process is analogous to the formation of 5-nitroisocoumarin 
56 from methyl 2-(2-dimethylaminoethenyl)-3-nitrobenzoate 55 by passage through a 
silica column. However, the enol of the aldehyde 176 does not cyclise by nucleophilic 
attack on the adjacent nitrile carbon, in contrast to the cyclisation of the enol methyl 2-(2-






























It was anticipated that formation of the enolate of 176 would result in cyclisation to the 
isocoumarin 177 upon aqueous workup.  This was the case, treatment of 176 with 
diisopropylamine gave 177 but, again, the yield was disappointing (13%). The 1H NMR 
spectrum of 177 was interesting, as an allylic coupling was observed between 3-H and 
the methyl group, with a 4J value of 1.2 Hz. Attempts to convert 177 to the isoquinolin-1-
one using the standard protocol failed and alternative routes to the 4-substituted targets 




Scheme 37. Proposed mechanism for the formation of the aldehyde 176. 
3.6.2 Attempted iodination and successful bromination of 5-nitroisoquinolin-1-one 
 
The 4-position of 5-nitroisoquinolin-1-one is the most nucleophilic (see above). This 
electronic difference had already bee n exploited in forming 4-acyl-5-nitroisoquinolin-1-
one and it was feasible that other electrophilic substitution reactions, such as acid-
catalysed bromination or iodination, would be possible. As the ultimate aim was to 
perform palladium-catalysed couplings upon the 4-halo-isoquinolinone, the preferred 4-
substituent was iodine as this is a potentially better leaving group than is bromine. 
Unfortunately, treatment of 56 with iodine in acetic acid gave only starting material, even 
after heating at 100°C for 24 h, and the same was true when the more electrophilic N-
iodosuccinimide was employed as the iodinating agent. At this point, a switch to bromine 
was considered; bromine is more electrophilically reactive than is iodine and Horning et 
al.
171 had reported that treatment of 2-methyl-5-nitroisoquinolin-1-one 180 with one 
molar equivalent of bromine at room temperature gave a 1:1 mixture of 4-bromo-2-
methyl-5-nitroisoquinolin-1-one 181 and the bromohydrin 4-bromo-3-hydroxy-5-


















Scheme 38.  Bromination of 2-methyl-5-nitroisoquinolin-1-one 180, as reported by Horning.171 
 
The group noted that 182 could be dehydrated to 181 when heated to its melting point. As 
it was unlikely that substitution at the 1-position would affect the reaction pathway (all 
Horning’s reactions were conducted using N-alkylated isoquinolin-1-ones), the reaction 
of 5-nitroisoquinolin-1-one 38 with bromine under the same conditions was attempted. 
This gave the anticipated mixture of 4-bromo-5-nitroisoquinolin-1-one 49 and 4-bromo-
3-hydroxy-5-nitroisoquinolin-1-one 183, upon aqueous workup. Upon heating the bromo-

























Scheme 39.  Bromination of 38 to form 49 and reduction of the nitro function. (i) Br2, AcOH; (ii) Sn(II)Cl2, 
EtOH; (iii) Heat. 
 
A slight variation in reaction conditions (heating a concentrated solution at 60°C for 16 
h) resulted in precipitation of the desired product 49 upon cooling, whilst the 
bromohydrin remained in solution. This variation caused the overall yield to increase to 




3.6.3 Attempted palladium and copper-catalysed cross-couplings with 4-bromo-5-
nitroisoquinolin-1-one 
 






The first of these was the Suzuki coupling; compound 49 was treated with with 
phenylboronic acid in DMF, with sodium carbonate as base and tetrakis(triphenyl-
phosphine)palladium (Pd(Ph3P)4) as catalyst, over a range of temperatures (80-150°C).  
Only starting material was recovered and it was reasoned that the bulky nitro group, 
adjacent to the bromine, was causing sufficient steric hindrance to prevent the coupling 
from taking place. Therefore, the nitro function was reduced to the leaner amino group 
using tin(II) chloride, prior to performing the coupling reactions. The use of hydrogen in 
the presence of palladium metal was avoided in order to avoid any reductive 
debromination of 49.  The Suzuki reaction was then repeated with 184 as starting 






R Ph  
Scheme 40.  Attempted Suzuki cross-couplings of 49 (R = NO2) and 184 (R = NH2). 
 
 
A change in conditions was required and Barder et al.172 had reported a series of Suzuki 
couplings using extremely hindered aryl halides and phenyl boronic acids, in high yields.  
The group attributed the success of these transformations to the use of the novel ligand, 
2-(2’,6’-dimethoxybiphenyl)-dicyclohexylphosphine (SPhos) 185.  Encouraged by these 
reports, the Suzuki reaction was repeated using Barder’s conditions.  49 or 184 were 
stirred with tris(dibenzylideneacetone)dipalladium (Pd2dba3)/SPhos, potassium phosphate 
(K3PO4) and two equivalents of phenyl boronic acid, in DMF or toluene.  No reaction 
took place and, as a result, our attentions turned to the Stille cross-coupling.  49 and 184 
were both treated with tetraphenyltin and catalytic Pd[Ph3P]4 in DMF but the only 
products isolated were the starting aryl halides or small quantities of debrominated 
material.  
 
The Ullmann reaction involves the condensation of two aryl halides in the presence of an 
excess of copper powder or copper (II) salts at high temperature. The exact mechanism 
for the reaction is unknown but it is likely the process involves the formation of a Ar-
Cu(I) species which undergoes oxidative addition with one equivalent of aryl halide and 
then reductive elimination to give the biaryl. It was hoped that the high temperature 
required for the Ullmann coupling would render the 4-bromoisoquinolin-1-ones 49 and 
184 reactive. However, no coupling took place and only a mixture of debrominated and 
starting material was recovered even after heating to 180°C for 3 d. 
 
The failure of 49 or 184 to undergo organometalic cross-couplings meant that an 
alternative approach must be sought and the first of these was via lithiation of a protected 
derivative of 49. 
 
3.6.4 Synthesis of 4-bromo-1-methoxy-5-nitroisoquinoline 
 
It was rationalised that 49 could undergo lithium-for-bromine exchange, allowing the 
formation of 4-substituted compounds by treatment with appropriate electrophiles.  
However, the presence of an exchangeable lactam proton was a concern, as it was 
conceivable that self-quenching could occur, depending on the relative rates of lithium-
bromine exchange versus proton abstraction. In order to circumvent this problem, the 
protection of the lactam as a methoxy-lactim was proposed. A report in the literature169 
outlined the conversion of 4-bromoisoquinolin-1-one 186 to 4-bromo-1-methoxy-
isoquinoline 187 by treatment of 186 with Vilsmeier’s reagent to form the 1-chloro 
derivative 188, followed by treatment with sodium methoxide (the final conversion was 
also very similar to the conversion of 1,3-dichloro-5-nitroisoquinoline to 3-chloro-1-















49 R = NO2
186 R = H
188 R = H
189 R = NO2
46 R = NO2




Scheme 41.  Synthesis of 4-bromo-1-methoxy-5-nitroisoquinoline 46. (i) DMF, oxalyl chloride, 89%; (ii) 
MeOH, Na, 82%. 
 
Pleasingly, it was found that this protocol could be extended to the 5-nitro analogues and 
4-bromo-1-chloro-5-nitroisoquinoline 189 was formed in very good yield (89%) 
following the reported procedure. Displacement of the chlorine with methoxide to 46 was 
unexpectedly slow (3 d) and low yielding (56%) when sodium methoxide was added as a 
solid to the reaction mixture. A significant reduction in reaction time (16 h) and yield 
(82%) was achieved when sodium methoxide was formed in situ, as per the earlier 
synthesis of 3-chloro-1-methoxy-5-nitroisoquinoline 171. 
 
3.6.5 Lithiations of 4-bromo-1-methoxy-5-nitroisoquinoline 
 
The protected lactam 46 was treated with butyllithium (BuLi) at -78°C in order to form 
the anion at the 4-position; this carbanion was quenched with iodomethane. 1H NMR and 
TLC analysis of the crude material showed a complex mixture of products which were 
purified by column chromatography. It was possible to isolate the desired 1-methoxy-4-










46 190  
 
 
Scheme 42. Synthesis of 190 via lithiation of 46. (i) n-BuLi , THF; (ii) MeI, 9%. 
 
Unfortunately, the protocol could not be extended to the use of other electrophiles and 




3.6.6 Palladium-catalysed cross-couplings with 4-bromo-1-methoxy-5-
nitroisoquinoline 
 
It had initially been proposed that steric hindrance had prevented any palladium-catalysed 
cross-coupling involving 49 from taking place. However, there are numerous examples in 
the literature of high-yielding Suzuki cross-coupling reactions between extremely 
hindered substrates. One example is the reaction of the boronic acid 191 with the aryl 
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Scheme 43. Reported synthesis of the hindered biaryl 193 via Suzuki cross-coupling.172 (i) Pd2(dba)3, 
SPhos, K3PO4, toluene, 93% 
 
Therefore, it was thought that the protected lactam 46 may be a suitable candidate for 
Suzuki coupling and that the change in electronic distribution and solubility compared to 
49 may bring a change in reactivity. 
 
This was the case, as 49 was caused to react with phenylboronic acid under the now 
standard Suzuki reaction conditions (Pd2(dba)3, SPhos, K3PO4, toluene, 100°C) and gave 
194 as the sole product in very good 86% yield. Conversion to the 5-aminoisoquinolin-1-
one 195 was straightforward in two steps using the established procedures of 
demethylation with hydrobromic acid to give 196 then palladium-catalysed reduction of 

















46 194 R = H
198 R = CF3
196 R = H
199 R = CF3
195 R = H
197 R = CF3
 
 
Scheme 44. Synthesis of 195 and 197. (i) Pd2(dba)3, SPhos, K3PO4, ArB(OH)2, toluene, 194 86% and 198 
81%; (ii) HBr, 196 65% and 199 65%; (v) Pd/C, H2, 195 51% and 197 53%.  
 
 
Also required was the p-trifluoromethylphenyl derivative 197 and this was to be prepared 
using the same three-step synthesis. It was pleasing that the yield of the Suzuki reaction 
was only slightly affected (reduced by 5%) when the electron-deficient 4-
trifluoromethylphenylboronic acid was employed as reactant. As electron-deficient 
boronic acids are less nucleophilic than their electron-rich counterparts, they undergo 
transmetallation more slowly. Additionally, they are more prone to homocoupling.173  
 
The final 4-aryl compound to be synthesised in this series was the electron-rich p-
methoxyphenyl analogue 200. It would not be possible to prepare this by the route that 
had been developed, as the deprotection step would also result in the demethylation of the 
methoxy substituent. A different form of protection was required and the formation of the 
benzyloxylactim was preferred. This would allow deprotection of the lactam and 
reduction of the nitro group in one step via catalytic hydrogenation. The lactim was 
prepared by first forming the anion of benzyl alcohol with sodium hydride in DMF then 































The benzyl ether 201 was formed in good 71% yield and a small amount of the side 
product 202 was also isolated. It is likely that this was formed from dimethylamine, itself 
formed by decompositon of DMF, reacting at the electrophilic 1-C in 189. The Suzuki 
coupling to 203 was effective and the deprotection / reduction proceeded in 47% yield, 
which was adequate especially as two transformations were achieved in a single step.  
 
Following the success of the Suzuki couplings using the novel protected lactam substrates 
46 and 201, it was speculated as to why such difficulties had been encountered with the 
unprotected molecule 49. One explanation is that the lactam carbonyl may coordinate to 
the palladium, rendering it catalytically inactive. Alternatively, the main factor 
determining reactivity may be solubility in organic solvents. The lactam function renders 
the molecule much more polar and intramolecular hydrogen bonding reduces solubility in 
the solvents used in cross-coupling reactions. When this is masked as a lactim, polarity is 
decreased and solubility in organic solvents is increased. 
 
One factor that was initially considered to be of high importance in determining whether 
or not a cross-coupling reaction would occur was steric hindrance. It was proposed that 
Scheme 45. Synthesis of 200. (i) BnOH, NaH, DMF, 201 71% and 202 12%; (ii) Pd2(dba)3, 
SPhos, K3PO4, 4-MeOPhB(OH)2, toluene, 61%; (iii) Pd/C, H2, 47%. 
















Scheme 46. Synthesis of the hindered 205. (i) Pd2(dba)3, SPhos, K3PO4 ,phenanthren-9-ylboronic acid, 
toluene, 42%; (iii) Pd/C, H2. 
 
Although the yield was significantly lower than for the couplings of the less hindered 
phenylboronic acids, coupled product 204 was formed in acceptable yield. This was 
pleasing as the peri nitro group is likely to cause significant crowding at the 4-position of 
the product when adjacent to a group as bulky as a phenanthryl. The selection of 
couplings performed thus far illustrates the versatility of the Suzuki cross coupling with 
46 in that electron-deficient, electron-rich, electron-neutral and now severly sterically 
hindered boronic acid substrates are tolerated. Crystals were grown in order to confirm 
the 3D structure of the molecule and this is discussed in a later section.  
 
The deprotection / reduction step appeared to result in conversion to the amine 205, as 
shown by mass spectrometry and tlc analysis. However, 205 was insoluble in all solvents 
suitable for NMR spectroscopic analysis, so full characterisation was not possible. This 
also meant that the molecule was not suitable for biological evaluation as the PARP-1/2 







3.6.7 Stille cross-coupling with 4-bromo-1-methoxy-5-nitroisoquinoline 
 
The low yields and unpredictability of the lithiation reactions of 46 meant that a more 
efficient route was required for the synthesis of 5-nitro-4-alkylisoquinolin-1-ones was 
required. Following the success of the Suzuki-coupling, the alkyl version of this reaction 
was considered but earlier attempts to introduce a benzyl substituent at the 4-position by 
this method had failed, therefore Stille coupling of 46 with tetramethyltin was attempted. 
The same tris(dibenzylideneacetone)dipalladium(0)/SPhos catalyst and toluene solvent 
system (the Stille coupling does not require a base) as the Suzuki reaction were 
employed. Due to the low boiling point of tetramethyltin (74-75°C), the reaction was 



















Scheme 47. Synthesis of 207 via Stille cross-coupling. (i) Me4Sn, Pd2(dba)3, SPhos, toluene, 72%; (ii) HBr, 
70%; (iii) Pd/C, H2, HCl, 65%.  
 
TLC analysis showed the reaction proceeded very slowly and there was incomplete 
conversion to product after 7 d. Upon workup, only a small amount of starting material 
was isolated and the yield of 72% was obtained. Conversion to 206 and then the final 
amino 207 compound was straightforward using the previously established methods. 
 
Although time pressures prevented further investigation of this novel route to 4-
substituted isoquinolin-1-ones, it is likely that numerous other aryl, alkenyl, alkyl and 
allyl substituents will be tolerated as couplings with tetramethyltin are generally more 
difficult to perform than with other organotin reagents. 
 
 
3.6.8 SAR with 4-substituted isoquinolin-1-ones 
 
Table 8 shows the biological data for the 4-substituted-5AIQs and 5-AIQ for comparison. 
  
Table 8. Inhibition of the activities of PARP-1 and PARP-2 by 4-substituted isoquinolin-1-ones; data for 5-
AIQ 5 are shown for comparison 
Cpd. 
No. 
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205 and 207 were not evaluated due to solubility problems in the solvent (DMSO) 
the assays were performed in. The 4-bromo derivative 184 showed increased 
potency over both isoforms than 5-AIQ and was slightly (2.5 fold) selective for 
PARP-2. The 5-nitro-4-phenyl derivative 196 showed activity against both isoforms 
and was approximately 3-fold less potent than was 5-AIQ; this was expected, as 
electron withdrawing groups in the 5-position of isoquinolin-1-ones are known to 
reduce potency.
110
 Conversely, 195 was 2-fold more potent than was 5-AIQ against 
both isoforms. An electron-donating substituent reduced potency against both 
isoforms but activity against PARP-1 was affected more therefore 200 was ca. 2-fold 
selective for PARP-2. An electron-withdrawing group only reduced activity against 
PARP-2 very slightly, whilst reducing activity against PARP-1 by a factor of eight, 
meaning that 197 was 7.6-fold selective for PARP-2. 
 
 
3.6.9 Buchwald-Hartwig cross-coupling 
 
To investigate further the scope of the cross-coupling reactions possible with 46, a series 
of Buchwald-Hartwig reactions were attempted. Thus 46 was treated with a range of 
phenol derivatives under the standard conditions. The anticipated products would be 
precursors to compounds that were broadly isosteric to 4-benzylisoquinolin-1-ones which 









208 X = NH
209 X = O
210 X = S
46  
 
Scheme 48. Attempted Buchwald-Hartwig couplings with 46. (i) Pd2(dba)3, SPhos, K3PO4, PhXH, toluene. 
208 34%, 209 0%, 210 0%. 
 
The sole successful coupling was that between 46 and aniline in low yield. A report174 
that the Pd-ligand and the solvent could have a dramatic effect on the outcome of 
Buchwald-Hartwig reactions was encouraging and these adjustment of these variables 




















Figure 32. Ligands for the Buchwald-Hartwig reaction.  211 = XPhos, 185 = SPhos, 212 = BuXPhos, 213 
= JohnPhos.  
 
The nature of the base can also have a significant influence on outcome of the Buchwald-
Hartwig reaction and the use of potassium t-butoxide (KOBut ) was investigated. None of 
the variations allowed that 209 or 210 could be formed but it was possible to increase the 




Table 9 shows the yields obtained when Buchwald-Hartwig reaction conditions with 46 
were varied. 
 
Table  9. Chemical yields obtained when reactions conditions were varied in Buckwald-Hartwig couplings 
of 46 with aniline. 














30 36 38 32 38 34 
SPhos 185 32 38 36 34 40 45 
BuXPhos 
212 
11 5 10 9 9 14 
JohnPhos 
213 
0 0 0 0 0 0 
 
The ligand JohnPhos was ineffective and this was perhaps due to the fact that this 
compound is relatively electron-poor in comparison with the other ligands used in this 
synthesis.  Electron-rich ligands tend to hasten the ‘oxidative addition’ step in palladium-
catalysed coupling and tend to perform better in difficult syntheses. BuXPhos was not as 
effective as SPhos and XPhos and the strong base KOBut performed better than K3PO4. 
The optimum conditions were an SPhos/Pd2(dba)3 catalyst system with  KOBu
t as base 
and dioxane as solvent; these conditions resulted in a 45% yield.  
  
3.7 X-ray crystallography of 1-methoxy-5-nitro-4-phenylisoquinoline (194), 1-
(benzyloxy)-4-bromo-5-nitroisoquinoline (201) and 1-(benzyloxy)-5-nitro-4-
(phenanthren-9-yl)isoquinoline (204) and methyl 2-(1-oxo-1,2-dihydroisoquinolin-5-
ylamino)acetate (214) 
  







Figure 33. Large crystals of 1-methoxy-5-nitro-4-phenylisoquinoline 194 shown on a ruler. 
 









Figure 34.  X-ray crystallographic structure of 194. 
 
The obtained structure confirms the successful Suzuki coupling of 46 with phenylboronic 
acid despite previous failures with the unprotected lactone 49. The molecule exists as a 
monomer in this crystal structure due to the absence of sufficient H-bond donor/acceptor 
groups. It can be seen that the phenyl ring remains in plane with the isoquinoline core and 
this would be expected in order that conjugation could occur. The peri nitro group is, 
however, bent out of plane illustrating the steric crowding at the 4,5-positions. As one 
would expect, the methoxy group points away from the molecule.  
 
 









Figure 35. X-ray crystallographic structure of 201. 
 
The structure confirms the successful protection of 46 as the benzyloxylactim. The 
molecule is essentially planar with the benzyloxy function pointing away from the core. 
Again, the nitro group is peri to a large group in the 4-position (bromine). This results in 
the nitro funtion bending out of the plane of the isoquinoline core to a similar degree as 
observed in the crystal structure of 194 when the 4-substituent was a phenyl group. Akin 
to 194, the molecule exists as a monomer in crystalline form.   
 
 








Figure 36. X-ray crystallographic structure of 204. 
 
This crystal proves the structure of 204 and confirms the successful Suzuki coupling of 
201 with the bulky phenanthren-9-ylboronic acid. The severe steric crowding in 204 can 
be observed in the X-ray crystallographic structure. The presence of the extremely bulky 
4-substituent has a profound effect. Both the phenanthrenyl group and the peri nitro 
group are twisted out of plane to the isoquinoline and are parallel to one another. This is 
in contrast to 194 where the smaller phenyl ring remains in plane and most probably 
conjugated with the isoquinolinone core but the nitro group is twisted out of plane. It can 
be observed from the crystal that free rotation of the phenanthrene group is highly 
unlikely and this would suggest that the molecule exists as a pair of atropisomers. The 
benzyloxy function points away from the isoquinoline and the molecule is monomeric in 
this crystalline form. 
 
 







Figure 37. X-ray crystallographic structure of 214. 
 
 
Crystals of compound 59 were grown in methanol in order to confirm its structure. 
Unfortunately this resulted in esterification, probably catalysed by residual HCl in the 
sample, and formation of the methyl ester 214. However, the two structures are very 
similar and it can be observed that in the X-ray crystallographic structure of 214 the 
compound is a dimer due to the presence of two intermolecular hydrogen bonds. The two 
lactam hydrogens act as hydrogen bond donors whilst the ring carbonyls act as acceptors. 
It is likely that these H-bonds are present in most isoquinolin-1-ones and contribute to the 
high melting points and crystalline structure of these molecules. No H-bonding is 
observed ester portion of the molecule. The ester groups point away from the isoquinolin-







 3.8 Disubstituted isoquinolin-1-ones 
 
In general, substituting at the 3- and 4-positions of 5-AIQ had caused an increase in 
potency against PARP-1/2 and benzoylation at the 5-position had caused an increase in 
selectivity for PARP-2 over PARP-1. It was hoped that a combination of these 
modifications in the same molecule would lead to a potent and selective inhibitor of 
PARP-2. Four compounds would be prepared the 3-methyl-5-benzoyl 215, 3-phenyl-5-
benzoyl 216, 4-phenyl-5-benzoyl 217 and, to test if substitution in the p-position of the 
benzoyl phenyl ring had any biological effect, 218 would also be synthesised. This set 
would be screened for actrivity and further examples prepared, if required. 
 
3.8.1 Synthesis of disubstituted isoquinolin-1-ones 
 
The 3- or 4-substituted isoquinoline-1-one core of the molecule would be prepared using 
the methods established. Therefore 5-amino-3-methlyisoquinolin-1-one 119 was prepared 
by Hurtley reaction of pentane-1,4-dione with 34, reaction with ammonia and reduction 
of the nitro group in the standard way (Pd/C and H2). The 3-phenyl analogue 33 was 
prepared by Friedel-Crafts reaction of 56 with benzoyl chloride then conversion to the 
final amine in the usual way. Finally, the 5-amino-4-phenylisoquinolin-1-one 195 was 
prepared by Suzuki reaction of 46 with phenyl boronic acid followed by deprotection / 
reduction as discussed above. 
 
The substituted 5-AIQs were then benzoylated in pyridine using the standard protocol 















215 R1 = Me, R2 = H, R3 = H
216 R1 = Ph, R2 = H, R3 = H
218 R1 = Ph, R2 = H, R3 = I
217 R1 = Me, R2 = Ph, R3 = H
119 R1 = Me, R2 = H
33 R1 = Ph, R2 = H
195 R1 = H , R2 = Ph
 
 
Scheme 49. Synthesis of disubstituted isoquinolin-1-ones. (i) ArCOCl, pyridine. 
 
 
3.8.2 SAR of disubstituted isoquinolin-1-ones 
 
The chemical yields and biological data for the disubstituted compounds are presented in 
Table 10.   
Table 10. Acylation yields and inhibition of the activities of PARP-1 and PARP-2 by 5-
benzamido-3-substituted and -4-substituted isoquinolin-1-ones; data for 5-AIQ 5 are 





















































The yields obtained following the synthesis of the disubstitued compounds were 
generally good when using the standard procedure (reaction of the 3- or 4-aryl 5-amino-
isoquinoline-1-one with the relevant acid chloride in pyridine). Purification issues caused 
a drop in the yield of 217 as problems were encountered when attempting to recrystallise 
the compound and column chromatography was required. 
 
A drastic drop in potency towards PARP-1 was observed with the disubstituted 
compounds. Unfortunately, this drop was mirrored with PARP-2, although to a lesser 
extent in 215, 216 and 218, which were approximately 3-fold selective for this isoform. 
The 4,5-disubstituted 217 was devoid of activity against either isoform. 
 
The disappointing lack of potency or significant selectivity of this compound set meant 
that no further examples were prepared. 
 
3.9 A novel and highly efficient synthesis of 5-AIQ 
 
It has been detailed above that the current routes to 5-AIQ are unsatisfactory. The 
Polonovski rearrangement is unreliable and low yielding in our hands.  The DMFDMA 
condensation is limited by the necessity for column chromatography, restricting the scale 
of the reaction and resulting in a low overall yield of 18%.  The reductive cyclisation 
route is multistep; requiring column chromatography at many stages and has a poor 
overall yield of 9%.   
 
Towards the end of this work, the synthetic route to 5-AIQ was modified, significantly 
increasing the overall yield and eliminating the need for chromatography. In designing a 
new and efficient synthesis for 5-AIQ from commercially available starting material, the 
order of events was important. 1-Chloroisoquinoline 90 can be converted to the 
corresponding isoquinolin-1-one via hydrolysis. The most nucleophilic carbon in 
isoquinolin-1-one is C4, therefore nitration at the lactam stage would give 4-
nitroisoquinolin-1-one and with this in mind we chose to nitrate 90 in which the 
heterocylic ring is deactivated by the chloro-substituent and electrophilic attack is 














90 219 38 5
 
 
Scheme 50. A novel synthesis of 5-AIQ. (i) HNO2/H2SO4, 92%; (ii) AcOH/H2O, 82%; (iii) Pd/C, H2, 70%. 
 
This first step proceeded smoothly in the desired 5-position giving 219 in 92% yield. 
Conversion to the isoquinolin-1-one 38 was achieved by hydrolysis with acetic acid and 
water. Then catalytic hydrogenation with 10% Pd/C in EtOH and HCl gave 5AIQ:HCl in 
an overall yield of 53%. The only purification steps required in this synthesis are 
filtration and recrystallisation, allowing for large scale preparation of this important 








4. MTS Cell proliferation assay 
 4.1 Background to MTS assay  
  
The MTS cell proliferation assay is a colorimetric assay which is used as a rapid means 
of assessing the cytotoxicity of a particular compound. The brief principles of the assay 
are that (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS), when incubated with phenozine metosulphate and living cells is 
reduced by mitochondrial reductases to formazan. Formazan is UV active and therefore 
its concentration can be measured. Cytotoxic compounds reduce the amount of formazan 
formed and IC50 values can be generated by screening a range of concentrations and 
plotting the data obtained. 
 
 
4.2 Biological results 
 
A selection of the PARP inhibitors synthesised were screened using the MTS assay and 
the results are presented in Table 10. 
 
Table 10. Cytotoxicity of selected isoquinolin-1-ones against HT29 human colon carcinoma cells. 





















































































 None of the 5-substituted compounds tested were active in the assay. Of the 4-substituted 
compounds only 195 (IC50 = 17.9) was active. Over half of the 3-substituted compounds 
showed activity and the 3-phenyl 33 (IC50 = 2.2) was highly active. Substitution of the 
phenyl ring caused a reduction in activity and the p-trifluoromethylphenyl 117 was 
inactive. The 3-ethyl 120 was not active but extension of the alkyl chain to 3-pentyl 121 
(IC50  = 34.0) rendered the molecule active. Activity in the MTS assay did not correspond 
with PARP-1 or PARP-2 activity which suggests an off-target effect. 
 


























The inital aims and objectives of this project were to synthesise a series of 5-substituted 
isoquinolin-1-ones with carboxylic acids tethered to the 5-position and series of 3- and 4-
substituted isoquinolin-1-ones with bulky lipophilic groups in the relevant positions. All 
synthesised inhibitors would be evaluated for PARP-1 and PARP-2-inhibitory activity. 
During the course of the work, a further set of 5-substituted compounds were required, 
based around a selective PARP-2 inhibitor reported in the literature. A final set of 
disubstituted targets were proposed in the hope that the combined functionalities would 
lead to potent and selective PARP-2 inhibitors. 
 
The first 5-substituted target isoquinolinone-5-NHCH2CO2H 59 was synthesised in 
acceptable yield by alkylation of 5-AIQ with ethyl bromoacetate, followed by hydrolysis. 
Problems were encountered in the synthesis of the homologue 61; treatment of 5-AIQ 
with methyl propenoate in the presence of sodium hydride resulted in abstraction of the 
lactam proton and alkylation at the 2-position forming 60. The isoquinolinone-5-
propenoic acid 26 was prepared in in excellent yield using the Heck reaction of 65 with 
propenoic acid. Reduction to the alkane using Pd/C and H2 provided another initial target 
27. The acid 28 was prepared following literature precedent by hydrolysis of 76. Several 
methods were attempted to synthesise 63 including palladium-catalysed coupling of 75 
with either diethyl malonate or ethylacetoacetate and Stille reaction 75 with 
trimethylallyltin. None of these were successful but the requirement for quantities of 5-
bromoisoquinolin-1-one 64 meant that a new synthesis for this molecule was developed. 
The key step involved the selective installation of bromine in the 5-position of 1-
chloroisoquinoline using the swamping catalyst method. This new synthesis was 
significantly more reliable and efficient than all other published syntheses of 64. 
 
The initial 5-substituted compounds were evaluated for activity against PARPs-1 and -2. 
Surprisingly, the most potent PARP-1 inhibitor was 60 which lacked an amide NH. In 
general, the inhibitors were not selective for either isoform, although 59 and 27 showed a 
ca. 3-fold selectivity for PARP-2 over PARP-1. A further series of 5-
acylaminoisoquinolin-1-ones was generated in good yields by treating 5-AIQ with the 
appropriate acid chloride in pyridine. The biological results from this series were more 
promising and the inhibitor which showed the highest degree of selectivity (ca. 9-fold) 
for PARP-2 was the unsubstituted 5-benzamidoisoquinolinone 101. The PARP-2 
selective inhibitors 22 and 99 that have been reported in the literature were also 
evaluated. It was interesting that 22 was 3-fold PARP-1 selective (reported selectivity 
4.71 for PARP-2) in our assays. 99 showed ca. 3-fold selectivity for PARP-2 in our 
system, in contrast to the reported 60-fold selectivity. 
 
The initial 3-alkyl and 3-arylisoquinolin-1-ones were prepared using the established route 
of Hurtley reaction of 34 with the appropriate β-diketone to form the isocoumarin, 
followed by reaction with ammonia and then palladium-catalysed reduction to the amine. 
A novel route to 3-aryl-5-nitroisocoumarins by Friedel-Crafts reaction of 56 with various 
acid chlorides was developed. The reaction was optimised for Lewis acid (SnCl4), 
reaction temperature (150oC) and solvent (PhNO2). The scope of the reaction was found 
to be limited to electron-deficient or electron-neutral acid chlorides. Reaction of 56 with 
[13C]-carbonyl benzoyl chloride gave 148 in which the 13C is located in the 3-position of 
the heterocycle, proving that the benzoyl carbon framework is incorporated intact. The 
yields of this new synthesis were comparable with the Hurtley route and therefore it is 
synthetically useful. In addition, the Friedel-Crafts route allows for the synthesis of 3-
aryl-5-nitroisocoumarins with electron-withdrawing substituents on the phenyl ring (e.g. 
154), whereas the Hurtley route does not. However, the Hurtley route allows access to 3-
alkyl-5-nitroisocoumarins and the Friedel-Crafts route does not. The Friedel-Crafts route 
was used to prepare the remaining 3-aryl compounds. A novel route to 158 was 
developed following the synthesis of 3-chloro-1-methoxy-5-nitroisoquinoline 171 which 
served as an ideal intermediate for Suzuki coupling with 3-methylphenylboronic acid. 
The overall yield of this synthesis was much greater than that of the Friedel-Crafts route. 
It is likely that this route will allow for later synthesis of a diverse range of 5-amino-3-
arylisoquinolin-1-ones due to the versatility of the Suzuki reaction. An attempt to 
introduce a 3-methyl substituent to 171 using the Stille reaction failed. 
 
The synthesised 3-substituted compounds were assayed for activity against the two PARP 
isoforms studied. In general both the 3-alkyl and 3-aryl the compounds were between 2- 
and 10-fold more potent than 5-AIQ against both PARP isoforms but there were some 
exceptions. All activity was lost with 121 and the position of the methyl group on the 3-
phenyl ring had a dramatic effect on potency; the o- and m- derivatives 157 and 158 were 
some 100-fold less potent against PARP-1 than 118. The p-iodophenyl derivative 161 
was 3-fold selective for PARP-2 but none of the compounds showed any major 
selectivity. 
 
Several approaches were investigated for the synthesis of 4-substituted 5-
aminoisoquinolin-1-ones. Friedel-Crafts reaction of 38 with benzoyl chloride and AlCl3 
gave the undesired 2-substituted 145. A switch to a Brønsted acid catalyst and acetic 
anhydride gave the desired 4-substituted 146 but all attempts to reduce the ketone failed. 
Methylation of the carbanion derived from 2,6-dicyanotoluene 41, followed by 
condensation with DMFDMA, gave the aldehyde 176 which cyclised to the isocoumarin 
177 upon formation of the enolate with diisopropylamine. However, the yields were very 
low and conversion to the isoquinolin-1-one did not occur when standard protocol was 
followed. Following the improved synthesis of 4-bromo-5-nitroisoquinolin-1-one 49, 
both palladium and copper-catalysed coupling reactions were attempted. These reactions 
failed, probably owing to poor solubility in the reaction medium, and the protected 
derivative 46 was prepared. It was possible to form the 4-methyl analogue 190 by 
lithiation of 46 and treatment with methyl iodide. This procedure did not extend to not 
extend to other electrophiles and the yield was poor. A much higher yield of 190 was 
obtained following Stille coupling of 46 with tetramethyltin and conversion to the target 
isoquinolin-1-one was straightforward. The Suzuki reaction of 46 was employed to 
synthesise the 4-substituted 195 and 197 in high yields and the structure of 195 was 
confirmed by X-ray crystallography. Standard Suzuki conditions of Pd2(dba)3, SPhos, 
potassium phosphate and toluene were developed. For the synthesis of 200, a different 
protected intermediate was required. This was prepared by reaction of 189 with sodium 
benzyloxide and the structure of the formed 201 was confirmed by X-ray crystallography. 
The coupling of 201 and 4-methoxyphenylboronic acid was successfully performed and 
deprotection and reduction of the nitro group were achieved in acceptable yield in a 
single step. The scope of the reaction for sterically hindered substrates was tested by the 
preparation of 204 which was formed in moderate yield. The X-ray crystallographic 
structure of 204 showed that the 4-substituent and the peri nitro group were twisted out of 
plane to the isoquinoline. A series of Buchwald-Hartwig reactions were attempted with 
46 but the only success was with aniline, forming 208. The reaction was optimised for 
ligand (SPhos), base (KOBut) and solvent (1,4-dioxane). 
 
The 4-arylisoquinolin-1-ones were assessed for activity against PARP-1 and PARP-2. 
Compound 195 was 2-fold more potent than was 5-AIQ against both isoforms and was 
therefore not selective. A drop in potency against PARP-1 was observed with 200 and 
also 197 which was ca. 8-fold selective for PARP-2. 
 
A short series of 3,5- and 4,5-disubstituted 5-AIQs was generated utilising the chemistry 
that had been developed throughout this work. Upon biological evaluation it was 
observed that these modifications caused a drastic drop in potency towards both PARP 
isoforms. The disappointing biological data meant that no further disubstituted 
compounds were prepared. 
 
A selection of the synthesised compounds was tested in the MTS cell proliferation assay 
(HT29 human colon carcinoma cells). Some of the 3-substituted compounds showed low 
micromolar activity but the 4- and 5-substituted compounds were not active. Activity in 
this assay was not correlated with PARP-1 or PARP-2-activity, which suggests an off-
target effect. 
 
Finally, a new three-step synthesis of 5-AIQ was developed in which the only 
purification procedures required were filtration and recrystallisation. The overall yield of 
this route was considerably higher than all other published routes. In addition, it was also 
reliable (unlike the Polonowski rearrangement of 51) and could be performed on large 
scales (unlike the formation of 56 by reaction of 52 with DMFDMA).     
 
In this work, the chemistry of isoquinolin-1-ones has been significantly advanced. Novel 
and synthetically useful routes to 3-, 4- and 5-substituted isoquinolin-1-ones have been 
developed. Biological evaluation of the compounds showed that five had a better 
selectivity profile for PARP-2 over PARP-1 than the best literature compound 99, in our 
assays. It would appear that modifications at the 4- and 5-positions of 5-AIQ are of 
paramount importance for selectivity.  
 
5.2 Future work 
 
The promising biological activity of many of the compounds synthesised in this project 
warrants further investigation. Ideally, the compounds should be tested in the same assay 
systems when comparing inhibitory activity against different PARP isoforms. Therefore, 
future work could focus on the development of a Flash Plate assay for PARP-2 or, if this 
was not possible, an ELSIA based assay for PARP-1. It would also be of interest to test 
the most selective inhibitors of PARP-2 from this project in vivo, for example comparing 
the effect of the inhibitors on PARP activity in cells derived from PARP-1 and PARP-2 
knockout mice and also from wild-type mice. These further biological tests would give 
insights into the true selectivity of the compounds. 
 
It would appear that modifications at the 4- and 5-positions of 5-AIQ are of paramount 
importance for selectivity. 5-substituted 5-AIQs have been extensively studied and future 
work could focus on the synthesis of 5-amino-4-arylisoquinolin-1-ones in which the 
phenyl ring is decorated with electron-withdrawing substituents. Additionally, as only 
one example has been studied, a further selection of 4-alkyl 5-AIQs could be prepared by 
Stille reaction of 46 with suitable substrates followed by deprotection and reduction. 
    
The palladium-catalysed chemistry to prepare 3-arylisoquinolin-1-ones from 171 also 
deserves further investigation as this is likely to be the most efficient and versatile route 
to these compounds.  The activity of some of the 3-arylisoquinolin-1-ones in the MTS 
assay is interesting and this potential off-target effect could be investigated. It is possible 
that inhibition of a different PARP isoform causes the observed cytotoxicity, therefore 
testing this series and further examples in other isoform-specific assays would be of 
interest. 
     
As the effect of 3,4-disubstitution in isoquinolin-1-ones on PARP inhibitory activity has 
not been investigated, these compounds could be prepared in future work. This could 
possibly be achieved by selective bromination of protected 3-alkyl or 3-arylisoquinolin-1-
ones followed by palladium catalysed coupling chemistry.  
 
Finally, although the 3,5-disubstituted compounds suffered from a dramatic drop in 
potency against both PARP isoforms, it was possible to retain some activity against 
PARP-2 whilst almost abolishing activity against PARP-1. For this reason, a small 
number of further examples could be prepared in an attempt to improve the potency and 


















All melting points were determined using a Reichert-Jung Thermo Galen Kofler block 
and are uncorrected. IR spectra were recorded on a Perkin-Elmer RXI FT-IR 
spectrometer, either as a liquid (film) or as a KBr disc (KBr). υmax values are given in  
cm-1. NMR spectra were recorded on either JEOL-Varian GX 270 (270.05 MHz 1H; 
67.8 MHz 13C) or Varian Mercury EX 400 (399.65 MHz 1H; 100.4 MHz 13C; 376.05 
MHz 19F) spectrometers. Tetramethylsilane was used as an internal standard for samples 
dissolved in CDCl3 and (CD3)2SO. Multiplicities are indicated as follows; s (singlet), br 
(broad singlet), d (doublet), dd (doublet doublet), dt (doublet triplet), t (triplet), q 
(quartet) and m (multiplet). Coupling constants (J) are expressed in Hz. Where indicated, 
2-D experiments were used to assign 1H NMR and 13C NMR signals. Mass spectra were 
Electrospray (ES) at the University of Bath Mass Spectrometry Service using a VG 7070 
Mass Spectrometer, the University of Bath Department of Pharmacy and Pharmacology 
High Resolution Mass Spectrometry Service using a Bruker microOTOF. Elemental 
analysis (CHN) was carried out at the School of Pharmacy, University of London, 
Microanalysis Service. Thin layer chromatography (TLC) was performed on silica gel 60 
F254-coated aluminium sheets (Merck) and visualisation was accomplished by UV light 
(254 nm). Flash column chromatography was performed using silica gel 60 (0.040-0.063 
mm, Merck) as the stationary phase.  
 
Reagents were purchased from Aldrich, Lancaster or Acros chemical companies and 
were used without further purification. Solutions in organic solvents were dried over 
magnesium sulfate and solvents were evaporated under reduced pressure. Experiments 










To 5-nitroisoquinolin-1-one 38 (1.6 g, 8.4 mmol) in EtOH (100 mL) and aq. HCl (34%, 4 
mL), a slurry of 10% Pd on charcoal (1.0 g) in EtOH (20 mL) was added. The mixture 
was stirred under H2 for 2 h. The suspension was then filtered through Celite
®. The 
Celite® pad and residue were suspended in water (600 mL) and heated. The hot 
suspension was filtered through a second Celite® pad. Evaporation of the solvent and 
drying gave 5 (1.1 g, 66%) as white crystals: mp 248-252°C (decomp.) (lit.130 250-
260°C (decomp.)); 1H NMR (D2O) δ 6.76 (1 H, d, J = 7.5 Hz, 4-H), 7.39 (1 H, d, J = 7.5 
Hz, 3-H), 7.59 (1 H, t, J = 8.0 Hz, 7-H), 7.79 (1 H, d, J = 8.0 Hz, 6-H), 8.27 (1 H, d, J = 
8.0 Hz, 8-H). 
 




5-Iodoisoquinolin-1-one 65 (200 mg, 0.74 mmol), propenoic acid (0.06 mL, 70 mg, 0.49 
mmol), palladium (II) acetate (16 mg, 74 µmol) and triethylamine (0.26 mL, 186 mg, 
1.84 mmol) in propanenitrile (0.6 mL) were heated under reflux for 1 h. Hydrochloric 
acid (2 M, 20 mL) was added and the precipitate was collected and dried to give 26 (152 
mg, 97%) as a pale green solid; Rf = 0.05 (hexane / ethyl acetate, 1:1); mp 314-318
oC 
(lit.131 315-318oC); 1H NMR ((CD3)2SO) δ 6.58 (1 H, d, J = 15.8 Hz, =CHCO2), 6.74 (1 
H, d, J = 7.3 Hz, 4-H), 7.30 (1 H, d, J = 7.3, Hz, 3-H), 7.52 (1 H, t, J = 7.7 Hz, 7-H), 8.10 
(1 H, d, J = 15.8 Hz, ArCH=), 8.12 (1 H, d, J = 7.7 Hz, 8-H), 8.27 (2 H, d, J = 7.7 Hz, 6-
H), 11.47 (1 H, br s, NH), 12.60 (1 H, br s, CO2H).  




To the alkene 26 (160 mg, 8.4 mmol) in EtOH (20 mL) and aq. HCl (34%, 4 mL), a 
slurry of 10% Pd on charcoal (100 mg) in EtOH (5 mL) was added. The mixture was 
stirred under H2 for 2 h and then filtered through Celite
®. Evaporation of the solvent from 
the filtrate and drying gave 27 (105 mg, 66%) as white crystals: mp 260-263°C; 1H NMR 
((CD3)2SO) δ 2.54 (2 H, t, J = 7.8 Hz, ArCH2), 3.09 (2 H, t, J = 7.8 Hz, CH2COOH), 
3.17-3.42 (1 H, br, CO2H), 6.62 (1 H, d, J = 7.4 Hz, 4-H), 7.21 (1 H, br d, J = 7.8 Hz, 3-
H), 7.38 (1 H, t, J = 7.4 Hz, 7-H), 7.55 (1 H, d, J = 7.4 Hz, 6-H), 8.07 (1 H, d, J = 7.4 Hz, 
8-H), 11.29 (1 H, br s, NH); 13C NMR δ 27.4, 34.8, 100.7, 125.1, 125.9, 126.5, 128.9, 
132.2, 136.1, 136.3, 162.0, 173.7. MS (ESI +ve) m/z 240.0682 (M + Na) (C12H11NaNO3 
requires 240.0637); 218.0819 (M + H) (C16H15N2O requires 218.0817). 




5-Cyanoisoquinolin1-one 76 (427 mg, 2.5 mmol) was heated under reflux with potassium 
hydroxide in ethanol (20% w/v, 12 mL), under nitrogen, until the production of ammonia 
ceased (3 d). The mixture was acidified with concentrated hydrochloric acid and the 
solvent was evaporated. The residue was taken up into methanol and filtered. 
Concentration of the filtrate gave 28 (0.394 g, 83%) as a white solid; Rf = 0.2  
(chloroform / methanol / acetic acid, 100:10:1); mp >300oC (lit.131 >300 oC); 1H NMR 
(CD3OD) δ 7.28 (1 H, d, J = 7.7 Hz, 4-H), 7.56 (1 H, t, J = 7.7 Hz, 7-H), 7.76 (1 H, d, J = 





SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, benzoyl chloride (140.5 mg, 1.04 mmol) was added and the mixture was 
stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with ice-water (2.0 
mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were washed (NaOH, 
brine) and dried (MgSO4). Evaporation and chromatography (hexane / EtOAc 15:1) gave 
31 (40 mg, 42%) as a pale yellow solid: Rf = 0.57 (hexane/EtOAc 4:1); mp 145-146°C 
(lit.158 mp 142-143°C); IR νmax 1739 (C=O), 1626 (C=C), 1525 & 1341 (NO2) cm
–1; 1H 
NMR δ 7.48-7.51 (3 H, m, Ph 3,4,5-H3), 7.59 (1 H, t, J = 7.8 Hz, 7-H), 7.85 (1 H, brs, 4-
H), 7.92 (2 H, m, Ph 2,6-H2), 8.48 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.61 (1 H, ddd, J = 8.2, 
1.2, 0.8 Hz, 8-H); 13C NMR δ 96.3, 122.3, 125.9, 127.1, 129.0, 131.1, 131.2, 131.6, 
131.9, 135.8, 144.2, 156.8, 160.3. 
 
 
















3-Nitrophthalic acid (10.5 g, 50 mmol) in hot aqueous NaOH (10%, 40 mL) was added to 
Hg(OAc)2 (17.5 g, 55 mmol) in hot AcOH (2.5 mL) and H2O (70 mL). The mixture was 
heated at 170°C for 70 h and was then filtered. The precipitate was washed (H2O, then 
EtOH) and dried to give 2-hydroxymercuri-3-nitrobenzoic acid 127 as a cream solid. 
Compound 134 was then heated under reflux in aqueous NaOH (3.5%, 250 mL). 
Aqueous HCl (2 M, 6 mL) was then slowly added, with vigorous stirring, and the 
solution was allowed to cool to room temperature. AcOH (3 mL) was then added. The 
cream precipitate dissolved upon addition of a mixture of NaBr (6.0 g, 59 mmol) and Br2 
(9.5 g, 60 mmol) in H2O (10 mL). The solution was heated under reflux for 24 h, cooled 
and neutralised with aqueous NaOH. It was then filtered and acidified (aq. HCl (9 M)). 
The precipitate formed was filtered, dried and recrystallised (EtOH) to give 34 (9.1 g, 
74%) as a white solid: Rf = 0.24 (hexane / EtOAc 1:4); mp 183-185°C (lit.
162 mp 187-
188°C); 1H NMR ((CD3)2SO) δ 7.70 (1 H, t, J = 7.9 Hz, 5-H), 7.93 (1 H, dd, J = 7.9, 1.5 








Compound 56 (1.5 g, 7.9 mmol) in 2-methoxyethanol (45 mL) was saturated with NH3 
and boiled under reflux for 2 h. The solvent and excess reagent were evaporated until 
10 mL remained. The concentrate was stored at 4°C for 16 h and the precipitated crystals 
were filtered, washed (H2O, then EtOH) and recrystallised (EtOH) to give 38 (1.1 g, 
73%) as pale yellow crystals: Rf = 0.49 (hexane / EtOAc 2:3); mp 244–246°C (decomp.) 
(lit.162 mp 247-249°C); 1H NMR ((CD3)2SO) δ 6.97 (1 H, dd, J = 7.7, 0.7 Hz, 4-H), 7.45 
(1 H, dd, J = 7.7, 1.8 Hz, 3-H), 7.66 (1 H, t, J = 7.7 Hz, 7-H), 8.46 (1 H, dd, J = 7.7, 1.5 
Hz, 6-H), 8.58 (1 H, ddd, J = 7.7, 1.5, 0.7 Hz, 8-H), 11.80 (1 H, brs, NH). 
Method B: 
1-Chloro-5-nitroisoquinoline 212 (5.00g, 24 mmol) was added to aq AcOH (100 mL) and 
the mixture was stirred at 100°C for 40 h. The cooled suspension was then poured onto 
ice; the precipitated crystals were filtered, washed (H2O) and recrystallised (EtOH) to 










Compound 189 (0.78 g, 2.70 mmol) and NaOMe (0.28 g, 4.9 mmol) were heated under 
reflux in dry MeOH (20 mL) for 3 d. The excess solvent was evaporated until 5 mL 
remained; the residue was diluted with H2O and extracted (CHCl3). Evaporation of the 
solvent and drying gave 46 (0.43 g, 56%) as a yellow solid: Rf = 0.68 (hexane / EtOAc 
5:1); mp 154-157°C; 1H NMR (CDCl3) δ 4.18 (3 H, s, OMe), 7.63 (1 H, t, J = 7.8 Hz, 7-
H), 7.88 (1 H, dd, J = 7.8, 1.1 Hz, 6-H), 8.29 (1 H, s, 3-H), 8.48 (1 H, dd, J = 7.8, 1.1 Hz, 
8-H); 13C NMR δ 54.6, 104.2, 110.0, 121.9, 126.3, 126.9, 128.5, 146.2, 147.0, 160.3; 
Anal. Found: C, 42.43; H, 2.63; N, 9.69. Calc. For for C10H7BrN2O3: C, 42.43; H, 2.49; 
N, 9.90%. 
 
 Method B: 
To 189 (5.0 g, 17.4 mmol) in dry MeOH (90 mL) was added finely divided sodium (0.70 
g, 31 mmol) and the mixture was heated under reflux for 16 h. The excess solvent was 
then evaporated until 20 mL remained and the residue was diluted with H2O and 



















Br2 (0.84 g, 5.3 mmol) in AcOH (1 mL) was slowly added to a suspension of 38 (1.0 g, 
5.3 mmol) in AcOH (30 mL). After 2 h, the cooled mixture was poured onto ice H2O (60 
mL) and stirred for 5 min. Extraction (CH2Cl2), drying, evaporation and chromatography 
(hexane/EtOAc 6:1) gave 49 (0.53 g, 37%) as a pale orange solid: Rf = 0.54 (hexane / 
EtOAc 1:1); mp 229-232°C (lit.175 mp 233-235°C); 1H NMR ((CD3)2CO) δ 7.73 (1 H, s, 
3-H), 7.77 (1 H, t, J = 7.8 Hz, 7-H), 8.10 (1 H, dd, J = 7.8, 1.6 Hz, 6-H), 8.61 (1 H, dd, J 
= 8.6, 1.9 Hz, 8-H).  
 
Further elution gave 183 (0.24 g, 30%) as a pale yellow solid: mp 170-172°C (lit.175mp 
175-177°C); 1H NMR ((CD3)2CO) δ 5.52 (1 H, dd, J = 5.7, 1.2 Hz, 3-H), 6.73 (1 H, d, J 
= 5.9 Hz, 4-H), 7.82 (1 H, t, J = 7.9 Hz, 7-H), 8.00 (1 H, dd, J = 7.9, 1.5 Hz, 6-H), 8.30 (1 




Br2 (5.0 g, 31.8 mmol) in AcOH (5 mL) was slowly added to a suspension of 38 (6.0 g, 
32 mmol) in AcOH (15 mL). The mixture was heated to 60°C and stirred for 16 h, then 
cooled and poured onto ice H2O (60 mL). The precipitate was collected, washed (MeOH) 
and dried to give 49 (4.5 g, 52%). Also isolated was 183 (2.4 g, 26%) as a pale yellow 
solid: data as above. 




2-Methyl-3-nitrobenzoic acid 57 (10.0 g, 55 mmol) was heated under reflux in MeOH 
(200 mL) and conc. H2SO4 (1 mL) for 48 h, then poured into ice-water (300 mL). The 
precipitate was filtered, washed (H2O) and recrystallised (MeOH) to give 52 (10.2 g, 
94%) as white crystals; mp 63-64°C (lit.162 mp 65-66°C); IR νmax 1724 (C=O), 1522 & 
1363 (NO2) cm
–1; 1H NMR δ 2.63 (3 H, s, ArMe), 3.94 (3 H, s, OMe), 7.38 (1 H, t, J = 










The ester 52 (5.00 g, 25.6 mmol) was heated with dimethylformamide dimethyl acetal 
(2.5 g, 21 mmol) in DMF (30 mL) at 150°C for 16 h. Evaporation, chromatography 
(hexane / EtOAc 10:1) and recrystallisation (EtOH) gave 56 (2.6 g, 53%) as pale yellow 
crystals: Rf = 0.34 (hexane / EtOAc 10:1); mp 171–172°C (lit.
162 mp 171-172°C); IR νmax 
1732 (C=O), 1618 (C=C), 1522 & 1342 (NO2) cm
–1; 1H NMR δ 7.39 (1 H, dd, J = 6.0, 
0.5 Hz, 4-H), 7.44 (1 H, d, J = 6.0 Hz, 3-H), 7.68 (1 H, t, J = 8.0 Hz, 7-H), 8.50 (1 H, dd, 
J = 8.0, 1.3 Hz, 6-H), 8.64 (1 H, ddd, J = 8.0, 1.3, 0.5 Hz, 8-H). 
 






Compound 5 (1.0 g, 4.4 mmol), Pri2NEt (1.4 g, 11 mmol), ethyl bromoacetate (885 mg, 
5.3 mmol) and NaI (100 mg, 0.7 mmol) were stirred at 80°C in DMF (60 mL) for 16 h. 
Evaporation and recrystallisation (MeOH) gave 58 (121 mg, 19%) as buff crystals: Rf = 
0.25 (EtOAc / hexane 4:1); mp 199-201°C; IR νmax 3437 (NH), 1728 (C=O), 1654 (C=O) 
cm–1; 1H NMR ((CD3)2SO) δ 1.19 (3 H, t, J = 7.2 Hz, Me), 4.01 (2 H, d, J = 4.9 Hz, 
CH2N), 4.12 (2 H, q, J = 7.2 Hz, OCH2), 6.44 (1 H, t, J = 4.9 Hz, CH2NH), 6.56 (1 H, d, 
J = 7.8 Hz, 4-H), 6.72 (1 H, d, J = 7.8 Hz, 3-H), 7.11 (1 H, m, 6-H), 7.22 (1 H, t, J = 7.8 
Hz, 7-H), 7.46 (1 H, d, J = 7.8 Hz, 8-H), 11.2 (1 H, br, NH); 13C NMR δ 14.1, 44.8, 60.4, 
99.2, 110.5, 114.4, 125.5, 126.8, 126.9, 127.0, 143.1, 162.0, 171.1. MS (ES +ve) m/z 
269.0911 (M + Na) (C13H14N2O3Na requires 269.0902), 247.1136 (M + H) (C13H15N2O3 
requires 247.1083). 
 





HOOC HCl  
The ester 58 (94.0 mg, 0.39 mmol) was heated under reflux in aq. HCl (17%, 4.0 mL) for 
3 h. Evaporation gave 59 (86 mg, 87%) as an amber solid: Rf = 0 (EtOAc); mp 275-
280°C (decomp.); IR νmax 3134 (NH), 2523 (OH), 1737 (C=O), 1608 (C=O) cm
–1; 1H 
NMR ((CD3)2SO) δ 3.91 (2 H, s, CH2), 5.23-6.22 (3 H, m, OH, NH2), 6.58 (1 H, dd, J = 
7.9, 0.8 Hz, 4-H), 6.72 (1 H, d, J = 7.6 Hz, 3-H), 7.10 (1 H, brd, J = 7.0 Hz, 6-H), 7.22 (1 
H, t, J = 8.2 Hz, 7-H), 7.45 (1 H, d, J = 7.9 Hz, 8-H), 11.21 (1-H, brs, NH); 13C NMR 
δ 44.8, 99.2, 110.4, 110.5, 114.2, 135.5, 126.9, 127.0, 143.2, 162.0, 172.5. MS m/z 














NaH (80 mg, 3.5 mmol) was added to 5 (0.40 g, 1.8 mmol) in dry THF (40 mL), 
followed by methyl propenoate (0.17g, 1.9 mmol) and the mixture was stirred for 2 
h. Evaporation and recrystallisation (MeOH) gave 60 (0.30g, 67%) as pale buff 





H NMR ((CD3)2SO) δ 2.67 (2 H, t, J = 7.0 Hz, CH2CO2), 4.09 (2 H, t, J 
= 7.0 Hz, NCH2), 4.36 (3 H, s, CH3), 5.62-5.91 (2 H, br, NH2), 6.72 (1 H, d, J = 7.5 Hz, 
4-H), 6.84 (1 H, d, J = 7.5 Hz, 6-H), 7.16 (1 H, t, J = 7.8 Hz, 7-H), 7.31 (1 H, d, J = 7.4 
Hz 3-H), 7.41 (1 H, d, J = 7.8 Hz 8-H); 
13
C NMR (HMBC / HMQC) δ 33.1 
(CH2CO2), 44.9 (NCH2), 53.9 (OCH3), 100.3 (4-C), 114.1 (6-C), 114.8 (8-C), 123.8 
(4a-C), 126.4 (8a-C), 127.2 (7-C), 130.6 (3-C), 144.3 (5-C), 161.2 (1-C), 172.6 
(COOMe); MS (ES +ve) m/z 269.0922 (M + Na) (C13H14N2O3Na requires 269.0902), 
247.1168 (M + H) (C13H15N2O3 requires 247.1083). 






The ester 60 (302 mg, 1.23 mmol) was heated under reflux in aq. HCl (17%, 4.0 mL) for 
24 h. Evaporation gave 62 (281 mg, 85%) as an amber solid: Rf = 0 (EtOAc); mp 199-
201°C; IR νmax 3240 (NH), 2580 (O-H), 1721 (C=O), 1638 (C=O) cm
-1; 1H NMR 
((CD3)2SO) δ 2.68 (2 H, t, J = 7.0 Hz, CH2CO2), 4.10 (2 H, t, J = 7.0 Hz, NCH2), 5.62-
5.91 (2 H, br, 2 × NH), 6.72 (1 H, d, J = 7.4 Hz, 4-H), 6.84 (1 H, dd, J = 7.8, 1.1 Hz, 6-
H), 7.16 (1 H, t, J = 7.8 Hz, 7-H), 7.31 (1 H, d, J = 7.4 Hz 3-H), 7.41 (1 H, d, J = 7.8 Hz 
8-H); 13C NMR (HMBC / HMQC) δ 33.1 (CH2CO2), 44.9 (NCH2), 53.9, 100.3 (4-C), 
114.1 (6-C), 114.8 (8-C), 123.8 (4a-C), 126.4 (8a-C), 127.2 (7-C), 130.6 (3-C), 144.3 (5-
C), 161.2 (1-C), 172.6 (COOH).MS m/z 233.0927 (M + H) (C12H13N2O3 requires 
233.0936). 




5-Bromo-1-chloroisoquinoline 91 (3.0 g, 12 mmol), AcOH (50 mL) and H2O (50 mL) 
were heated to 100oC and allowed to reflux for 48 h. The solution was then allowed to 
cool and the precipitate was washed (H2O) and dried to give 64 (1.9g, 70%) as a white 
solid: Rf = 0.14 (hexane / EtOAc 1:1); mp 240-242
oC (lit.135 242-244oC); 1H NMR 
((CD3)2SO) δ 6.66 (1 H, d, J = 7.2 Hz, 4-H), 7.38 (1 H, d, J = 7.1 Hz, 7-H), 7.42 (1 H, d, 
J = 7.2 Hz, 3-H), 8.02 (1 H, d, J = 7.1 Hz, 6-H), 8.21 (1 H, d, J = 7.1 Hz, 8-H), 11.56 (1 






Compound 75 (600 mg, 2.2 mmol) in 2-methoxyethanol (100 mL) was saturated with 
NH3 and boiled under reflux for 2 h, then the solvent and excess reagent were evaporated 
until 5 mL remained. The concentrate was stored at 4°C for 16 h and the precipitated 
crystals were filtered, washed (H2O, then EtOH) and recrystallised (acetone) to give 65 
(182 mg, 62%) as pale buff crystals: Rf = 0.36 (hexane / EtOAc 2:3); mp 236–244°C 
(decomp.) (lit.135 mp 238-244°C); 1H NMR ((CD3)2SO) δ 6.54 (1 H, d, J = 7.3 Hz, 4-H), 
7.24 (1 H, t, J = 7.8 Hz, 7-H), 7.32 (1 H, d, J = 7.3 Hz, 3-H), 8.23 (2 H, m, 6,8-H2), 11.54 
(1 H, br s, NH). 
 





Compound 69 (14.1 g, 50 mmol) was heated under reflux with propenoic acid (4.7 g, 66 
mmol), Pd(OAc)2 (111 mg, 0.49 mmol), Et2N (12.6 g, 124 mmol) in propanenitrile (200 
mL) for 1.5 h. HCl (2 M, 800 mL) was then added to the cooled mixture. Filtration of a 
solution of the resulting precipitate gave the acid 70 (8.5 g, 76%) as a white solid: mp 
198-200oC (lit.135 202-204oC); 1H NMR δ 6.58 (1 H, d, J = 16.2 Hz, 2-H), 7.35 (1 H, dt, J 
= 7.7, 1.5 Hz, Ar 4-H), 7.44 (1 H, t, J = 7.7 Hz, Ar 5-H), 7.72 (1 H, dd, J = 7.7, 1.5 Hz, 
Ar 6-H), 7.83 (1 H, d, J = 16.2 Hz, 3-H), 7.91 (1 H, dd, J = 7.7, 1.5 Hz, Ar 3-H), 12.65 (1 
H, br, CO2H).   
 














Compound 70 (3.3 g, 15 mmol) was stirred with thionyl chloride (10 mL) and DMF (0.05 
mL) for 16 h then the excess reagents were removed by evaporation. The residue (crude 
71) in 1,4-dioxane (5 mL) was added to sodium azide (2.9 g, 44 mmol) in water (6 mL) 
and 1,4-dioxane (6 mL) over 15 min. The mixture was stirred for 45 min and then diluted 
with H2O (11 mL) extracted with DCM. The dried extract was evaporated to give a 
residue (crude 64) which, in DCM (10 mL), was added to boiling bis(2-(2-
methoxyethoxy)ethyl) ether (12 mL) in portions. The solution was heated under reflux 
for 1 h and then cooled. The resulting solid was recrystallised (acetone) to give 64 (0.3 g, 





To 5-nitroisocoumarin 56 (1.00g, 5.23 mmol) in THF (100 mL), a slurry of 10% Pd on 
charcoal (125 mg) in THF (20 mL) was added. The mixture was stirred under H2 for 2 h. 
The suspension was then filtered through Celite®. Concentration of the filtrate and drying 
gave 74 (0.75 g, 89%) as yellow crystals: mp 186-188°C (lit.176 185-187°C); 1H NMR 
(CDCl3) δ 4.02 (2 H, br s, NH), 6.45 (1 H, dd, J = 8.0, 0.5 Hz, 4-H), 7.04 (1 H, dd, J = 
8.0, 1.2 Hz, 6-H), 7.26 (1 H, d, J = 8.0 Hz, 3-H), 7.34 (1 H, t, J = 8.0 Hz, 7-H), 7.77 (1 H, 





Sodium nitrite (370 mg, 5.33 mmol) in H2O (30 mL) was added to 5-aminoisocoumarin 
74 (1.0 g, 6.2 mmol) in aq. HCl (4.5 M, 36 mL) at 0°C. A solution of KI (1.4g, 8.6 mmol) 
in H2O (35 mL) was then added over 10 min. The mixture was stirred for 2 h then 
extracted with EtOAc. Evaporation and chromatography (hexane/EtOAc 4:1) gave 75 
(0.98 g, 58%) as pale yellow crystals: Rf = 0.68 (hexane / EtOAc 4:1); mp 155–156°C 
(lit.177 mp 155-156°C); 1H NMR CDCl3 δ 7.31 (1 H, d, J = 6.3 Hz, 4-H), 7.36 (1 H, d, J = 
6.3 Hz, 3-H), 7.60 (1 H, t, J = 8.2 Hz, 7-H), 8.41 (1 H, d, J = 8.2 Hz, 6-H), 8.56 (1 H, d, J 












2,6-Dicyanotoluene 41 (1.0 g, 7 mmol) in freshly distilled ethyl formate (25 ml) was 
stirred at 0-5oC with potassium tert-butoxide (4.4 g, 38 mmol) for 25 min. Addition of 
Et2O caused a yellow precipitate to form, which was filtered off. The yellow solid was 
dissolved in water and the solution was acidified with acetic acid, saturated with sodium 
chloride and extracted with chloroform. The organic extract was dried and the solvent 
was evaporated. Chromatography (twice) (CHCl3 / EtOAc, 2:1, hexane / EtOAc, 4:1) 
yielded 5-cyanoisocoumarin 77 (0.33 g, 14%) as colourless crystals: Rf = 0.85 (CHCl3 / 
EtOAc, 2:1); mp 213-215oC (lit.131 212-214 oC); 1H NMR (CDCl3) δ 6.89 (1 H, d, J = 5.7 
Hz, 4-H), 7.46 (1 H, d, J = 5.7 Hz, 3-H), 7.66 (1 H, t, J = 7.7 Hz, 7-H), 8.04 (1 H, d, J = 
7.7 Hz, 6-H), 8.52 (1 H, d, J = 7.7 Hz, 8-H). Further elution gave 5-cyanoisoquinolin-1-
one 76 (0.15 g, 6.5%) as a pale yellow solid: Rf = 0.22 (chloroform / ethyl acetate, 2:1); 
mp 292-294oC (lit.131 296-300oC); 1H NMR ((CD3)2SO) δ 6.60 (1 H, J = 7.0 Hz, 4-H), 
7.47 (1 H, d, J = 7.0 Hz, 3-H), 7.63 (1 H, t, J = 7.7 Hz, 7-H), 8.26 (1 H, d, J = 7.7 Hz, 6-







AlCl3 (5.0 g, 37 mmol) and 1-chloroisoquinoline 90 (4.0 g, 24 mmol) were heated to 
160oC until molten. Br2 (5.9 g, 37 mmol) was then added, slowly over 5 h through a 
sintered condenser. The mixture was allowed to stir for a further 30 min, then allowed to 
cool and poured onto ice. Extraction (Et2O), drying and evaporation and washing 
(MeOH) gave 91 (3.8 g, 65%) as an off-white solid: Rf = 0.68 (hexane/EtOAc 9:1); mp 
158-160oC (lit.145 159-160oC; 1H NMR (CDCl3) 7.54 (1 H, t, J = 8.2 Hz, 7-H), 7.98 (1 H, 
d, J = 5.9 Hz, 4-H), 8.01 (1 H, d, J = 8.0 Hz, 6-H), 8.34 (1 H, d J = 8.0 Hz, 8-H), 8.37 (1 











To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added benzoyl chloride 
(0.03 mL, 39 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h; Evaporation and 
recrystallisation (EtOAc) gave 101 (57 mg, 86%) as an off-white solid: Rf = 0.16 
(EtOAc); mp >310oC (decomp.); 1H NMR ((CD3)2SO) δ 6.52 (1 H, d, J = 7.4 Hz, 4-H), 
7.18 (1 H, dd, J = 7.4, 5.5 Hz, 3-H), 7.50-7.61 (4 H, m, 7,3’,4’,5’-H4), 7.75 (1 H, d, J = 
7.6 Hz, 6-H), 8.04 (2 H, d, J = 7.0 Hz, 2’,6’-H2), 8.13 (1 H, d, J = 7.8 Hz, 8-H), 10.33 (1 
H, s, PhCONH), 11.32 (1 H, d, J = 4.7 Hz, 2-NH); 13C NMR δ 100.6, 124.8, 125.9, 
127.0, 127.8 (C2), 128.5 (C2), 128.9, 130.5, 131.8, 133.2, 134.1, 134.2, 161.6, 166.0; MS 
(ESI +ve) m/z 287.0801 (M + Na) (C16H12NaN2O2 requires 287.0796); 265.0952 (M + H) 
(C16H13N2O2 requires 265.0977); Anal. Found: C, 72.67; H, 4.48; N, 10.42. Calc. for 













To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-bromobenzoyl 
chloride (61 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h. Evaporation and 
recrystallisation (EtOAc) gave 102 (86 mg, 81%) as a yellow solid: Rf = 0.18 (EtOAc); 
mp 258-260oC; 1H NMR ((CD3)2SO) δ 6.51 (1 H, d, J = 7.4 Hz, 4-H), 7.18 (1 H, dd, J = 
7.4, 5.7 Hz, 3-H), 7.52 (1 H, t, J = 7.8 Hz, 7-H), 7.71 (2 H, d, J = 8.2 Hz, Ar 3,5-H2), 7.74 
(1 H, d, J = 7.4 Hz, 6-H), , 7.99 (2 H, d, J = 8.2 Hz, Ar-2,6-H2), 8.13 (1 H, d, J = 7.8 Hz, 
8-H), 10.40 (1 H, s, ArCONH) 11.34 (1 H, d, J = 5.1 Hz, 2-NH); 13C NMR 99.9, 125.0, 
125.9, 127.0, 128.7, 128.5, 128.9, 129.7, 130.4, 132.9, 132.9, 135.2, 136.6, 161.5, 165.2; 
MS (ESI +ve) m/z 345.0026 (M + H) (C16H12
81BrN2O2 requires 345.0062), 343.1414 (M 
+ H) (C16H12
79BrN2O2 requires 343.0082); Anal. Found: C, 55.85; H, 3.14; N, 8.02. Calc. 











To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-methylbenzoyl 
chloride (0.04 mL, 43 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h; 
Evaporation and recrystallisation (EtOAc) gave 103 (57 mg, 82%) as an off-white solid: 
Rf = 0.19 (EtOAc); mp 297-300
oC; 1H NMR δ 2.40 (3 Η, s, CH3), 6.50 (1 H, d, J = 7.0 
Hz, 4-H), 7.18 (1 H, dd, J = 7.2, 6.7 Hz, 3-H), 7.35 (2 H, d, J = 7.6 Hz, 3’, 5’-H2), 7.51 (1 
H, d, J = 8.2 Hz), 7.72 (2 H, d, J = 7.6 Hz, 2’, 6’-H2), 8.11 (1 H, d, J = 8.2 Hz, 8-H), 
10.25 (1 H, s, ArCONH), 11.31 (1 H, br s, 2-NH); 13C NMR δ 21.0, 100.6, 124.7, 127.0, 
127.8, 128.8, 129.0, 130.5, 131.3, 133.2, 134.2, 141.8, 161.6, 165.9; MS (ESI +ve) m/z 
301.0941 (M + Na) (C17H14NaN2O2 requires 301.0953); 279.1119 (M + H) (C17H15N2O2 
requires 279.1134); Anal. Found: C, 73.23; H, 4.98; N, 10.22. Calc. for C17H14N2O2: C, 









To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-iodobenzoyl 
chloride (74 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h. Evaporation and 
recrystallisation (EtOAc) gave 104 (74 mg, 76%) as a pale grey solid: Rf = 0.18 (EtOAc); 
mp >290 oC; 1H NMR ((CD3)2SO) δ 6.51 (1 H, d, J = 7.4 Hz, 4-H), 7.18 (1 H, dd, J = 7.4, 
5.7 Hz, 3-H), 7.51 (1 H, t, J = 7.8 Hz, 7-H), 7.74 (1 H, d, J = 7.4 Hz, 6-H), 7.82 (2 H, d, J 
= 8.2 Hz, Ar 3,5-H2), 7.95 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 8.14 (1 H, d, J = 7.8 Hz, 8-H), 
10.39 (1 H, s, ArCONH) 11.33 (1 H, d, J = 5.1 Hz, 2-NH); 13C NMR δ 99.5, 100.6, 
124.9, 125.9, 127.0, 128.9,129.7, 130.42, 132.9, 133.6, 134.2, 137.4, 161.6, 165.4; MS 
(ES +ve) m/z 390.9950 (M + H) (C16H12IN2O2 requires 390.9944); Anal. Found: C, 











To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-nitrobenzoyl 
chloride (52 mg, 0.28 mmol). The mixture was stirred at 90 oC for 16 h. Evaporation and 
recrystallisation (EtOAc) gave 105 (55 mg, 71%) as an orange solid: Rf = 0.15 (EtOAc); 
mp >190oC (decomp.); 1H NMR ((CD3)2SO) δ 6.55 (1 H, d, J = 7.5 Hz, 6-H), 7.20 (1 H, 
dd, J = 7.5, 5.2 Hz, 3-H), 7.53 (1 H, t, J = 7.9 Hz, 7-H), 7.79 (1 H, d, J = 7.2 Hz, 4-H), 
8.16 (1 H, d, J = 7.9 Hz, 8-H), 8.26 (2 H, d, J = 8.5 Hz, Ar 3,5-H2), 8.40 (2 H, d, J = 8.54 
Hz, Ar 2,6-H2), 10.66 (1 H, s, ArCONH), 11.36 (1 H, d, J = 5.2 Hz, 2-NH); 
13C NMR δ 
100.46 (5-C), 123.6, 125.2, 126.0, 129.1, 129.3, 130.4, 132.6, 134.1, 139.9, 134.2, 149.3, 
161.6, 164.6; MS (ESI +ve) m/z 332.0639 (M + Na) (C16H11NaN3O4 requires 332.0647), 
310.0827 (M + H) (C16H12N3O4 requires 310.0828); Anal. Found: C, 61.96; H, 3.38; N, 











 To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-
trifluoromethylbenzoyl chloride (70 mg, 0.28 mmol). The mixture was stirred at 90 oC for 
16 h. Evaporation and recrystallisation (EtOAc) gave 106 (60 mg, 72%) as a pale orange 
solid: Rf = 0.15 (EtOAc); mp 319-321°C; 
1H NMR ((CD3)2SO) δ 6.54 (1 H, d, J = 7.3 Hz, 
4-H), 7.19 (1 H, dd, J = 7.3, 4.9 Hz, 3-H), 7.53 (1 H, t, J = 7.7 Hz, 7-H), 7.77 (1 H, d, J = 
7.7 Hz, 6-H), 7.94 (1 H, d, J = 7.7 Hz, 8-H), 8.15 (2 H, d, J = 8.2 Hz, Ar 3,5-H2), 8.23 (2 
H, d, J = 8.2 Hz, Ar 2,6-H2), 10.56 (1 H, s, ArCONH) 11.35 (1 H, d, J = 4.9 Hz, 2-NH); 
13C NMR (HMBC / HMQC) δ 100.5 (4-C), 125.1 (8-C), 125.9 (q, J = 31.5 Hz, Ph 3,5-
C2), 126.8 (7-C), 126.9 (8a-C), 128.9 (Ph 2,6-C2), 130.3 (6-H), 130.9 (q, J = 31.5 Hz, Ph 
4-C), 132.6 (5-C), 134.0 (4a-C), 137.9 (CF3), 149.5 (Ph 1-C), 161.5 (1-C); MS (ESI +ve) 
m/z 355.0666 (M + Na) (C17H11F3NaN2O2 requires 355.0670), 333.0844 (M + H) 
(C17H12F3N2O2 requires 333.0851); Anal. Found: C, 61.23; H, 3.68; N, 8.66. Calc. for 




















To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-fluorobenzoyl 
chloride (0.04 mL, 46 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h. 
Evaporation and recrystallisation (EtOAc) gave 107 (71 mg, 68%) as a pale orange solid: 
Rf = 0.16 (EtOAc); mp 302-305°C; 
1H NMR ((CD3)2SO) δ 6.54 (1 H, d, J = 7.4 Hz, 4-H), 
7.18 (1 H, dd, J = 7.4, 6.2 Hz, 3-H), 7.33 (2 H, dd, J = 9.0, 8.6 Hz, Ar 3,5-H2), 7.54 (1 H, 
d, J = 8.2 Hz, 7-H), 7.69 (1 H, d, J = 8.2 Hz, 6-H), 8.03 (2 H, dd, J = 9.0, 5.0 Hz, Ar 2,6-
H2), 8.14 (1 H, d, J = 8.2 Hz, 8-H), 10.44 (1 H, br s, ArCONH), 11.33 (1 H, br, 2-NH); 
13C NMR δ 102.1, 116.3, 116.5, 126.1, 127.3 (m, CF3), 129.5, 131.2 (m, Ar 4-C), 131.3, 
131.8, 133.6, 135.2, 163.0, 166.7; MS (ESI +ve) m/z 305.0710 (M + Na) 
(C16H11FNaN2O2 requires 305.0702), 283.0889 (M + H) (C16H12FN2O2 requires 
283.0883) Anal. Found: C, 67.98; H, 3.68; N, 9.62. Calc. for C17H11F3N2O2: C, 68.05; H, 










To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-chlorobenzoyl 
chloride (0.04 mL, 49 mg, 0.28 mmol). The mixture was stirred at 90 oC for 16 h. 
Evaporation and recrystallisation (EtOAc) gave 108 (58 mg, 77%) as a pale orange solid: 
Rf = 0.17 (EtOAc); mp 347-349°C; 
1H NMR ((CD3)2SO) δ 6.51 (1 H, J = 7.5 Hz, 4-H), 
7.18 (1 H, dd, J = 7.5, 5.2 Hz, 3-H), 7.51 (1 H, J = 7.8 Hz, 7-H), 7.63 (2 H, d, J = 8.2 Hz, 
Ar 3,5-H2), 7.74 (1 H, d, J = 7.8 Hz, 6-H), 8.04 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 8.13 (1 H, 
d, J = 7.8 Hz, 8-H), 10.41 (1 H, s, ArCONH), 11.34 (1 H, d, J = 4.6 Hz, 2-NH); 13C NMR 
δ 100.6, 125.0, 125.9, 127.0, 128.5, 127.0, 128.5 (C2), 128.9, 129.7 (C2), 130.4, 132.9, 
132.9, 134.2, 136.6, 161.6, 165.0; MS (ESI +ve) m/z 323.0334 (M + Na) 
(C16H11
37ClNaN2 NaO2 requires 323.0337) 321.0399 (M + Na) (C16H11
35ClNaN2 NaO2 
requires 321.0407), 299.0584 (M + H) (C16H12ClN2O2 requires 299.0587); Anal. Found: 








To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 2-iodobenzoyl 
chloride (74 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h. Evaporation and 
recrystallisation (EtOAc) gave 109 (60 mg, 61%) as a pale brown solid: Rf = 0.19 
(EtOAc); mp 317-320oC; 1H NMR ((CD3)2SO) δ 6.77 (1 H, d, J = 7.9 Hz, 4-H), 7.20 (1 
H, t, J = 7.9, 5.6 Hz, 3-H), 7.25 (1 H, dt, J = 7.6, 1.8 Hz, Ar 4-H), 7.54-7.63 (3 H, m, 7-H 
and Ar 3,5-H2), 7.90 (1 H, d, J = 7.9 Hz, 6-H), 7.96 (1 H, d, J = 7.9 Hz, 8-H), 8.12 (1H, 
d, J = 7.6 Hz, Ar 6-H), 10.41 (1 H, s, ArCONH), 11.34 (1 H, d, J = 5.6 Hz, 2-NH); 13C 
NMR δ 93.6, 100.5, 124.6, 125.9, 127.1, 128.1, 128.2, 128.7, 129.2, 131.0, 132.5, 133.2, 
139.0, 161.5, 166.4; MS (ES +ve) m/z 390.9952 (M + H) (C16H12IN2O2 requires 
390.9944) Anal. Found: C, 49.12; H, 2.66; N, 7.26. Calc. for C16H11IN2O2: C, 49.25; H, 












To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-methylbenzoyl 
chloride (0.04 mL, 43 mg, 0.28 mmol). The mixture was stirred at 90 oC for 16 h. 
Evaporation and recrystallisation (EtOAc) gave 110 (57 mg, 63%) as an off-white solid: 
Rf = 0.17 (EtOAc); mp 310-313°C; 
1H NMR ((CD3)2SO) δ 2.54 (3 H, s, Me), 6.62 (1 H, 
d, J = 7.5 Hz, 4-H), 7.21 (1 H, dd, J = 7.5, 5.2 Hz, 3-H), 7.29-7.33 (2 H, m, Ar 3,5-H2), 
7.41 (1 H, t, J = 7.4 Hz, Ar 4-H), 7.51 (1 H, t, J = 7.4 Hz, 7-H), 7.58 (1 H, d, J = 7.4 Hz, 
6-H) 7.82 (1 H, d, J = 7.4 Hz, Ar 6-H), 8.10 (1 H, d, J = 7.4 Hz, 8-H), 10.24 (1 H, s, 
ArCHNH), 11.32 (1 H, d, J = 5.1 Hz, 2-NH); 13C NMR δ 19.5, 100.4, 124.5, 125.6, 
125.9, 127.0, 127.4, 128.9, 129.7, 130.6, 131.0, 132.9, 133.6, 135.4, 136.8, 161.6, 168.6. 
MS (ESI +ve) m/z 301.0956 (M + Na) (C17H13N2NaO2 requires 301.0953), 279.1130 (M 
+ H) (C17H14N2O2 requires 279.1133); Anal. Found: C, 73.33; H, 5.02; N, 10.11. Calc. 










To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added thiophene-2-
carbonyl chloride (0.03 mL, 41 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 
h. Evaporation and recrystallisation (EtOAc) gave 111 (34 mg, 51%) as an off-white 
solid: Rf = 0.14 (EtOAc); mp 288-291°C; 
1H NMR ((CD3)2SO) δ 6.51 (1 H, d, J = 7.4 Hz, 
4-H), 7.19 (1 H, dd, J = 7.4, 5.4 Hz, 3-H), 7.23 (1 H, dd, J = 4.9, 3.6 Hz,  Ar 4-H), 7.52 
(1 H, t, J = 7.8 Hz, 7-H), 7.70 (1 H, d, J = 7.8 Hz, 6-H), 7.83 (1 H, d, J = 4.9 Hz, Ar 5-H), 
8.03 (1 H, d, J = 3.6 Hz,  Ar 3-H), 8.13 (1 H, d, J = 7.8 Hz, 8-H), 10.41 (1 H, s, 
ArCONH), 11.33 (1 H, d, J = 5.4 Hz, 2-NH); 13C NMR δ 100.2, 125.5, 126.6, 127.2, 
128.7, 129.3, 129.9, 131.2, 132.3, 132.9, 134.7, 139.4, 161.2, 162.2; MS (ESI +ve) m/z 
293.0347 (M + Na) (C14H10N2NaO2S requires 293.0361), 271.0529 (M + H) 
(C14H11N2O2S requires 271.0541); Anal. Found: C, 61.11; H, 3.55; N, 10.62. Calc. for 








To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added cyclohexane-
carbonyl chloride (0.04 mL, 41 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 
h. Evaporation and recrystallisation (EtOAc) gave 112 (46 mg, 68%) as an off-white 
solid: Rf = 0.18 (EtOAc); mp 302-305
oC; 1H NMR ((CD3)2SO) δ 1.23 (1 H, ca. q, J = 
12.5 Hz, CHx, 4ax-H), 1.30 (2 H, ca. q, J = 12.6 Hz, CHx, 3ax,5ax-H2), 1.43 (2 H, dq, J = 
12.1, 2.3 Hz, CHx, 2ax,6ax-H2), 1.66 (1 H, brd, J = 12.1 Hz, CHx,4eq-H), 1.77 (2 H, ca. d, J 
= 12.5 Hz, CHx, 3eq,5eq-H2), 1.87 (2 H, ca. d, J = 12.5 Hz, CHx, 2eq,6eq-H2), 2.50 (1 H, m, 
CHx, 1-H). 6.57 (1 H, d, J = 7.5 Hz, 4-H), 7.18 (1 H, dd, J = 7.3, 6.2 Hz, 3-H). 7.42 (1 H, 
t, J = 7.8 Hz, 7-H), 7.76 (1 H, d, J = 7.8 Hz, 6-H), 8.02 (1 H, d, J = 7.8 Hz, 8-H), 9.66 (1 
H, s, cHexCONH), 11.30 (1 H, d, J = 5.1 Hz, 2-NH); 13C NMR δ 25.3 (C2), 25.4, 29.3 
(C2), 44.2, 100.0, 123.6, 125.8, 126.9, 128.5, 128.6, 132.6, 133.1, 161.6, 174.8; MS (ESI 
+ve) m/z 563.2616 (2 M + Na) (C32H36N4NaO4 requires 563.2634), 541.2798 (2 M + H) 
(C32H37N4O4 requires 541.2815) 293.1248 (M + Na) (C16H18N2NaO2 requires 293.1266), 
271.1140 (M + H) (C16H19N2O2 requires 271.1147); Anal. Found: C, 71.31; H, 6.52; N, 







 To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added 2,2-
dimethylpropanoyl chloride (0.03 mL, 34 mg, 0.28 mmol). The mixture was stirred at 
90oC for 16 h. Evaporation and recrystallisation (EtOAc) gave 113 (46 mg, 68%) as an 
off-white solid: Rf = 0.21 (EtOAc); mp 305-307
oC; 1H NMR ((CD3)2SO) δ 1.28 (9 H, s, 3 
× Me), 6.38 (1 H, d, J = 7.4 Hz, 4-H), 7.18 (1 H, dd, J = 7.4, 4.3 Hz, 3-H), 7.45 (1 H, t, J 
= 7.6 Hz, 7-H), 7.53 (1 H, d, J = 7.6 Hz, 6-H), 8.08 (1 H, d, J = 7.6 Hz, 8-H), 9.36 (1 H, 
s, ButCONH), 11.29 (1 H, br, 2-NH); 13C NMR δ 27.4 (C3), 40.1, 100.5, 124.6, 125.8, 
126.9, 128.7, 130.7, 133.4, 134.5, 161.7, 177.1; MS (ESI +ve) m/z 267.1109 (M + Na) 
(C14H16N2NaO2 requires 267.1109), 245.1291 (M + H) (C14H17N2O2 requires 245.1290); 









To 5AIQ.HCl 5 (50 mg, 0.25 mmol) in pyridine (2.0 mL) was added adamantane-1-
carbonyl chloride (56 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h. 
Evaporation and recrystallisation (EtOAc) gave 114 (48 mg, 59%) as an off-white solid: 
Rf = 0.23 (EtOAc); mp 303-306
oC; 1H NMR ((CD3)2SO) δ 1.73 (6 H, m, 3 × CH2), 1.97 
(6 H, m, 3 × CH2), 2.04 (3 H, m, 3 × CH), 6.36 (1 H, d, J = 7.4 Hz, 4-H), 7.18 (1 H, dd, J 
= 7.4, 6.2 Hz, 3-H), 7.42 (1 H, t, J = 7.7 Hz, 7-H), 7.52 (1 H, d, J = 7.7 Hz, 6-H), 8.07 (1 
H, d, J = 7.7 Hz, 8-H), 9.29 (1 H, s, adamantaneCONH), 11.29 (1 H, d, J = 4.9 Hz, 2-
NH); 13C NMR δ 27.7 (C3, CH), 36.1 (C6, CH2), 38.5, 38.6 (C6, CH2), 100.5, 124.5, 
125.8, 126.9, 128.7, 130.7, 133.4, 134.4, 161.7, 176.6; MS (ESI +ve) m/z 345.1574 (M + 
Na) (C20H22N2 NaO2 requires 345.1579), 323.1769 (M + H) (C20H23N2O2 requires 
323.1768); Anal. Found: C, 69.46; H, 6.46; N, 8.06. Calc. for C20H22N2O2: C, 69.55; H, 
6.42; N, 8.11%. 
 5-Amino-3-(4-chlorophenyl)isoquinolin-1-one hydrochloride (115) 
NH
O
NH3Cl Cl  
 
To 139 (170 mg, 0.57 mmol) in EtOH (10 mL) and aq. HCl (34%, 0.4 mL), a slurry of 
10% Pd on charcoal (80 mg) in EtOH (5 mL) was added. The mixture was stirred under 
H2 for 2 h. The suspension was then filtered through Celite
®. The Celite® pad and residue 
were suspended in water (100 mL) and heated. The hot suspension was filtered through a 
second Celite® pad. Evaporation of the solvent and drying gave 115 (90 mg, 52%) as a 
pale buff solid: Rf = 0.74 (MeOH); mp >350°C (lit.
162 mp >350°C); 1H NMR ((CD3)2SO) 
δ 7.08 (1 H, s, 4-H), 7.14 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.28 (1 H, t, J = 7.8 Hz, 7-H), 
7.56 (2 H, d, J = 9.0 Hz, Ar 3,5-H2), 7.64 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 7.83 (2 H, d, J = 










5-Amino-3-(4-trifluoromethylphenyl)isoquinolin-1-one hydrochloride (116) 
NH
O
NH3Cl CF3  
 
To 140 (140 mg, 0.42 mmol) in EtOH (10 mL) and aq. HCl (34%, 0.4 mL), a slurry of 
10% Pd on charcoal (70 mg) in EtOH (5 mL) was added. The mixture was stirred under 
H2 for 2 h. The suspension was then filtered through Celite
®. The Celite® pad and residue 
were suspended in water (100 mL) and heated. The hot suspension was filtered through a 
second Celite® pad. Evaporation of the solvent and drying gave 116 (60 mg, 42%) as a 
pale buff solid: Rf = 0.76 (MeOH); mp >350°C (lit.
162 mp >350°C); 1H NMR ((CD3)2SO) 
δ 7.14 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 7.18 (1 H, s, 4-H), 7.31 (1 H, t, J = 7.8 Hz, 7-H), 
7.63 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 7.85 (2 H, d, J = 8.2 Hz, Ar 3,5-H2), 8.01 (2 H, d, J 
= 8.2 Hz, Ar 2,6-H2), 11.60 (1 H, br s, NH); 
19F NMR ((CD3)2SO) δ -59.50 (3 F, s, CF3). 
 







To 141 (160 mg, 0.57 mmol) in EtOH (10 mL) and aq. HCl (34%, 0.4 mL), a slurry of 
10% Pd on charcoal (80 mg) in EtOH (5 mL) was added. The mixture was stirred under 
H2 for 2 h. The suspension was then filtered through Celite
®. The Celite® pad and residue 
were suspended in water (100 mL) and heated. The hot suspension was filtered through a 
second Celite® pad. Evaporation of the solvent and drying gave 118 (129 mg, 79%) as a 
pale buff solid: Rf = 0.72 (MeOH); mp >350°C (lit.
162 mp >350°C); 1H NMR ((CD3)2SO) 
δ 2.23 (3 H, s, Me), 6.48 (1 H, s, 4-H), 7.31 (2 H, d, J = 7.8 Hz, Ar 3,5-H2), 7.36 (1 H, t, 
J = 7.8 Hz, 7-H), 7.61 (1 H, d, J = 7.8 Hz, 6-H), 7.75 (1 H, d, J = 7.8 Hz, 8-H), 7.96 (2 H, 






4-Chloroacetophenone 131 (2.3 g, 15 mmol) in Ac2O (6.2 g, 62 mmol) was added to 
BF3.(AcOH)2 (8.6 g, 46 mmol) at 0°C. The mixture was stirred for 30 min and allowed to 
stand at room temperature for 24 h. The mixture was then poured into aq. NaOAc (13%, 
50 mL) and boiled under reflux for 1 h. Extraction (Et2O), evaporation and 
chromatography (hexane / EtOAc 4:1) afforded 128 (2.5 g, 84%) as pale orange crystals: 
Rf = 0.54 (hexane / EtOAc 4:1); mp 56-58°C (lit.
162 mp 58-59°C); 1H NMR (CDCl3) δ 
2.20 (2.85 H, s, enol-form CH3), 2.30 (0.15 H, s, keto-form CH3), 4.07 (0.1 H, s, keto-
form CH2), 6.13 (0.95 H, s, enol-form =CH), 7.40 (1.9 H, d, J = 8.6 Hz, enol-form Ar 
3,5-H2), 7.43 (0.1 H, d, J = 8.6 Hz, keto-form Ar 3,5-H2), 7.79 (1.9 H, d, J = 8.6 Hz, 
enol-form Ar 2,6-H2), 7.87 (0.1 H, d, J = 8.2 Hz, keto-form Ar 2,6-H2), 16.09 (0.95 H, 






4-(Trifluoromethyl)acetophenone 132 (2.5 g, 13 mmol) in Ac2O (5.5 g, 54 mmol) was 
added to BF3.(AcOH)2 (7.6 g, 40 mmol) at 0°C. The mixture was stirred for 30 min and 
allowed to stand at room temperature for 24 h. The mixture was then poured into aq. 
NaOAc (13%, 100 mL) and boiled under reflux for 1 h. Extraction (Et2O), evaporation 
and chromatography (hexane / EtOAc 7:3) gave 129 (2.1 g, 68%) as pale orange crystals: 
Rf = 0.57 (hexane / EtOAc 4:1); mp 48-50°C (lit.
162 mp 48-49°C); 1H NMR (CDCl3) δ 
2.23 (2.88 H, s, enol-form CH3), 2.32 (0.12 H, s, keto-form CH3), 4.13 (0.08 H, s, keto-
form CH2), 6.19 (0.96 H, s, enol-form =CH), 7.68 (2 H, d, J = 8.2 Hz, enol-form Ar 3,5-
H2), 7.71 (0.08 H, d, J = 8.2 Hz, keto-form Ar 3,5-H2), 7.95 (2 H, d, J = 8.2 Hz, enol-
form Ar 2,6-H2), 8.04 (0.08 H, d, J = 8.2 Hz, keto-form Ar 2′,6′-H2), 15.98 (1 H, br s, 






4-Methylacetophenone 133 (2.0 g, 14.9 mmol) in Ac2O (6.2 g, 61 mmol) was added to 
BF3.(AcOH)2 (8.5 g, 45 mmol) at 0°C. The mixture was stirred for 30 min and allowed to 
stand at room temperature for 24 h. The mixture was then poured into aq. NaOAc (13%, 
100 mL) and boiled under reflux for 1 h. Extraction (Et2O), evaporation and 
chromatography (hexane / EtOAc 20:1) afforded 130 (2.1 g, 80%) as a colourless oil: Rf 
= 0.40 (hexane / EtOAc 20:1); 1H NMR (CDCl3) δ 2.20 (2.67 H, s, enol-form COCH3), 
2.30 (0.33 H, s, keto-form COCH3), 2.41 (2.67 H, s, enol-form ArCH3), 2.59 (0.33 H, s, 
keto-form ArCH3), 4.08 (0.22 H, s, keto-form CH2), 6.16 (0.89 H, s, enol-form =CH), 
7.24 (2 H, d, J = 8.2 Hz, Ar 3,5-H2), 7.78 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 16.22 (0.89 H, 














NO2 Cl  
 
Method A: 
To a stirred solution of 34 (7.1 g, 36 mmol) and potassium t-butoxide (1.7 g, 15 mmol) in 
2-methylpropan-2-ol (50 mL) was added 128 (1.8 g, 7.3 mmol) and Cu powder (47 mg, 
0.7 mmol). The mixture was boiled heated reflux for 16 h, then poured into H2O (350 ml) 
and acidified with aq. HCl (2 M). Extraction (Et2O), evaporation and chromatography 
(hexane / EtOAc 8:1) gave 135 (720 mg, 33%) as pale yellow crystals; Rf = 0.64 (hexane 
/ EtOAc 8:1); mp 203-205°C; (lit.162 mp 204-205°C); 1H NMR δ 7.47 (2 H, d, J = 6.6 Hz, 
Ar 3,5-H2), 7.62 (1 H, t, J = 8.0 Hz, 7-H), 7.87 (2 H, d, J = 6.9 Hz, Ar 2,6-H2), 7.88 (1 H, 
brs, 4-H), 8.50 (1 H, dd, J = 8.3, 1.9 Hz, 6-H), 8.63 (1 H, brd, J = 8.0 Hz, 8-H). 
 
Method B: 
SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 4-chlorobenzoyl chloride (217.0 mg, 1.04 mmol) was added and the 
mixture was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with 
ice-water (2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were 
washed (NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / 











 Method A: 
 
To a stirred solution of 34 (3.6 g, 16 mmol) and potassium t-butoxide (700 mg, 6.3 
mmol) in 2-methylpropan-2-ol (50 mL) was added 129 (760 mg, 3.1 mmol) and Cu 
powder (20 mg, 0.3 mmol). The mixture was heated under reflux for 16 h, then poured 
into H2O (350 mL) and acidified with aq. HCl (2 M). Extraction (Et2O), evaporation and 
chromatography (hexane / EtOAc 9:1) gave 137 (125 mg, 12%) as yellow crystals: Rf = 
0.52 (hexane / EtOAc 4:1); mp 162-163°C (lit.162 mp 163-164°C); IR νmax 1724 (C=O), 
1626 (C=C), 1537 & 1344 (NO2) cm
–1; 1H NMR δ 7.67 (1 H, t, J = 8.2 Hz, 6-H), 7.75 (2 
H, d, J = 8.2 Hz, Ar 3,5-H2), 7.93 (1 H, d, J = 0.8 Hz, 4-H), 8.03 (2 H, d, J = 8.2 Hz, Ar 
2,6-H2), 8.51 (1 H, dd, J = 8.2, 1.6 Hz), 8.57 (1 H, ddd, J = 8.2, 1.6, 0.8 Hz, 8-H); 
19F 




SnCl4 (149 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 4-trifluoromethylbenzoyl chloride (217 mg, 1.04 mmol) was added and the 
mixture was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with 
ice-water (2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were 
washed (NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / 









To a stirred solution of 34 (22.7 g, 0.1 mol) and potassium t-butoxide (5.8 g, 52 mmol) in 
2-methylpropan-2-ol (50 mL) was added 130 (6.3 g, 26 mmol) and Cu powder (170 mg, 
2.7 mmol). The mixture was heated under reflux for 16 h, then poured into H2O (350 mL) 
and acidified with aq. HCl (2 M). Extraction (Et2O), evaporation and chromatography 
(hexane / EtOAc 10:1) gave 138 (1.5 g, 20%) as pale yellow crystals: Rf = 0.49 (hexane / 
EtOAc 4:1); mp 181-182°C (lit.162 mp 181-182°C); 1H NMR δ 2.42 (3 H, s, Me), 7.29 (2 
H, d, J = 8.6 Hz, Ar 3,5-H2), 7.57 (1 H, t, J = 8.2 Hz, 7-H), 7.82 (1 H, s, 4-H), 7.83 (2 H, 




SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 4-methylbenzoyl chloride (161 mg, 1.04 mmol) was added and the mixture 
was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with ice-water 
(2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were washed 
(NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / EtOAc 










NO2 Cl  
 A solution of 135 (180 mg, 0.6 mmol) in 2-methoxyethanol (50 mL) was saturated with 
NH3, boiled under reflux for 4 h, then evaporated until 10 mL remained. The concentrate 
was stored at 4°C for 16 h and the precipitated crystals were filtered, washed (H2O, then 
EtOH) and recrystallised (MeOH) to give 139 (460 mg, 64%) as bright yellow crystals: 
Rf = 0.33 (hexane / EtOAc 1:4); mp 231-233°C (decomp.) (lit.
162 mp 231-232°C 
(decomp.)); 1H NMR ((CD3)2SO) δ 7.22 (1 H, d, J = 0.8 Hz, 4-H), 7.59 (2 H, d, J = 8.6 
Hz, Ar 3,5-H2), 7.65 (1 H, t, J = 8.2 Hz, 7-H), 7.79 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 8.47 






NO2 CF3  
 
A solution of 137 (280 mg, 0.84 mmol) in 2-methoxyethanol (25 mL) was saturated with 
NH3, boiled under reflux for 4 h and then evaporated until 10 mL remained. The 
concentrate was stored at 4°C for 16 h and the precipitated crystals were filtered, washed 
(H2O, then EtOH) and recrystallised (MeOH) to give 140 (67 mg, 24%) as yellow 
crystals: Rf = 0.43 (hexane / EtOAc 1:4); mp 228-230°C (lit.
162 mp 230-231°C); 1H NMR 
((CD3)2SO) δ 7.28 (1 H, s, 4-H), 7.68 (1 H, t, J = 7.8 Hz, 7-H), 7.88 (2 H, d, J = 8.2 Hz, 
Ar 3,5-H2), 7.97 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 8.47 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.58 








A solution of 138 (250 mg, 0.89 mmol) in 2-methoxyethanol (30 mL) was saturated with 
NH3, boiled under reflux for 4 h, then evaporated until 10 mL remained. The concentrate 
was stored at 4°C for 16 h and the precipitated crystals were filtered, washed (H2O, then 
EtOH) and recrystallised (MeOH) to give 141 (199 mg, 80%) as bright yellow crystals: 
Rf = 0.23 (hexane / EtOAc 3:2); mp 175-176°C; (lit.
162 mp 174-175°C); 1H NMR 
((CD3)2SO) δ 2.37 (3 H, s, Me), 7.20 (1 H, d, J = 0.8 Hz, 4-H), 7.32 (2 H, d, J = 8.2 Hz, 
Ar 3,5-H2), 7.62 (1 H, t, J = 8.2 Hz, 7-H), 7.66 (2 H, d, J = 8.2 Hz, Ar 2,6-H2), 8.45 (1 H, 





 (70.6 mg, 0.53 mmol) was added to 38 (100 mg, 0.53 mmol) in benzoyl chloride 
(3.1 g, 22.3 mmol) and the mixture was stirred at 100°C under Ar for 3 d. The cooled 
mixture was quenched with ice-water (5.0 mL) and extracted with EtOAc (2 × 20 mL). 
The combined extracts were washed (aq. NaOH, brine) and dried. Evaporation, chrom-
atography (hexane / EtOAc 4:1) and recrystallisation gave 145 (40 mg, 26%) as pale 
yellow crystals: Rf = 0.61 (hexane / EtOAc 2:3); mp 151-153°C; IR νmax 1668 (C=O), 
1662 (C=O) 1626 (C=C), 1519 & 1340 (NO2) cm
–1; 1H NMR δ 7.41 (1 H, dd, J = 8.2, 0.9 
Hz, 4-H), 7.50 (2 H, t, J = 8.7 Hz, Ph 3,5-H2), 7.59-7.65 (3 H, m, 3,7-H2, Ph 4-H), 7.81 (2 
H, d, J = 8.7 Hz, Ph 2,6-H2), 8.44 (1 H, dd, J = 8.2, 1.1 Hz, 8-H), 8.66 (1 H, d, J = 8.2 
Hz, 6-H); 13C NMR δ 101.8, 126.6, 127.6, 128.6, 128.8, 129.2, 130.4, 138.9, 131.0, 
131.2, 132.4, 134.2, 134.4, 145.2, 160.2, 170.1. MS (ES +ve) m/z 317.0524 (M + Na) 










Compound 38 (80 mg, 0.42 mmol) in Ac2O (3 mL) and conc. H2SO4 (50 µL) were heated 
at 100°C for 22 h. Evaporation, chromatography (acetone) and recrystallisation (EtOH) 
gave 146 (36 mg, 36%) as yellow crystals: Rf = 0.63 (EtOAc); mp 303-305 °C; IR νmax 
3436 (NH), 1761 (C=O), 1661 (C=O), 1518 & 1315 (NO2) cm
–1; 1H NMR ((CD3)2SO) δ 
2.47 (3 H, s, Me), 7.73 (1 H, t, J = 7.8 Hz, 7-H), 8.19 (1 H, d, J = 7.8 Hz, 3-H), 8.26 (1 H, 
d, J = 7.8 Hz, 6-H), 8.52 (1 H, d, J = 8.2 Hz, 8-H) 12.86 (1 H, brs, NH); 13C NMR 
(HMBC / HMQC) δ 27.4 (2’-C), 125.9 (4a-C), 127.5 (7-C), 129.4 (8a-C), 129.6 (6-C), 
132.0 (8-C), 133.3 (4-C), 137.9 (3-C), 146.9 (5-C), 160.5 (1-C), 196.1 (1’-C); Anal. 










SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, [Carbonyl-13C]-benzoyl chloride (140.5 mg, 1.04 mmol) was added and the 
mixture was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with 
ice-water (2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were 
washed (NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / 
EtOAc 15:1) gave 148 (37 mg, 39%) as a pale yellow solid: Rf =0.57 (hexane/EtOAc 
4:1); mp 145-146°C (lit.158 142-143°C for unlabelled compound); 1H NMR δ 7.49-7.51 
(3 H, m, Ph 3,4,5-H3), 7.60 (1 H, t, J = 8.2 Hz, 7-H), 7.87 (1 H, brd, J = 5.5 Hz, 4-H), 
7.94 (2 H, m, Ph 2,6-H2), 8.49 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.61 (1 H, ddd, J = 7.8, 
1.2, 0.8 Hz, 8-H); 13C NMR (HMBC / HMQC) δ 96.3 (d, J = 75.1 Hz, 4-C), 122.3 (d, J = 
3.8 Hz, 4a-C or 8a-C), 125.9 (d, J = 1.5 Hz, Ph 2,6-C2 or Ph 3,5-C2), 127.1 (CH, s), 129.0 
(CH, d, J = 4.6 Hz), 131.1 (d, J = 68.2 Hz, Ph 1-C), 131.2 (s, CH), 131.6 (s, CH), 131.9 
(s, 8a-C or 4a-C), 135.8 (s, 8-C), 144.3 (d, J = 5 Hz, 5-C), 156.8 (s, 3-C), 156.8 (d, J = 
75.9 Hz, 3-C for 3,4-13C2 isotopomer), 156.8 (d, J = 67.5 Hz, 3-C for 1’,3-
13C2 isotop-
omer), 160.3 (d, J = 3.1 Hz, 1-C); MS (ES +ve) m/z 559.1052 (2 M + Na) 
(13C2
12C28H18N2Na1O8 requires 559.1028), 537 (2 M + H), 291.0476 (M + Na) 
(13C1






SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 4-nitrobenzoyl chloride (193 mg, 1.04 mmol) was added and the mixture 
was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with ice-water 
(2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were washed 
(NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / EtOAc 
15:1) gave 154 (9.8 mg, 12%) as a pale yellow solid: Rf =0.54 (hexane/EtOAc 4:1); mp 
211-214 °C; IR νmax 1724 (C=O), 1626 (C=C), 1537 & 1344 (NO2) cm
–1; 1H NMR δ 7.70 
(1 H, d, J = 8.0 Hz, 7-H), 8.03 (1 H, brs, 4-H), 8.11 (2 H, d, J = 7.2 Hz, Ar 2,6-H2), 8.36 
(2 H, d, J = 7.2 Hz, Ar 3,5-H2), 8.54 (1 H, dd, J = 8.3, 1.1 Hz, 6-H), 8.67 (1 H, brd, J = 
8.2 Hz, 8-H); 13C NMR (HMBC / HMQC) δ 99.2 (4-C), 122.8 (Cq), 124.3 (2’,6’-C2), 
126.7 (3’,5’-C2), 128.5 (CH), 131.0 (Cq), 131.2 (Cq), 131.8 (CH), 135.9 (CH), 137.0 (Cq), 
149 (Cq), 154 (Cq), 159 (1-C); MS m/z 335.0288 (M + Na) (C15H8N2NaO6 requires 
335.0280); Anal. Found: C, 57.64; H, 2.51; N, 8.79. Calc. for C15H8N2O6: C, 57.70; H, 









SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 3-methylbenzoyl chloride (161 mg, 1.04 mmol) was added and the mixture 
was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with ice-water 
(2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were washed 
(aq. NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / 
EtOAc 15:1) gave 155 (21.3 mg, 21%) as a pale yellow solid: Rf =0.53 (hexane:EtOAc; 
mp 152-154°C; IR νmax 1731 (C=O), 1621 (C=C), 1518 & 1337 (NO2) cm
–1; 1H NMR δ 
2.43 (3 H, s, Me) 7.30 (1 H, d, J = 7.4 Hz, Ar 4-H), 7.40 (1 H, t, J = 7.7 Hz, Ar 5-H), 7.58 
(1 H, t, J = 8.0 Hz, 7-H), 7.71 (1 H, d, J = 7.7 Hz, Ar 6-H), 7.73 (1 H, s, Ar 2-H), 7.83 (1 
H, s, 4-H), 8.47 (1 H, d, J = 8.2 Hz, 6-H), 8.61 (1 H, d, J = 7.7 Hz, 8-H); MS m/z 
282.0761 (M + H) (C16H12NO4 requires 282.0766); Anal. Found: C, 68.58; H, 4.07; N, 
4.79. Calc. for C16H12NO4: C, 68.32; H, 3.94; N, 4.98%. 





To 158 (200 mg, 0.71 mmol) in EtOH (10 mL) and aq. HCl (34%, 0.4 mL), a slurry of 
10% Pd on charcoal (80 mg) in EtOH (5 mL) was added. The mixture was stirred under 
H2 for 2 h. The suspension was then filtered through Celite
®. The Celite® pad and residue 
were suspended in water (100 mL) and heated. The hot suspension was filtered through a 
second Celite® pad. Evaporation of the solvent and drying gave 157 (161 mg, 52%) as a 
buff solid: Rf = 0.36 (MeOH); mp >350°C (decomp); 
1H NMR ((CD3)2SO) δ 2.32 (3 H, 
s, Me), 6.61 (1 H, s, 4-H), 7.16 (1 H, t, J = 7.2 Hz, 7-H), 7.32-7.38 (5 H, m, 6-H and Ar-, 
3,4,5,6-H4), 7.66 (1 H, d, J = 7.2 Hz, 8-H), 11.40 (1 H, s, NH); 
13C NMR δ 19.7, 99.9, 
123.1, 124.1, 125.8, 126.6, 127.4, 129.5, 129.5, 130.3, 132.4, 133.6, 135.3, 135.4, 136.1, 
155.2; MS (ESI +ve) m/z 273.1001 (M + Na) (C16H14NaN2O requires 273.1004); 






To 155 (320 mg, 1.14 mmol) in EtOH (30 mL), a slurry of 10% Pd on charcoal (160 mg) 
in EtOH (10 mL) was added. The mixture was stirred under H2 for 2 h. The suspension 
was then filtered through Celite®. Evaporation of the solvent from the filtrate and drying 
gave 159 (177 mg, 62%) as a pale buff solid: Rf = 0.12 (hexane / EtOAc 1:4); mp 340-
342°C; 1H NMR ((CD3)2SO) δ 2.39 (3 H, s, Me), 5.76 (2 H, br s, NH2), 6.88 (1 H, d, J = 
7.6 Hz, 6-H), 7.09 (1 H, s, 4-H), 7.18 (1 H, d, J = 7.6 Hz, 8-H), 7.24 (1 H, t, J = 7.6 Hz, 
7-H), 7.34-7.38 (1 H, d, Ar 4-H), 7.42 (1 H, t, J = 7.4 Hz, Ar 5-H), 7.63 (1 H, d, J = 7.4 
Hz, Ar 6-H), 7.68 (1 H, s, Ar 2-H) 11.25 (1 H, br s, NH); 13C NMR δ 21.0, 98.5, 113.9, 
115.2, 124.5, 125.6, 126.8, 127.0, 127.1, 129.3, 130.7, 134.3, 137.6, 138.2, 144.7, 163.0; 
MS (ESI +ve) m/z 273.0987 (M + Na) (C16H14NaN2O requires 273.1104); 251.1182 (M + 






NO2 I  
SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 4-iodobenzoyl chloride (277.1mg, 1.04 mmol) was added and the mixture 
was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with ice-water 
(2.0 mL) and upon standing a precipitate developed which was collected by filtration. 
Washing (EtOAc) and drying gave 156 (76.0 mg, 34%) as a pale yellow solid: Rf = 0.66 
(hexane / EtOAc 10:1); mp 211-213°C; 1H NMR ((CD3)2SO) δ 7.24 (1 H, s, 4-H), 7.62 (1 
H, t, J = 7.8 Hz, 7-H), 7.66 (2 H, d, J = 8.4 Hz, Ar 3,5-H2), 7.88 (2 H, d, J = 8.4 Hz, Ar 
3,5-H2), 8.50 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.65 (1 H, dd, J = 7.8, 1.2 Hz, 8-H);
 13C 
NMR δ 90.7, 96.6, 127.3, 127.5, 128.3, 128.5, 131.5, 135.8, 137.9, 138.3, 143.4, 144.9, 
152.4. MS (ESI +ve) m/z 415.9390 (M + Na) (C15H8NaINO4 requires 415.9396); 




NO2 I  
A solution of 159 (360 mg, 1.2 mmol) in 2-methoxyethanol (80 mL) was saturated with 
NH3 and boiled under reflux for 4 h. The solvent and excess reagent were evaporated 
until 10 mL remained. The concentrate was stored at 4°C for 16 h and the precipitated 
crystals were filtered, washed (H2O, then EtOH) and recrystallised (MeOH) to give 160 
(198 mg, 59%) as bright yellow crystals: Rf = 0.31 (hexane / EtOAc 1:4); mp 254-256°C; 
1H NMR ((CD3)2SO) δ 7.26 (1 H, s, 4-H), 7.60 (2 H, d, J = 8.4 Hz, Ar 3,5-H2), 7.69 (1 H, 
t, J = 7.8 Hz, 7-H), 7.92 (1 H, d, J = 8.4 Hz, Ar 2,6-H2), 8.47 (1 H, dd, J = 7.8, 1.2 Hz, 6-
H), 8.60 (1 H, dd, J = 7.8, 1.2 Hz, 8-H), 12.12 (1 H br s, NH); 13C NMR δ 97.2, 97.4, 
125.9, 126.7, 129.2, 129.9, 130.8, 133.0, 133.1, 137.4, 137.7, 143.3, 144.4, 161.3; MS 
(ESI +ve) m/z 414.9560 (M + Na) (C15H9NaIN2O3 requires 414.9556); 392.9731 (M + H) 




NH2 I  
A mixture of 160 (588 mg, 1.5 mmol) and SnCl2 (870 mg, 4.6 mmol) in EtOH (40 ml) 
was heated at 70°C for 4 h, then poured into ice-H2O (200 ml). The resulting suspension 
was made alkaline (aq. NaOH) and the precipitate was filtered. Extraction of the filtrate 
(EtOAc), evaporation and recrystallisation (hexane, EtOAc) gave 161 (277 mg, 51%) as a 
pale buff powder: Rf = 0.26 (hexane / EtOAc 1:4); mp 238-241°C; 
1H NMR ((CD3)2SO) 
δ 5.81 (2 H, br s, NH2) 7.26 (1 H, d, J = 7.8 Hz, 6-H), 7.39 (1 H, s, 4-H), 7.14 (1 H, d, J = 
7.8 Hz, 8-H), 7.39 (1 H, t, J = 7.8 Hz, 7-H), 7.64 (2 H, d, J = 8.4 Hz, Ar 3,5-H2), 7.83 (2 
H, d, J = 8.4 Hz, Ar 2,6-H2) 11.89 (1 H, br s, NH); 
13C NMR δ 99.0, 99.9, 113.7, 115.2, 
128.4, 129.8, 130.1, 133.0, 135.9, 137.3, 137.9, 144.6, 145.0, 164.8; MS (ESI +ve) m/z 











A solution of 163 (360 mg, 1.2 mmol) in 2-methoxyethanol (80 mL) was saturated with 
NH3 and boiled under reflux for 4 h. The solvent and excess reagent were evaporated 
until 10 mL remained. The concentrate was stored at 4°C for 16 h and the precipitated 
crystals were filtered, washed (H2O, then EtOH) and recrystallised (MeOH) to give 162 
(198 mg, 59%) as bright yellow crystals: Rf = 0.31 (hexane / EtOAc 1:4); mp 254-256°C; 
1H NMR ((CD3)2SO) δ 2.33 (3 H, s, Me), 7.34 (2 H, t, J = 8.0 Hz, Ar 4,5-H2), 7.40 (2 H, 
d, J = 8.2 Hz, Ar 3,6-H2), 7.67 (1 H, t, J = 8.0 Hz, 7-H), 8.48 (1 H, dd, J = 8.0, 1.2 Hz, 6-
H), 8.61 (1 H, dd, J = 8.0, 1.2 Hz, 8-H); 13C NMR δ 19.5, 99.0, 125.6, 125.9, 126.6, 
129.3, 129.6, 129.7, 130.5, 133.2, 134.5, 134.5, 136.0, 144.6, 145.0, 160.9; MS (ESI +ve) 
m/z 303.0752 (M + Na) (C16H12NaN2O3 requires 303.0746), 281.0922 (M + H) 






SnCl4 (148.5 mg, 0.57 mmol) was added to 56 (100 mg, 0.52 mmol) in PhNO2 (1.0 mL). 
After 30 min, 2-methylbenzoyl chloride (161 mg, 1.04 mmol) was added and the mixture 
was stirred at 150°C under Ar for 3 d. The cooled mixture was quenched with ice-water 
(2.0 mL) and extracted with EtOAc (2 × 20 mL). The combined extracts were washed 
(NaOH, brine) and dried (MgSO4). Evaporation and chromatography (hexane / EtOAc 
15:1) gave 163 (37 mg, 25%) as a bright yellow solid: Rf = 0.51 (hexane / EtOAc 4:1); 
mp 132-134°C; 1H NMR (CDCl3) δ 2.54 (3 H, s, Me), 7.29-7.34 (2 H, m, Ar 4,5-H2), 
7.40 (1 H, dt, J = 7.2, 1.6 Hz, Ar 3-H), 7.52 (1 H, d, J = 0.8 Hz, 4-H), 7.57 (1 H, dd, J = 
7.2, 1.6 Hz, Ar 6-H), 7.64 (1 H, t, J = 8.0 Hz, 7-H), 8.51 (1 H, dd, J = 8.0, 1.2 Hz, 6-H), 
8.67 (1 H, ddd, J = 8.0, 1.2, 0.8 Hz, 8-H); 13C NMR δ 20.9, 100.6, 100.6, 122.2, 126.3, 
127.4. 129.4, 130.6, 131.4, 131.5, 131.8, 132.1, 135.8, 137.0, 144.3, 158.9, 160.6; MS 
(ESI +ve) m/z 304.0581 (M + Na) (C16H11NaNO4 requires 304.0586); 251.0769 (M + H) 







A solution of 155 (360 mg, 1.2 mmol) in 2-methoxyethanol (80 mL) was saturated with 
NH3 and heated under reflux for 4 h. The solvent and excess reagent were evaporated 
until 10 mL remained. The concentrate was stored at 4°C for 16 h and the precipitated 
crystals were filtered, washed (H2O, then EtOH) and recrystallised (MeOH) to give 164 
(198 mg, 59%) as bright yellow crystals: Rf = 0.31 (hexane / EtOAc 1:4); mp 325-328°C; 
1H NMR ((CD3)2SO) δ 2.46 (3 H, s, Me), 7.22 (1 H, s, 4-H), 7.34 (1 H, d, J = 7.4 Hz, Ar 
4-H), 7.42 (1 H, t, J = 7.4 Hz, Ar 5-H), 7.57 (1 H, d, J = 7.5, Ar 6-H), 7.62 (1 H, s, Ar 2-
H), 7.65 (1 H, t, J = 7.9 Hz, 7-H), 8.47 (1 H, dd, J = 7.8, 1.1 Hz, 6-H), 8.59 (1 H, dd, J = 
7.8, 1.1 Hz, 8-H); 13C NMR δ 20.9, 97.0, 124.3, 125.2, 126.5, 127.6, 128.8, 129.7, 130.7, 
130.9, 133.1, 133.4, 138.2, 144.3, 144.7, 161.3; MS (ESI +ve) m/z 281.0922 (M + H) 




Compound 173 (250 mg, 0.8 mmol) was stirred in ag. HBr (78 %, 40 mL) at 80°C for 4 
h. Evaporation and recyrstallisation gave 155 (195 mg, 85%) as bright yellow crystals: 







To a cooled solution of 1,3-dichloroisoquinoline 172 (1.00 g, 5.05 mmol) in conc. H2SO4 
(5 mL) was added aq. HNO3 (70%, 0.43 g, 6.7 mmol) in conc. H2SO4 (3 mL) dropwise at 
0-5°C. The mixture was stirred at 0°C for 2 h, then poured onto ice. The precipitate was 
collected, washed (H2O), dried under vacuum and recrystallised (EtOAc / hexanes) to 
give 168 (1.12 g, 91%) as pale yellow needles: mp 175-177°C (lit.178 mp 168-170°C); 1H 
NMR δ 7.79 (1 H, t, J = 7.8 Hz, 7-H), 8.53 (1 H, s, 4-H), 8.61 (1 H, dd, J = 7.8, 0.8 Hz, 








To 168 (6.0 g, 25 mmol) in anhydrous MeOH (90 mL) was added finely divided sodium 
(0.7 g, 31.5 mmol) and the mixture was heated under reflux for 16 h. The excess solvent 
was then evaporated until 20 mL remained and the residue was diluted with H2O and 
extracted (CHCl3). Evaporation of the solvent and drying gave 171 (4.8 g, 82%) as a 
yellow solid: Rf = 0.54 (hexane / EtOAc 10:1); mp 172-174°C; 
1H NMR δ 4.04 (3 H, s, 
OMe), 7.60 (1 H, t, J = 8.0 Hz, 7-H), 8.22 (1 H, s, 3-H), 8.51 (1 H, dd, J = 8.0, 1.2 Hz, 6-
H), 8.58 (1 H, dd, J = 8.0, 1.2 Hz, 8-H); 13C NMR δ 55.1, 109.8, 119.4, 119.4, 125.0, 








Compound 171 (0.84 g, 3.53 mmol), Pd2(dba)3 (0.18 g, 0.35 mmol), SPhos (0.14 g, 0.70 
mmol), K3PO4 (1.5g, 7.06 mmol) and 3-methylphenylboronic acid (0.72g 5.30 mmol) 
were placed in a dry flask. Degassed toluene (20 mL) was added and the mixture was 
stirred at 100°C for 16 h. Evaporation and chromatography (hexane/EtOAc 15:1) gave 
173 (0.70 g, 67%) as yellow crystals: Rf = 0.69 (hexane / EtOAc 10:1); mp 166-169°C;
 
1H NMR (CDCl3) δ 2.36 (3 H, s, ArMe), 4.11 (3 H, s, OMe), 7.13 (1 H, d, J = 7.8 Hz, Ar 
4-H), 7.27 (1 H, t, J = 7.8 Hz, Ar 5-H), 7.36 (1 H, t, J = 7.4 Hz, 7-H), 7.83 (1 H, s, Ar 2-
H), 7.85 (1 H, d, J = 7.6 Hz Ar 6-H), 8.23-8.26 (2 H, m, 6-H and 4-H), 8.39 (1 H, d, J = 
7.4 Hz 8-H); 13C NMR (HMBC / HMQC) δ 21.6 (ArMe), 54.0 (OMe), 104.9 (4-C), 
124.2 (Ar 6-C), 124.2 (7-C), 127.6 (Ar 2-C) 128.5 (6-C), 128.6 (Ar 5-C), 130.1 (Ar 4-C), 
131.1 (8-C), 131.3 (Cq), 138.2 (Ar 1-C), 138.5 (Cq),151.8 (3-C), 151.9 (5-C), 160.3 (1-C); 







LiN(SiMe3)2 in dry THF (1.0 M, 15.4 mL, 15.4 mmol) was added to 2,6-dicyanotoluene 
41 (2.0 g, 14 mmol) in dry THF (30 mL) at -78°C under N2. After 30 min, MeI (2.1 mL, 
2.39 g, 16.8 mmol) was added; the mixture allowed to warm to room temperature and 
was stirred for a further 2 h. The reaction mixture was quenched with ice-water and 
extracted with CHCl3. Evaporation and recrystallisation gave 174 (1.7 g, 78%) as pale 
yellow crystals: Rf = 0.91 (hexane / EtOAc 4:1); mp 115-117°C (lit.
170 mp 116-118°C); 
1H NMR δ 1.36 (3 H, t, J = 7.6 Hz, Me), 3.06 (2 H, q, J = 7.6 Hz, CH2), 7.42 (1 H, t, J = 








Compound 174 (1.0 g, 6 mmol) was boiled under reflux in dimethylformamide dimethyl 
acetal (10.0 g, 84 mmol) under N2 for 5 d. 4-Methylbenzenesulfonic acid monohydrate 
(100 mg, 0.53 mmol) was added and the mixture was stirred for a further 2 d. 
Evaporation and chromatography (hexane / EtOAc 3:2) gave 176 (136 mg, 12%) as a 
yellow solid: Rf = 0.77 (hexane / EtOAc 4:1); mp 229-232°C; 
1H NMR δ 1.80 (3 H, d, J 
= 7.7 Hz, Me), 4.24 (1 H, q, J = 7.4 Hz, CH), 7.56 (1 H, t, J = 7.8 Hz, 5-H), 7.92 (2 H, d, 
J = 7.8 Hz, 4,6-H2), 9.84 (1 H, s, CHO); 
13C NMR δ 14.3, 51.1, 114.8, 116.2, 128.8, 






Compound 176 (100 mg, 0.54 mmol) was stirred with Pri2NH (60 mg, 0.59 mmol) in 
THF (10 mL) for 24 h. Evaporation and chromatography (hexane/EtOAc 6:1) gave 177 
(13 mg, 13%) as a white solid: Rf = 0.61 (hexane / EtOAc 4:1); mp 237-239°C; 
1H NMR 
δ 2.52 (3 H, d, J = 1.2 Hz, Me), 7.17 (1 H, q, J = 1.2 Hz, 3-H), 7.62 (1 H, t, J = 7.8 Hz, 7-
H), 8.08 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.57 (1 H, dd, J = 7.8, 1.2 Hz); 13C NMR δ 15.4, 
107.8, 111.7, 122.8, 128.2, 135.1, 135.2, 137.4, 141.7, , 143.8, 160.8. MS (ES +ve) m/z 








A mixture of 49 (0.27 g, 1.0 mmol) and SnCl2 (0.65 g, 3.2 mmol) in EtOH (10 mL) was 
heated at 80°C for 4 h, then poured into ice-H2O (40 mL). The resulting suspension was 
made alkaline with aq. NaOH and the precipitate was filtered. Extraction of the filtrate 
(EtOAc), evaporation and chromatography (EtOAc:hexane 4:1) gave 189 (0.14 g, 54%) 
as a buff solid: Rf = 0.33 (EtOAc:hexane 1:4); mp 213-216°C (lit
175 210-212°C); 1H 
NMR ((CD3)2SO) δ 5.91 (2 H, br s, NH2), 7.74 (1 H, s, 3-H), 7.02 (1 H, dd, J = 8.4, 1.5 
Hz, 6-H), 7.20 (1 H, s, 3-H), 7.26 (1 H, t, J = 8.4 Hz, 7-H), 7.54 (1 H, dd, J = 8.0, 1.4 Hz, 








Vilsmeier’s reagent was prepared by adding oxalyl chloride (5.3 mL, 7.67 g, 60.4 mmol) 
dropwise over 30 min to DMF (4.7 mL, 4.4 g, 60.4 mmol) in 1,2-dichloroethane (35 mL) 
at 0°C. The suspension was stirred at room temperature for 10 min, then 49 (7.3 g, 27.3 
mmol) was added. The mixture was then heated at 80°C for 6 h, allowed to cool and 
diluted with CH2Cl2. Washing (H2O), drying and evaporation of solvent gave 189 (7.0 g, 
89%) as a yellow solid: mp 164-166°C; 1H NMR (CDCl3) δ 7.82 (1 H, t, J = 7.6 Hz, 7-
H), 8.01 (1 H, dd, J = 7.6, 1.2 Hz, 6-H), 8.62 (1 H, s, 3-H), 8.65 (1 H, dd, J = 7.6, 1.2 Hz, 
8-H); 13C NMR δ 112.4, 127.1, 127.8, 128.2, 128.6, 131.0, 147.4, 147.6, 152.0; MS (ESI 
+ve) m/z 240.0682 (M + Na) (C12H11NaNO3 requires 240.0637); 218.0819 (M + H) 









To 46 (100 mg, 0.35 mmol) in dry THF (9 mL) was added n-BuLi in THF (1.6 M, 0.24 
mL, 0.38 mmol) at -78°C. The suspension was stirred for 20 min. Iodomethane (55.4 mg, 
0.39 mmol) in THF (1 mL) was added and the mixture allowed to warm to room 
temperature over 1 h. The reaction was quenched with H2O and extracted (CH2Cl2). 
Evaporation and chromatography (hexane/EtOAc 15:1) gave 190 (7 mg, 9%)as a yellow-
orange solid: Rf = 0.54 (hexane / EtOAc 5:1); mp 90-93°C; 
1H NMR (CDCl3) δ 2.91 (3 
H, s, 4-Me), 4.09 (3 H, s, OMe), 7.50 (1 H, t, J = 8.6 Hz, 7-H), 7.75 (1 H, d, J = 7.4 Hz, 
8-H), 7.87 (1 H, s, 3-H) 8.42 (1 H, d, J = 7.4 Hz, 6-H); 13C NMR (HMBC / HMQC) δ 
16.00 (4-Me), 53.94 (OMe), 120.00 (4-C), 125.02 (7-C), 125.34 (4a-C), 125.66 (8-C), 
128.34 (6-C), 128.91 (8a-C), 143.24 (5-C), 143.58 (3-C), 159.99 (1-C); MS (ES +ve) m/z 










Compound 46 (1.00 g, 3.52 mmol), Pd2(dba)3 (0.18 g, 0.35 mmol), SPHOS (0.14 g, 0.70 
mmol) and SnMe4 (0.95 g, 5.28 mol) were placed in a dry flask. Degassed toluene (20 
mL) was added and the mixture was stirred at 100°C for 7 d. Evaporation and 
chromatography (hexane/EtOAc 15:1) gave 190 (0.77 g, 72%) as a yellow-orange solid: 








Compound 46 (1.00 g, 3.53 mmol), Pd2(dba)3 (0.18 g, 0.35 mmol), SPhos (0.14 g, 0.70 
mmol), K3PO4 (1.5g, 7.06 mmol) and benzeneboronic acid (0.64g 5.30 mmol) were 
placed in a dry flask. Degassed toluene (40 mL) was added and the mixture was stirred at 
100°C for 16 h. Evaporation and chromatography (hexane / EtOAc 10:1) gave 194 (0.85 
g, 86%) as yellow crystals: Rf = 0.79 (hexane / EtOAc 1:1); mp 118-120°C; 
1H NMR 
(CDCl3) δ 4.20 (3 H, s, OMe), 7.27-7.31 (2 H, m, Ph 2,6-H2), 7.38-7.43 (3 H, m, Ph 
3,4,5-H3), 7.62 (1 H, t, J = 8.0 Hz, 7-H), 7.97 (1 H, dd, J = 8.0, 1.2 Hz, 6-H or 8-H), 8.06 
(1 H, s, 3-H), 8.60 (1 H, dd, J = 8.0, 1.2 Hz, 8-H or 6-H); 13C NMR δ 54.4, 120.7, 124.5, 
125.5, 127.4, 127.7, 127.8, 128.1, 128.4, 129.1, 137.5, 144.7, 147.6, 160.3; MS (ES +ve) 
m/z 303.0740 (M + Na) (C16H11NaN2O3 requires 303.0746); 281.0915 (M + H) 
(C16H12N2O3 requires 281.0926); Anal. Found: C, 68.50; H, 4.26; N, 10.19. Calc. for 











To 196 (46 mg, 0.17 mmol) in EtOH (10 mL), a slurry of 10% Pd on charcoal (50 mg) in 
EtOH (5 mL) was added. The mixture was stirred under H2 for 6 h. The suspension was 
then filtered through Celite®. Evaporation of the solvent and drying gave 195 (21 mg, 
51%) as a pale yellow solid: Rf = 0.47 (hexane / EtOAc, 1:1); mp 236-240°C; 
1H NMR 
((CD3)2SO) δ 4.45 (2 H, s, NH2), 6.70 (1 H, brs, 3-H), 6.86 (1 H, dd, J = 7.8, 1.2 Hz, 6-
H), 7.23 (1 H, t, J = 7.8 Hz, 7-H), 7.36 (2 H, dd, J = 7.3, 1.2, Ph 2,6-H2), 7.41-7.47 (3 H, 
m, Ph 3,4,5-H3), 7.60 (1 H, d, J = 7.8, 1.2 Hz, 8-H), 11.20 (1 H, br, NH); 
13C NMR 
(HMBC / HMQC) δ 116.2 (8-C), 118.40 (6-C), 122.6 (4a-C) 125.4 (4-C), 127.4 (3-C), 
128.0 (7-C), 128.3 (Ph 4-C), 129.1 (Ph 3,5-C2), 130.2 (8a-C), 130.3 (Ph 2,6-C2), 141.1 
(Ph 1-C), 142.3 (5a-C), 160.1 (1-C); MS (ES +ve), m/z 259.0841 (M + Na) 
(C15H11NaN2O requires 259.0847), m/z 237.1017 (M + H) (C15H12N2O requires 
237.1022); Anal. Calcd. for C15H12N2O: C, 76.26; H, 5.12; N, 11.37. Found: C, 76.68; H, 






Compound 194 (182 mg, 0.65 mmol) was stirred in aq. HBr (48 %, 30ml) at 50°C for 4 
h. Evaporation and recyrstallisation (hexane / EtOAc) gave 196 (112 mg, 65%) as yellow 
crystals solid: Rf = 0.34 (hexane / EtOAc 1:1); mp 211-214°C; 
1H NMR ((CD3)2SO) δ 
7.20 (3 H, m, 3-H and Ph 2,6-H2), 7.32 (3 H, m, Ph 3,4,5-H3), 7.70 (1 H, t, J = 7.6 Hz, 7-
H), 8.14 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.58 (1 H, dd, J = 7.8, 1.2 Hz, 8-H); 13C NMR δ 
113.5, 126.4, 127.2, 127.6, 128.0, 128.2, 128.5, 129.0, 131.6, 133.1, 136.7, 147.0, 159.7; 
MS (ES +ve) m/z 289.0598 (M + Na) (C15H10NaN2O3 requires 289.0589); 267.0761 (M + 
H) (C15H11N2O3 requires 267.0770); Anal. Found: C, 68.60; H, 3.48; N, 10.49. Calc. for 









To 199 (56 mg, 0.18 mmol) in EtOH (10 mL), a slurry of 10% Pd on charcoal (50 mg) in 
EtOH (5 mL) was added. The mixture was stirred under H2 for 6 h. The suspension was 
then filtered through Celite®. Evaporation of the solvent and drying gave 197 (29mg, 
53%) as a pale yellow solid: Rf = 0.52 (hexane / EtOAc, 1:1); mp 265-267°C; 
1H NMR 
((CD3)2SO) δ 4.37 (2 H, s, NH2), 6.81 (1 H, brs, 3-H), 6.93 (1 H, dd, J = 7.8, 1.2 Hz, 6-
H), 7.27 (1 H, t, J = 7.8 Hz, 7-H), 7.57 (2 H, d, J = 7.6 Hz, Ar 2,6-H2), 7.63 (1 H, dd, J = 
7.8, 1.2 Hz, 6-H), 7.77 (1 H, d, J = 7.6 Hz, 8-H), 11.31 (1 H, brs, NH); 13C NMR δ 112.9, 
114.7, 115.8, 118.2, 120.9, 124.9 (m, Ph 3,5-C2), 127.5, 127.8, 127.9 (m, CF3), 128.8 (m, 
Ph C-4), 130.2, 130.5, 143.0, 144.2, 161.5; MS (ES +ve) m/z 327.0729 (M + Na) 
(C17H11F3NaN2O requires 327.0712), 305.0905 (M + H) (C17H12F3N2O requires 
305.0902); Anal. Calcd. for C17H11F3N2O: C, 63.16; H, 3.64; N, 9.21. Found: C, 63.21; 








Compound 46 (1.00 g, 3.53 mmol), Pd2(dba)3 (0.18 g, 0.35 mmol), SPhos (0.14 g, 0.70 
mmol), K3PO4 (1.5g, 7.06 mmol) and (4-trifluoromethylphenyl)boronic acid (1.00 g, 5.30 
mmol) were placed in a dry flask. Degassed toluene (40 mL) was added and the mixture 
was stirred at 100°C for 16 h. Evaporation and chromatography (hexane/EtOAc 10:1) 
gave 198 (1.00 g, 81%) as yellow crystals; Rf = 0.76 (hexane / EtOAc 1:1); mp 95-97°C; 
1H NMR (CDCl3) δ 4.25 (3 H, s, OMe), 7.43 (2 H, d, J = 8.8 Hz, Ar 2,6-H2), 7.68-7.72 (3 
H, m, 7-H and Ar 3,5-H3), 8.05 (1 H, dd, J = 8.4, 1.2 Hz, 6-H), 8.07 (1 H, s, 3-H), 8.66 (1 
H, dd, J = 8.4, 1.2 Hz, 8-H); 13C NMR δ 54.5, 120.7, 123.1, 125.4 (q, J = 3.7 Hz, Ar 3.5-
C2), 125.8, 127.3 (m, CF3), 127.6, 128.3, 129.4, 130.0 (m, Ar 4-C), 141.2, 145.0, 160.8; 
MS (ES +ve) m/z 371.0631 (M + Na) (C17H11F3NaN2O3 requires 371.0619), 349.0805 (M 
+ H) (C17H12F3N2O3 requires 349.0800); Anal. Calcd. for C17H11F3N2O3: C, 58.63; H, 


















Compound 198 (182 mg, 0.65 mmol) was stirred in aq. HBr (48 %, 30 mL) at 50°C for 4 
h. Evaporation and recrystallisation gave 199 (112 mg, 65%) as yellow crystals: Rf = 0.37 
(hexane / EtOAc 1:1); mp 283-285°C; 1H NMR ((CD3)2SO) δ 7.34 (1 H, d, J = 6.5 Hz, 3-
H), 7.46 (2 H, d, J = 7.8 Hz, Ar 3,5-H2), 7.70 (2 H, d, J = 7.8 Hz, Ar 2,6-H2), 7.73 (1 H, t, 
J = 8.2 Hz, 7-H), 8.22 (1 H, dd, J = 8.2, 1.2 Hz, 6-H), 8.61 (1 H, dd, J = 8.2, 1.2 Hz, 8-
H), 12.09 (1 H, d, J = ca. 5.5 Hz, NH); 
13C NMR δ 112.0, 125.1 (q, J = 3.8 Hz, Ar 3,5-
C2), 126.7, 127.7, 128.0, 128.1, 128.2, 129.3, 131.9 (m, Ar 4-C), 134.0 (m, CF3), 141.1, 
146.7, 159.8; Anal. Calc. for C16H9F3N2O3: C, 57.50; H, 2.71; N, 8.38. Found: C, 57.14; 








To 203 (100 mg, 0.26 mmol) in EtOH (15 mL), a slurry of 10% Pd on charcoal (80 mg) 
in EtOH (8 mL) was added. The mixture was stirred under H2 for 16 h. The suspension 
was then filtered through Celite®. Evaporation of the solvent and drying gave 200 (32 
mg, 47%) as a pale buff solid: Rf = 0.55 (hexane / EtOAc, 1:1); mp 240-243°C; 
1H NMR 
((CD3)2SO) δ 4.03 (3 H, s, Me), 4.62 (2 H, br s, NH2), 6.85 (1 H, dd, J = 7.8, 1.2 Hz, 6-
H), 6.93 (2 H, d, J = 8.6 Hz, Ar 3,5-H2), 7.34 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.39 (1 H, 
d, J = 8.6 Hz, Ar 3.5-H2), 7.46 (1 H, t, J = 7.8 Hz, 7-H), 7.60 (1 H, d, J = 7.8, 1.2 Hz, 8-
H), 10.86 (1 H, br, NH); 13C NMR; 55.4, 112.1, 112.7, 113.9, 114.3, 115.0, 122.4, 126.8, 
127.4, 127.5, 130.5, 143.4, 159.0, 161.4; MS (ES +ve) m/z 267.1105 (M + H) 
(C16H15N2O2 requires 267.1134; Anal. Calcd. for C16H14N2O2: C, 76.26; H, 5.12; N, 
















To NaH (300 mg, 12.5 mmol) in anhydrous DMF (10 mL) was added BnOH (680 mg, 
6.3 mmol) and the mixture was stirrred for 30 min. 189 (1.5 g, 5.2 mmol) in anhydrous 
DMF (30 mL) was added and the suspension was heated at 100°C for 48 h. The excess 
solvent was then evaporated until 5 mL remained and the residue was diluted with H2O 
and extracted (CHCl3). Evaporation and chromatography (hexane / EtOAc 15:1) gave 
201 (1.3 g, 71%) as a yellow solid: mp 106-108°C; Rf = 0.67 (hexane / EtOAc 10:1); 
1H 
NMR (CDCl3) δ 5.58 (2 H, s, CH2), 7.40 (3 H, m, Ph 3,4,5-H3), 7.52 (2 H, d, J = 7.1 Hz, 
Ph 2,6-H2), 7.62 (1 H, t, J = 7.8 Hz, 7-H), 7.90 (1 H, dd, J = 7.1, 1.2 Hz, 8-H), 8.33 (1 H, 
s, 3-H), 8.55 (1 H, dd, J = 7.1, 1.2 Hz, 6-H); 13C NMR (CDCl3) δ 68.96 (CH2), 104.5, 
122.0, 126.3, 126.9, 127.0, 128.2, 128.3, 128.5, 128.6, 136.1, 146.2, 147.1, 159.7; MS 
(ESI +ve) m/z 382.9826 (C16H11
81BrNaN2O3 requires 382.9830); 380.9860 (M + Na) 
(C16H11
79BrNaN2O3 requires 380.9851), 359.0039 (M + H) (C16H12
79BrN2O3 requires 
359.0031).  
Further elution gave 202 (184 mg, 12%) as a red-orange solid mp 127-130°C; Rf = 0.37 
(hexane / EtOAc 10:1); 1H NMR (CDCl3) δ 3.14 (6 H, s, NMe)2, 7.52 (1 H, t, J = 7.6 Hz, 
7-H), 7.88 (1 H, dd, J = 7.6, 1.2 Hz, 6-H), 8.26 (1 H, dd, J = 7.6, 1.2 Hz, 8-H), 8.30 (1 H, 
s, 3-H); 13C NMR (CDCl3)  (HMQC / HMBC) δ 43.06 NMe2, 103.28 (4-C), 122.78 (8a-
C), 124.21 (4-C), 126.38 (6-C), 127.95 (4a-C), 130.65 (8-C), 147.04 (3-C), 147.42 (5-C), 
160.87 (1-C); MS (ESI +ve) m/z 319.9840 (M + Na) (C11H10
81BrNaN3O2 requires 
319.9834); 317.9848 (M + Na) (C11H10







Compound 201 (500 mg, 1.4 mmol), Pd2(dba)3 (72 mg, 0.14 mmol), SPhos (168 mg, 0.70 
mmol), K3PO4 (594 mg, 2.8 mmol) and 4-methoxyphenylboronic acid (317 mg, 2.1 
mmol) were placed in a dry flask.Degassed toluene (20 mL) was added and the mixture 
was stirred at 100°C for 16 h. Chromatography (hexane / EtOAc, 20:1) gave 203 (330 
mg, 61%) as a yellow solid: Rf = 0.74 (hexane / EtOAc, 10:1); mp 162-164°C; 
1H NMR 
(CDCl3) δ 3.85 (3 H, s, OMe), 5.64 (2 H, s, CH2), 6.93 (2 H, d, J = 8.6 Hz, Ar 3,5-H2), 
7.21 (2 H, d, J = 8.6 Hz, Ar 2,6-H2), 7.36-7.45 (3 H, m, Ph 3,4,5-H3), 7.55 (2 H, d, J = 
7.5 Hz, Ph 2,6-H2), 7.60 (1 H, t, J = 8.2 Hz, 7-H), 7.95 (1 H, d, J = 7.4 Hz, 6-H or 8-H), 
8.04 (1 H, s, 3-H), 8.63 (1 H, d, J = 7.4 Hz, 8-H or 6-H); 13C NMR (HMBC / HMQC) δ 
55.2 (Me), 68.6 (CH2), 108.7, 113.8 (Ar 3,5-C2), 120.7 (8a-C), 124.4 (Ar 1-C), 125.4 (7-
C), 127.2 (6-C), 128.0 (Ph 4-C), 128.1 (4a-C), 128.2 (Ph 3.5-C2), 128.6 (Ph 2,6-C2), 
129.0 (8-C), 129.3 (Ar 2,6-C2), 129.8 (4-C), 131.5 (Ar 4-C), 136.7 (Ph 1-C), 147.7 (3-C), 
159.2 (5-C), 159.5 (1-C); MS (ES +ve) m/z m/z 409.1164 (M + Na) (C23H17N2NaO4 
requires 409.1164), 387.1366 (M + H) (C23H19N2O4 requires 387.1345); Anal. Calc. for 








Compound 201 (1.26 g, 3.53 mmol), Pd2(dba)3 (0.18 g, 0.35 mmol), SPhos (0.14 g, 0.70 
mmol), K3PO4 (1.5 g, 7.06 mmol) and benzeneboronic acid (1.00 g 5.30 mmol) were 
placed in a dry flask. Degassed toluene (50 mL) was added and the mixture was stirred at 
100°C for 16 h. Evaporation and chromatography (hexane/EtOAc 20:1) gave 204 (0.67 g, 
42%) as yellow-orange crystals: Rf = 0.72 (hexane / EtOAc 10:1); mp 102-105°C; 
1H 
NMR (CDCl3) δ 7.41 (1 H, t, J = 7.8 Hz, Ph 4-H), 7.47 (2 H, t, J = 7.8 Hz, Ph 3,5-H2), 
7.52 (1 H, td, J = 7.8, 1.2 Hz, Ar 3 or 6-H), 7.56 (1 H, s, Ar 9-H),  7.60-7.65 (3 H, m, Ph 
2,6-H2 and 7-H), 7.66-7.71 (2 H, m,), 7.82 (2 H, t, J = 7.4 Hz, Ar 2,7-H2), 7.85 (1 H, dd, 
J = 7.6, 1.2 Hz, 6-H), 8.71 (1 H, dd, J = 7.6, 1.2 Hz, 8-H), 8.74 (1 H, d, J = 7.8 Hz, Ar 4 
or 5-H), 8.79 (1 H, d, J = 7.8 Hz, Ar 4 or 5-H); 13C NMR δ 68.8 (CH2), 120.8, 122.1 (Ar 
1-C), 122.7 (Ar ), 123.1, 125.6, 126.4 (Ar 2 or 7-C), 126.6, 126.8, 127.0 (8-C), 127.0, 
128.2 (Ph 2,6-C2), 128.3 (Ph 4-C), 128.4, 128.7, 128.8 (Ph 3,5-C2),  129.0 (Ar 2 or 7-C), 
129.2, 130.3, 130.6, 131.0, 131.4, 132.7, 136.7 (Ph 1-C), 145.8 (3-C), 147.7 (5-C), 160.0 
(1-C); ); MS (ES +ve) m/z 479.1360 (M + Na) (C30H20N2NaO3 requires 479.1372), 
457.1571 (M + H) (C30H21N2O3 requires 457.1552). 











To 204 (200 mg, 0.44 mmol) in EtOH (10 mL), a slurry of 10% Pd on charcoal (100 mg) 
in EtOH (10 mL) was added. The mixture was stirred under H2 for 40 h. The suspension 
was then filtered through Celite® and the precipitate was collected to give 205 (39mg, 
26%) as a buff solid. 
 
This compound could not be fully characterised due to solubility issues. 
 
MS (ES +ve) m/z 359.1196 (M + Na) (C23H16NaN2O requires 359.1160), m/z 337.1331 








Compound 190 (200 mg, 0.92 mmol) was stirred in aq. HBr (48 %, 30 mL) at 80°C for 4 
h. Evaporation and recrystallisation (hexane / EtOAc) gave 206 (131 mg, 70%) as a pale 
buff solid mp: Rf = 0.34 (hexane / EtOAc 1:1); mp 211-214°C (lit.
175 mp 209-211°C); 1H 
NMR ((CD3)2CO) δ 2.02 (3 H, s, Me), 7.22 (1 H, d, J = 5.1 Hz, 3-H), 7.66 (1 H, t, J = 7.8 
Hz, 7-H), 8.13 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.50 (1 H, dd, 7.8, 1.3 Hz, 8-H), 11.64 (1 
H, br, NH). 






To 206 (116 mg, 0.56 mmol) in EtOH (10 mL) and aq. HCl (34%, 0.4 mL), a slurry of 
10% Pd on charcoal (0.1 g) in EtOH (4 mL) was added. The mixture was stirred under H2 
for 2 h. The suspension was then filtered through Celite. The Celite pad and residue 
were suspended in water (100 mL) and heated. The hot suspension was filtered through a 
second Celite pad. Evaporation of the solvent and drying gave 207 (78 mg, 65%) as a 
pale buff solid: mp 225-228°C (lit.175 mp 227-229°C); 1H NMR (D2O) δ 2.37 (3 H, s, 
Me), 6.94 (1 H, s, 3-H), 7.42 (1 H, t, J = 8.2 Hz, 7-H), 7.63 (1 H, d, J = 7.8 Hz, 6-H), 









Compound 46 (1.00 g, 3.53 mmol), Pd2(dba)3 (0.18 g, 0.35 mmol), SPhos (0.14 g, 0.70 
mmol), potassium tert-butoxide (0.79 g, 7.06 mmol) and aniline (0.49 g, 5.30 mmol) 
were placed in a dry flask. Degassed dioxane (40 mL) was added and the mixture was 
stirred at 100°C for 16 h. Evaporation and chromatography (hexane / EtOAc 10:1) gave 
208 (0.47 g, 45%) as a deep red solid; mp 124-126°C; 1H NMR (CDCl3) δ 4.17 (3 H, s, 
OMe), 5.56 (1 H, s, NH), 6.61 (2 H, dd, J = 7.4, 1.1 Hz, Ph 2,6-H2), 6.79 (1 H, t, J = 7.4 
Hz, Ph 4-H), 7.14 (2 H, t, J = 7.4 Hz, Ph 3,5-H2), 7.59 (1 H, d, J = 8.2 Hz, 7-H), 7.80 (1 
H, dt, J = 8.2, 1.2 Hz, 8-H), 8.14 (1 H, d, J = 1.1 Hz, 3-H), 8.51 (1 H, dd, J = 8.2, 1.2 Hz, 
6-H); 13C NMR δ 54.3, 114.2, 119.5, 121.2, 124.7, 125.8, 126.3, 127.8, 128.7, 129.3, 
142.3, 146.8, 158.7; MS (ES +ve) m/z 318.0850 (M + Na) (C16H13N3NaO3 requires 







To 5AIQ:HCl 5 (53 mg, 0.25 mmol) in pyridine (2.0 mL) was added benzoyl chloride 
(0.03 mL, 39 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h; Evaporation and 
recrystallisation (EtOAc) gave 215 (38 mg, 72%) as an off-white solid: Rf = 0.19 
(EtOAc); mp >310oC (decomp.); 1H NMR ((CD3)2SO) δ 2.12 (3 H, s, Me), 6.33 (1 H, s, 
4-H), 7.42 (1 H, t, J = 7.8 Hz, 7-H), 7.55 (2 H, t, J = 7.9 Hz, Ar 3,5-H2), 7.62 (1 H, t, J = 
7.9 Hz, Ar 4-H), 7.69 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.04-8.09 (3 H, m, Ar 2,6-H2 and 8-
H), 10.28 (1 H, s, PhCONH), 11.35 (1 H, s, 2-NH); 13C NMR δ 19.0, 98.7, 124.7, 124.9, 
125.1, 127.8, 128.4, 130.6, 131.7, 132.5, 134.2, 134.6, 138.5, 162.3, 166.0; MS (ES +ve) 
m/z 301.0948 (M + Na) (C17H14NaN2O2 requires 301.0953), m/z 279.1142 (M + H) 
(C17H15N2O2 requires 279.1134); Anal. Calcd. for C17H14N2O2: C, 73.37; H, 5.07; N, 









To 5AIQ:HCl 5 (68 mg, 0.25 mmol) in pyridine (2.0 mL) was added benzoyl chloride 
(0.03 mL, 39 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h; Evaporation and 
recrystallisation (EtOAc) gave 216 (54 mg, 64%) as an off-white solid: Rf = 0.22 
(EtOAc); mp >325oC (decomp.); 1H NMR ((CD3)2SO) δ 6.82 (1 H, s, 4-H), 7.45-7.58 (7-
H, m, Ph 3,4,5-H3, COPh 3,4,5-H3 and 7-H), 7.61 (1 H, t, J = 7.6 Hz, 7-H), 7.75 (2 H, J = 
6.8 Hz, Ph 2,6-H2), 7.83 (1 H, d, J = 7.6 Hz, 6-H), 8.05 (2 H, d, J = 6.8 Hz, COPh 2,6-C-
2), 8.15 (1 H, d, J = 7.6 Hz, 8-H), 10.38 (1 H, s, PhCONH), 11.66 (1 H, s, 2-NH);
 13C 
NMRδ 99.3, 124.5, 125.8, 126.0, 126.8, 127.9, 128.5, 128.8, 129.3, 129.3, 130.3, 131.8, 
33.5, 133.5, 134.1, 134.3, 140.0, 162.6, 166.2; MS (ES +ve) m/z 363.1119 (M + Na) 











To 5AIQ:HCl 5 (68 mg, 0.25 mmol) in pyridine (2.0 mL) was added benzoyl chloride 
(0.03 mL, 39 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h; Evaporation and 
chromatography (EtOAc then EtOAc / MeOH 4:1) gave 217 (31 mg, 36%) as a pale pink 
solid: Rf = 0.22 (EtOAc); mp >230-232
oC (decomp.); 1H NMR (CD3OD) δ 7.10-7.16 (3 
H, m, Ph 3,4,5-H3), 7.24 (1 H, s, 3-H), 7.26-7.36 (4 H, m, 7-H and COPh 3,4,5-H3), 7.62 
(2 H, d, J = 7.2 Hz, Ph 2,6-H2), 7.71 (1 H, d, J = 7.8 Hz, 6-H), 7.78 (1 H, d, J = 7.4 
Hz,COPh 2,6-H2), 8.42 (1 H, d, J = 7.8 Hz, 8-H); 
13C NMR δ 119.5, 127.7, 127.6, 128.4, 
128.6, 128.9, 129.2, 129.4, 129.9, 130.3, 130.9, 131.8, 133.0, 134.6, 140.2, 164.1, 168.3; 
MS (ES +ve) m/z 363.1133 (M + Na) (C22H16NaN2O2 requires 363.1109), m/z 341.1312 














To 5AIQ:HCl 5 (68 mg, 0.25 mmol) in pyridine (2.0 mL) was added 4-iodobenzoyl 
chloride (75 mg, 0.28 mmol). The mixture was stirred at 90oC for 16 h; Evaporation and 
recrystallisation (EtOAc) gave 218 (72 mg, 64%) as an off-white solid: Rf = 0.23 
(EtOAc); mp >325oC (decomp.); 1H NMR ((CD3)2SO) δ 6.82 (1 H, s, 4-H), 7.48-7.50 (3 
H, m, Ph 3,4,5-H3) 7.54 (1 H, t, J = 7.6 Hz, 7-H), 7.51 (2 H, dd, J = 8.0, 1.2 Hz, Ph 2,6-
H2), 7.72 7.82 (2 H, d, J = 8.2 Hz, Ar 3,5-H2), 7.83-7.86 (3 H, m, Ar 2,6-H2 and 6-H), 
8.17 (1 H, d, J = 7.6 Hz, 8-H), 10.42 (1 H, s, PhCONH), 11.63 (1 H, d, J = 4.7 Hz, 2-
NH); 13C NMR δ 99.0, 99.4, 124.6, 125.8, 125.9, 126.8, 128.8, 129.3, 129.8, 130.3, 
133.3, 133.5, 133.8, 134.1, 137.3, 139.9, 162.5, 165.6; MS (ES +ve) m/z 467.0267 (M + 
H) (C22H16IN2O2 requires 467.0256); Anal. Calcd. for C22H15IN2O2: C, 56.67; H, 3.24; N, 





















To a cooled solution of 1-chloroisoquinoline 90 (2.00g, 12.2 mmol) in conc. H2SO4 (10 
mL) was added aq. HNO3 (70%, 0.85g, 13.4 mmol) in conc. H2SO4 (5 mL) dropwise at 0-
5°C. The mixture was stirred at 0°C for 2 h, then poured onto ice. The precipitate was 
collected, washed (H2O), dried under vacuum and recrystallised (EtOAc / hexanes) to 
give 219 (2.34g, 92%) as pale yellow crystals: mp 181-183°C (lit.179 mp 183-184°C); 1H 
NMR (CDCl3)  7.81 (1 H, t, J = 8.2 Hz, 7-H), 8.41 (1 H, dd, J = 6.3, 1.2 Hz, 4-H), 8.49 





















1. Chambon, P.; Weill, J. D.; Mandel, P. Nicotinamide mononucleotide activation of 
new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. 
Res. Commun. 1963, 11, 39-43. 
2. Nguewa, P. A.; Fuertes, M. A.; Valladares, B.; Alonso, C.; Perez, J. M. 
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel 
therapeutical applications. Prog. Biophys. Mol. Biol. 2005, 88, 143-172. 
3. Auer, B. N. U.; Herzog, H.; Schneider, R.; Schweiger, M. Human nuclear NAD+ 
ADP-ribosyltranferase(polymerising): organization of the gene. DNA. 1989, 8, 575-580. 
4. Shizuta, Y.; Kameshita, I.; Ushiro, H.; Matsuda, M.; Suzuki, S.; Mitsuuchi, Y.; 
Yokoyama, Y.; Kurosaki, T. The domain structure and the function of poly(ADP-ribose) 
synthetase. Adv. Enzyme Regul. 1986, 25, 377-84. 
5. Zahradka, P.; Ebisuzaki, K. Poly(ADP-ribose) polymerase is a zinc 
metalloenzyme. Eur. J. Biochem. 1984, 142, 503-509. 
6. Langelier, M. F.; Servent, K. M.; Rogers, E. E.; Pascal, J. M. A third zinc-binding 
domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme 
activation. J. Biol. Chem. 2008, 283, 4105-4114. 
7. Schreiber, V.; Molinete, M.; Boeuf, H.; de Murcia, G.; Menissier-de Murcia, J. 
The human poly(ADP-ribose) polymerase nuclear localization signal is a bipartite 
element functionally separate from DNA binding and catalytic activity. EMBO. J. 1992, 
11, 3263-3269. 
8. Kaufmann, S. H.; Desnoyers, S.; Ottaviano, Y.; Davidson, N. E.; Poirier, G. G. 
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of 
chemotherapy-induced apoptosis. Cancer Res. 1993, 53, 3976-3985. 
9. Boulares, A. H.; Yakovlev, A. G.; Ivanova, V.; Stoica, B. A.; Wang, G.; Iyer, S.; 
Smulson, M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. 
Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J. Biol. 
Chem. 1999, 274, 22932-22940. 
10. Koonin, E. V.; Altschul, S. F.; Bork, P. BRCA1 protein products ...Functional 
motifs... Nature Genet. 1996, 13, 266-268. 
11. Zhang, X.; Morera, S.; Bates, P. A.; Whitehead, P. C.; Coffer, A. I.; Hainbucher, 
K.; Nash, R. A.; Sternberg, M. J.; Lindahl, T.; Freemont, P. S. Structure of an XRCC1 
BRCT domain: a new protein-protein interaction module. EMBO J. 1998, 17, 6404-6411. 
12. Uchida, K.; Hanai, S.; Ishikawa, K.; Ozawa, Y.; Uchida, M.; Sugimura, T.; Miwa, 
M. Cloning of cDNA encoding Drosophila poly(ADP-ribose) polymerase: leucine zipper 
in the auto-modification domain. Proc. Natl. Acad. Sci. USA. 1993, 90, 3481-3485. 
13. Ruf, A.; Mennissier de Murcia, J.; de Murcia, G.; Schulz, G. E. Structure of the 
catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. 
USA. 1996, 93, 7481-7485. 
14. Rolli, V.; O'Farrell, M.; Menissier-de Murcia, J.; de Murcia, G. Random 
mutagenesis of the poly(ADP-ribose) polymerase catalytic domain reveals amino acids 
involved in polymer branching. Biochemistry 1997, 36, 12147-12154. 
15. Schreiber, V.; Ame, J. C.; Dolle, P.; Schultz, I.; Rinaldi, B.; Fraulob, V.; 
Menissier-de Murcia, J.; de Murcia, G. Poly(ADP-ribose) polymerase-2 (PARP-2) is 
required for efficient base excision DNA repair in association with PARP-1 and XRCC1. 
J. Biol. Chem. 2002, 277, 23028-23036. 
16. Davidovic, L.; Vodenicharov, M.; Affar, E. B.; Poirier, G. G. Importance of 
poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp. 
Cell. Res. 2001, 268, 7-13. 
17. Okayama, H.; Honda, M.; Hayaishi, O. Novel enzyme from rat liver that cleaves 
an ADP-ribosyl histone linkage. Proc. Natl. Acad. Sci. USA. 1978, 75, 2254-2257. 
18. Poirier, G. G.; de Murcia, G.; Jongstra-Bilen, J.; Niedergang, C.; Mandel, P. 
Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure.  
Proc. Natl. Acad. Sci. USA. 1982, 79, 3423-3427. 
19. D'Amours, D.; Desnoyers, S.; D'Silva, I.; Poirier, G. G. Poly(ADP-ribosyl)ation 
reactions in the regulation of nuclear functions. Biochem. J. 1999, 342, 249-268. 
20. Huet, J.; Laval, F. Potentiation of cell killing by inhibitors of poly(adenosine 
diphosphate-ribose) synthesis in bleomycin-treated Chinese hamster ovary cells. Cancer. 
Res. 1985, 45, 987-991. 
21. Ben-Hur, E.; Chen, C. C.; Elkind, M. M. Inhibitors of poly(adenosine 
diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement 
of radiation response in Chinese hamster cells. Cancer. Res. 1985, 45, 2123-2127. 
22. Simbulan-Rosenthal, C. M.; Rosenthal, D. S.; Ding, R.; Jackman, J.; Smulson, M. 
E. Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: 
influence on genomic stability, chromatin organization, DNA repair, and DNA 
replication. Prog. Nucleic. Acid. Res. Mol. Biol. 1996, 55, 135-156. 
23. Stevnsner, T.; Ding, R.; Smulson, M.; Bohr, V. A. Inhibition of gene-specific 
repair of alkylation damage in cells depleted of poly(ADP-ribose) polymerase. Nucleic. 
Acids. Res. 1994, 22, 4620-4624. 
24. Ding, R.; Pommier, Y.; Kang, V. H.; Smulson, M. Depletion of poly(ADP-ribose) 
polymerase by antisense RNA expression results in a delay in DNA strand break 
rejoining. J. Biol. Chem 1992, 267, 12804-12812. 
25. Ding, R.; Smulson, M. Depletion of nuclear poly(ADP-ribose) polymerase by 
antisense RNA expression: influences on genomic stability, chromatin organization, and 
carcinogen cytotoxicity. Cancer. Res. 1994, 54, 4627-4634. 
26. de Murcia, J. M.; Niedergang, C.; Trucco, C.; Ricoul, M.; Dutrillaux, B.; Mark, 
M.; Oliver, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de 
Murcia, G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage 
in mice and in cells. Proc. Natl.  Acad. Sci. USA. 1997, 94, 7303-7307. 
27. Ame, J. C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. Bioessays 
2004, 26, 882-893. 
28. Caldecott, K. W. XRCC1 and DNA strand break repair. DNA Repair 2003, 2, 
955-969. 
29. Fortini, P.; Pascucci, B.; Belisario, F.; Dogliotti, E. DNA polymerase beta is 
required for efficient DNA strand break repair induced by methyl methanesulfonate but 
not by hydrogen peroxide. Nucleic Acids Res. 2000, 28, 3040-3046. 
30. Yang, Y.-G.; Cortes, U.; Patnaik, S.; Jasin, M.; Wang, Z.-Q. Ablation of PARP-1 
does not interfere with the repair of DNA double-strand breaks, but compromises the 
reactivation of stalled replication forks. Oncogene 2004, 23, 3872-3882. 
31. Audebert, M.; Salles, B.; Calsou, P. Effect of double-strand break DNA sequence 
on the PARP-1 NHEJ pathway. Biochem. Biophys. Res. Commun. 2008, 369, 982-988. 
32. Featherstone, C.; Jackson, S. P. Ku, a DNA repair protein with multiple cellular 
functions? Mutat. Res. 1999, 434, 3-15. 
33. Tuteja, R.; Tuteja, N. Ku autoantigen: a multifunctional DNA-binding protein. 
Crit. Rev. Biochem. Mol. Biol. 2000, 35, 1-33. 
34. Chang, P.; Jacobson, M. K.; Mitchison, T. J. Poly(ADP-ribose) is required for 
spindle assembly and structure. Nature 2004, 432, 645-649. 
35. Glover, D. M.; Leibowitz, M. H.; McLean, D. A.; Parry, H. Mutations in aurora 
prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995, 
81, 95-105. 
36. Crosio, C.; Fimia, G. M.; Loury, R.; Kimura, M.; Okano, Y.; Zhou, H.; Sen, S.; 
Allis, C. D.; Sassone-Corsi, P. Mitotic phosphorylation of histone H3: spatio-temporal 
regulation by mammalian Aurora kinases. Mol. Cell. Biol. 2002, 22, 874-885. 
37. Monaco, L.; Kolthur-Seetharam, U.; Loury, R.; Murcia, J. M.; de Murcia, G.; 
Sassone-Corsi, P. Inhibition of Aurora-B kinase activity by poly(ADP-ribosyl)ation in 
response to DNA damage. Proc. Natl. Acad. Sci. USA 2005, 102, 14244-14248. 
38. Kanai, M.; Uchida, M.; Hanai, S.; Uematsu, N.; Uchida, K.; Miwa, M. Poly(ADP-
ribose) polymerase localizes to the centrosomes and chromosomes. Biochem. Biophys. 
Res. Commun. 2000, 278, 385-389. 
39. Hassa, P. O.; Hottiger, M. O. The functional role of poly(ADP-ribose)polymerase 
1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell. Mol. Life Sci. 2002, 
59, 1534-1553. 
40. Kraus, W. L.; Lis, J. T. PARP goes transcription. Cell 2003, 113, 677-683. 
41. Hassa, P. O.; Hottiger, M. O. A role of poly (ADP-ribose) polymerase in NF-
kappaB transcriptional activation. Biol. Chem. 1999, 380, 953-959. 
42. Tulin, A.; Spradling, A. Chromatin loosening by poly(ADP)-ribose polymerase 
(PARP) at Drosophila puff loci. Science 2003, 299, 560-562. 
43. Kim, M. Y.; Mauro, S.; Gevry, N.; Lis, J. T.; Kraus, W. L. NAD+-dependent 
modulation of chromatin structure and transcription by nucleosome binding properties of 
PARP-1. Cell 2004, 119, 803-814. 
44. Hernandez, A. I.; Wolk, J.; Hu, J. Y.; Liu, J.; Kurosu, T.; Schwartz, J. H.; 
Schacher, S. Poly-(ADP-ribose) polymerase-1 is necessary for long-term facilitation in 
Aplysia. J. Neurosci. 2009, 29, 9553-9562. 
45. Oliver, F. J.; Menissier-de Murcia, J.; Nacci, C.; Decker, P.; Andriantsitohaina, 
R.; Muller, S.; de la Rubia, G.; Stoclet, J. C.; de Murcia, G. Resistance to endotoxic 
shock as a consequence of defective NF-κB activation in poly (ADP-ribose) polymerase-
1 deficient mice. EMBO. J. 1999, 18, 4446-4454. 
46. Andreone, T. L.; O'Connor, M.; Denenberg, A.; Hake, P. W.; Zingarelli, B. 
Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine 
fibroblasts. J. Immunol. 2003, 170, 2113-2120. 
47. Yu, S. W.; Wang, H.; Poitras, M. F.; Coombs, C.; Bowers, W. J.; Federoff, H. J.; 
Poirier, G. G.; Dawson, T. M.; Dawson, V. L. Mediation of poly(ADP-ribose) 
polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297, 259-
263. 
48. Boulares, A. H.; Zoltoski, A. J.; Sherif, Z. A.; Jolly, P.; Massaro, D.; Smulson, M. 
E. Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 
prevents lung inflammation in a murine model of asthma. Am. J. Respir. Cell. Mol. Biol. 
2003, 28, 322-329. 
49. Suzuki, Y.; Masini, E.; Mazzocca, C.; Cuzzocrea, S.; Ciampa, A.; Suzuki, H.; 
Bani, D. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-
like reaction in sensitized Guinea pigs. J. Pharmacol. Exp. Ther. 2004, 311, 1241-1248. 
50. Wayman, N.; McDonald, M. C.; Thompson, A. S.; Threadgill, M. D.; 
Thiemermann, C. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-
diphosphate ribose) polymerase, reduces myocardial infarct size. Eur. J. Pharmacol. 
2001, 430, 93-100. 
51. Thiemermann, C.; Bowes, J.; Myint, F. P.; Vane, J. R. Inhibition of the activity of 
poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal 
muscle. Proc. Natl. Acad. Sci. USA 1997, 94, 679-683. 
52. Zingarelli, B.; Cuzzocrea, S.; Zsengeller, Z.; Salzman, A. L.; Szabo, C. Protection 
against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of 
poly (ADP-ribose) synthetase. Cardiovasc. Res. 1997, 36, 205-215. 
53. Roesner, J. P.; Vagts, D. A.; Iber, T.; Eipel, C.; Vollmar, B.; Noldge-Schomburg, 
G. F. Protective effects of PARP inhibition on liver microcirculation and function after 
haemorrhagic shock and resuscitation in male rats. Intensive Care Med. 2006, 32, 1649-
1657. 
54. Chatterjee, P. K.; Chatterjee, B. E.; Pedersen, H.; Sivarajah, A.; McDonald, M. 
C.; Mota-Filipe, H.; Brown, P. A.; Stewart, K. N.; Cuzzocrea, S.; Threadgill, M. D.; 
Thiemermann, C. 5-Aminoisoquinolinone reduces renal injury and dysfunction caused by 
experimental ischemia/reperfusion. Kidney Int. 2004, 65, 499-509. 
55. McDonald, M. C.; Mota-Filipe, H.; Wright, J. A.; Abdelrahman, M.; Threadgill, 
M. D.; Thompson, A. S.; Thiemermann, C. Effects of 5-aminoisoquinolinone, a water-
soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ 
injury and dysfunction caused by haemorrhagic shock. Br. J. Pharmacol. 2000, 130, 843-
850. 
56. Shiratora, Y.; Aoki, S.; Takada, H.; Kiriyama, H.; Ohto, K.; Hai, K.; Teraoka, H.; 
Matano, S.; Matsumoto, K.; Kamii, K. Oxygen-derived free radical generating capacity 
of polymorphonuclear cells in patients with ulcerative colitis. Digestion 1989, 44, 163-
171. 
57. Zingarelli, B.; Szabo, C.; Salzman, A. L. Blockade of Poly(ADP-ribose) 
synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in 
murine colitis. Gastroenterology 1999, 116, 335-345. 
58. Cuzzocrea, S.; Mazzon, E.; Di Paola, R.; Genovese, T.; Patel, N. S.; Muia, C.; 
Threadgill, M. D.; De Sarro, A.; Thiemermann, C. 5-Aminoisoquinolinone reduces colon 
injury by experimental colitis. Naunyn. Schmiedebergs. Arch. Pharmacol. 2004, 370, 
464-473. 
59. Jijon, H. B.; Churchill, T.; Malfair, D.; Wessler, A.; Jewell, L. D.; Parsons, H. G.; 
Madsen, K. L. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a 
model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279, 641-651. 
60. Mazzon, E.; Dugo, L.; Li, J. H.; Di Paola, R.; Genovese, T.; Caputi, A. P.; Zhang, 
J.; Cuzzocrea, S. GPI 6150, a PARP inhibitor, reduces the colon injury caused by 
dinitrobenzene sulfonic acid in the rat. Biochem. Pharmacol. 2002, 64, 327-337. 
61. Mabley, J. G.; Jagtap, P.; Perretti, M.; Getting, S. J.; Salzman, A. L.; Virag, L.; 
Szabo, E.; Soriano, F. G.; Liaudet, L.; Abdelkarim, G. E.; Hasko, G.; Marton, A.; 
Southan, G. J.; Szabo, C. Anti-inflammatory effects of a novel, potent inhibitor of poly 
(ADP-ribose) polymerase. Inflamm. Res. 2001, 50, 561-569. 
62. Negri, C.; Scovassi, A. I.; Cerino, A.; Negroni, M.; Borzi, R. M.; Meliconi, R.; 
Facchini, A.; Montecucco, C. M.; Astaldi Ricotti, G. C. Autoantibodies to poly(ADP-
ribose)polymerase in autoimmune diseases. Autoimmunity 1990, 6, 203-209. 
63. Scovassi, A. I.; Negri, C.; Negroni, M.; Dal, V.; Borzi, R. M.; Meliconi, R.; 
Facchini, A.; Montecucco, C. M.; Astaldi Ricotti, G. C. Detection of circulating 
autoantibodies to poly(ADP-ribose)polymerase in autoimmune diseases. Ann. N.Y. Acad. 
Sci. 1992, 663, 508-509. 
64. Pacher, P.; Beckman, J. S.; Liaudet, L. Nitric oxide and peroxynitrite in health 
and disease. Physiol. Rev. 2007, 87, 315-424. 
65. Pacher, P.; Szabo, C. Role of the peroxynitrite-poly(ADP-ribose) polymerase 
pathway in human disease. Am. J. Pathol. 2008, 173, 2-13. 
66. Ame, J. C.; Rolli, V.; Schreiber, V.; Niedergang, C.; Apiou, F.; Decker, P.; 
Muller, S.; Hoger, T.; Menissier-de Murcia, J.; de Murcia, G. PARP-2, A novel 
mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J. Biol. Chem. 1999, 
274, 17860-17868. 
67. Menissier de Murcia, J.; Ricoul, M.; Tartier, L.; Niedergang, C.; Huber, A.; 
Dantzer, F.; Schreiber, V.; Ame, J. C.; Dierich, A.; LeMeur, M.; Sabatier, L.; Chambon, 
P.; de Murcia, G. Functional interaction between PARP-1 and PARP-2 in chromosome 
stability and embryonic development in mouse. EMBO J. 2003, 22, 2255-2263. 
68. Masson, M.; Niedergang, C.; Schreiber, V.; Muller, S.; Menissier-de Murcia, J.; 
de Murcia, G. XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase 
and Negatively Regulates Its Activity following DNA Damage. Mol. Cell. Biol. 1998,  
18, 3563-3571. 
69. Fisher, A. E.; Hochegger, H.; Takeda, S.; Caldecott, K. W. Poly(ADP-ribose) 
polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) 
glycohydrolase. Mol. Cell. Biol. 2007, 27, 5597-5605. 
70. Griffith, J. D.; Comeau, L.; Rosenfield, S.; Stansel, R. M.; Bianchi, A.; Moss, H.; 
de Lange, T. Mammalian telomeres end in a large duplex loop. Cell 1999, 97, 503-514. 
71. Muftuoglu, M.; Wong, H. K.; Imam, S. Z.; Wilson, D. M., 3rd; Bohr, V. A.; 
Opresko, P. L. Telomere repeat binding factor 2 interacts with base excision repair 
proteins and stimulates DNA synthesis by DNA polymerase beta. Cancer Res. 2006, 66, 
113-124. 
72. Wright, W. E.; Shay, J. W. Telomere-binding factors and general DNA repair. 
Nature Genet. 2005, 37, 116-118. 
73. Dantzer, F.; Giraud-Panis, M. J.; Jaco, I.; Ame, J. C.; Schultz, I.; Blasco, M.; 
Koering, C. E.; Gilson, E.; Menissier-de Murcia, J.; de Murcia, G.; Schreiber, V. 
Functional interaction between poly(ADP-Ribose) polymerase-2 (PARP-2) and TRF-2: 
PARP activity negatively regulates TRF-2. Mol. Cell. Biol. 2004, 24, 1595-1607. 
74. de Lange, T. Protection of mammalian telomeres. Oncogene 2002, 21, 532-540. 
75. Popoff, I.; Jijon, H.; Monia, B.; Tavernini, M.; Ma, M.; McKay, R.; Madsen, K. 
Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in 
interleukin-10-deficient mice. J. Pharmacol. Exp. Ther. 2002, 303, 1145-1154. 
76. Kofler, J.; Otsuka, T.; Zhang, Z.; Noppens, R.; Grafe, M. R.; Koh, D. W.; 
Dawson, V. L.; de Murcia, J. M.; Hurn, P. D.; Traystman, R. J. Differential effect of 
PARP-2 deletion on brain injury after focal and global cerebral ischemia. J. Cereb. Blood 
Flow Metab. 2006, 26, 135-141. 
77. Yelamos, J.; Monreal, Y.; Saenz, L.; Aguado, E.; Schreiber, V.; Mota, R.; Fuente, 
T.; Minguela, A.; Parrilla, P.; de Murcia, G.; Almarza, E.; Aparicio, P.; Menissier-de 
Murcia, J. PARP-2 deficiency affects the survival of CD4+CD8+ double-positive 
thymocytes. EMBO J. 2006, 25, 4350-4360. 
78. Bai, P.; Houten, S. M.; Huber, A.; Schreiber, V.; Watanabe, M.; Kiss, B.; de 
Murcia, G.; Auwerx, J.; Menissier-de Murcia, J. Poly(ADP-ribose) polymerase-2 controls 
adipocyte differentiation and adipose tissue function through the regulation of the activity 
of the retinoid X receptor/peroxisome proliferator-activated receptor-gamma heterodimer. 
J. Biol. Chem. 2007, 282, 37738-33746. 
79. Dantzer, F.; Mark, M.; Quenet, D.; Scherthan, H.; Huber, A.; Liebe, B.; Monaco, 
L.; Chicheportiche, A.; Sassone-Corsi, P.; de Murcia, G.; Menissier-de Murcia, J. 
Poly(ADP-ribose) polymerase-2 contributes to the fidelity of male meiosis I and 
spermiogenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 14854-14859. 
80. Johansson, M. A human poly(ADP-ribose) polymerase gene family (ADPRTL): 
cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. Genomics 1999, 
57, 442-445. 
81. Augustin, A.; Spenlehauer, C.; Dumond, H.; Menissier-De Murcia, J.; Piel, M.; 
Schmit, A. C.; Apiou, F.; Vonesch, J. L.; Kock, M.; Bornens, M.; De Murcia, G. PARP-3 
localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle 
progression. J. Cell. Sci. 2003, 116, 1551-1562. 
82. Lehtio, L.; Jemth, A. S.; Collins, R.; Loseva, O.; Johansson, A.; Markova, N.; 
Hammarstrom, M.; Flores, A.; Holmberg-Schiavone, L.; Weigelt, J.; Helleday, T.; 
Schuler, H.; Karlberg, T. Structural basis for inhibitor specificity in human poly(ADP-
ribose) polymerase-3. J. Med. Chem. 2009, 52, 3108-3111. 
83. Kickhoefer, V. A.; Siva, A. C.; Kedersha, N. L.; Inman, E. M.; Ruland, C.; 
Streuli, M.; Rome, L. H. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) 
polymerase. J. Cell. Biol. 1999, 146, 917-928. 
84. Kickhoefer, V. A.; Vasu, S. K.; Rome, L. H. Vaults are the answer, what is the 
question? Trends Cell Biol. 1996, 6, 174-178. 
85. Kickhoefer, V. A.; Rajavel, K. S.; Scheffer, G. L.; Dalton, W. S.; Scheper, R. J.; 
Rome, L. H. Vaults are up-regulated in multidrug-resistant cancer cell lines. J. Biol. 
Chem. 1998, 273, 8971-8974. 
86. Raval-Fernandes, S.; Kickhoefer, V. A.; Kitchen, C.; Rome, L. H. Increased 
susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-
induced tumorigenesis. Cancer Res. 2005, 65, 8846-8852. 
87. Smith, S.; Giriat, I.; Schmitt, A.; de Lange, T. Tankyrase, a poly(ADP-ribose) 
polymerase at human telomeres. Science 1998, 282, 1484-1487. 
88. Bennett, V. Ankyrins. Adaptors between diverse plasma membrane proteins and 
the cytoplasm. J. Biol. Chem. 1992, 267, 8703-8706. 
89. De Rycker, M.; Price, C. M. Tankyrase polymerization is controlled by its sterile 
alpha motif and poly(ADP-ribose) polymerase domains. Mol. Cel.l Biol. 2004, 24, 9802-
9812. 
90. Chiang, Y. J.; Hsiao, S. J.; Yver, D.; Cushman, S. W.; Tessarollo, L.; Smith, S.; 
Hodes, R. J. Tankyrase 1 and tankyrase 2 are essential but redundant for mouse 
embryonic development. PLoS One 2008, 3, e2639, 1-10. 
91. Seimiya, H.; Smith, S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, 
contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel 
acceptor, 182-kDa tankyrase-binding protein (TAB182). J. Biol. Chem. 2002, 277, 
14116-14126. 
92. Cook, B. D.; Dynek, J. N.; Chang, W.; Shostak, G.; Smith, S. Role for the related 
poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell. Biol. 
2002, 22, 332-342. 
93. Incles, C. M.; Schultes, C. M.; Kempski, H.; Koehler, H.; Kelland, L. R.; Neidle, 
S. A G-quadruplex telomere targeting agent produces p16-associated senescence and 
chromosomal fusions in human prostate cancer cells. Mol. Cancer Ther. 2004, 3, 1201-
1206. 
94. Strahl, C.; Blackburn, E. H. Effects of reverse transcriptase inhibitors on telomere 
length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 
1996, 16, 53-65. 
95. Dikmen, Z. G.; Gellert, G. C.; Jackson, S.; Gryaznov, S.; Tressler, R.; Dogan, P.; 
Wright, W. E.; Shay, J. W. In vivo inhibition of lung cancer by GRN163L: a novel 
human telomerase inhibitor. Cancer Res. 2005, 65, 7866-7873. 
96. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADP-ribose): novel 
functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7, 517-528. 
97. Ma, Q.; Baldwin, K. T.; Renzelli, A. J.; McDaniel, A.; Dong, L. TCDD-inducible 
poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Biochem. Biophys. Res. Commun. 2001, 289, 499-506. 
98. Gao, G.; Guo, X.; Goff, S. P. Inhibition of retroviral RNA production by ZAP, a 
CCCH-type zinc finger protein. Science 2002, 297, 1703-6. 
99. Ladurner, A. G. Inactivating chromosomes: a macro domain that minimizes 
transcription. Mol. Cell 2003, 12, 1-3. 
100. Karras, G. I.; Kustatscher, G.; Buhecha, H. R.; Allen, M. D.; Pugieux, C.; Sait, F.; 
Bycroft, M.; Ladurner, A. G. The macro domain is an ADP-ribose binding module. 
EMBO J. 2005, 24, 1911-1920. 
101. Yu, M.; Schreek, S.; Cerni, C.; Schamberger, C.; Lesniewicz, K.; Poreba, E.; 
Vervoorts, J.; Walsemann, G.; Grotzinger, J.; Kremmer, E.; Mehraein, Y.; Mertsching, J.; 
Kraft, R.; Austen, M.; Luscher-Firzlaff, J.; Luscher, B. PARP-10, a novel Myc-
interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. 
Oncogene 2005, 24, 1982-1993. 
102. Cortes, U.; Tong, W. M.; Coyle, D. L.; Meyer-Ficca, M. L.; Meyer, R. G.; Petrilli, 
V.; Herceg, Z.; Jacobson, E. L.; Jacobson, M. K.; Wang, Z. Q. Depletion of the 110-
kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic 
and endotoxic stress in mice. Mol. Cell. Biol. 2004, 24, 7163-7178. 
103. Clark, J. B.; Ferris, G. M.; Pinder, S. Inhibition of nuclear NAD nucleosidase and 
poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5'-methyl 
nicotinamide. Biochim. Biophys. Acta. 1971, 238, 82-85. 
104. Banasik, M.; Ueda, K. Inhibitors and activators of ADP-ribosylation reactions. 
Mol. Cell. Biochem. 1994, 138, 185-197. 
105. Shall, S. Proceedings: Experimental manipulation of the specific activity of 
poly(ADP-ribose) polymerase. J. Biochem. 1975, 77, 2-4. 
106. Purnell, M. R.; Whish, W. J. Novel inhibitors of poly(ADP-ribose) synthetase. 
Biochem. J. 1980, 185, 775-777. 
107. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of 
poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 1992, 
267, 1569-1575. 
108. Sims, J. L.; Sikorski, G. W.; Catino, D. M.; Berger, S. J.; Berger, N. A. 
Poly(adenosinediphosphoribose) polymerase inhibitors stimulate unscheduled 
deoxyribonucleic acid synthesis in normal human lymphocytes. Biochemistry 1982, 21, 
1813-1821. 
109. Griffin, R. J.; Pemberton, L. C.; Rhodes, D.; Bleasdale, C.; Bowman, K.; Calvert, 
A. H.; Curtin, N. J.; Durkacz, B. W.; Newell, D. R.; Porteous, J. K. Novel potent 
inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anticancer 
Drug Des. 1995, 10, 507-514. 
110. Suto, M. J.; Turner, W. R.; Arundel-Suto, C. M.; Werbel, L. M.; Sebolt-Leopold, 
J. S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors 
of poly(ADP-ribose) polymerase. Anticancer Drug Des. 1991, 6, 107-117. 
111. White, A. W.; Almassy, R.; Calvert, A. H.; Curtin, N. J.; Griffin, R. J.; 
Hostomsky, Z.; Maegley, K.; Newell, D. R.; Srinivasan, S.; Golding, B. T. Resistance-
modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of 
the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. 2000, 43, 4084-
4097. 
112. Skalitzky, D. J.; Marakovits, J. T.; Maegley, K. A.; Ekker, A.; Yu, X. H.; 
Hostomsky, Z.; Webber, S. E.; Eastman, B. W.; Almassy, R.; Li, J.; Curtin, N. J.; Newell, 
D. R.; Calvert, A. H.; Griffin, R. J.; Golding, B. T. Tricyclic benzimidazoles as potent 
poly(ADP-ribose) polymerase-1 inhibitors. J. Med. Chem. 2003, 46, 210-213. 
113. Southan, G. J.; Szabo, C. Poly(ADP-ribose) polymerase inhibitors. Curr. Med. 
Chem. 2003, 10, 321-340. 
114. Loh, V. M., Jr.; Cockcroft, X. L.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; 
Eversley, P. J.; Gomez, S.; Hoare, J.; Kerrigan, F.; Matthews, I. T.; Menear, K. A.; 
Martin, N. M.; Newton, R. F.; Paul, J.; Smith, G. C.; Vile, J.; Whittle, A. J. 
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of 
poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett. 2005, 15, 2235-2238. 
115. Cockcroft, X.-l.; Dillon, K. J.; Dixon, L. Phthalazinones 2: Optimisation and 
synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. 
Letters 2006, 16, 1040-1045. 
116. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X.-l.; Copsey, L.; Cranston, 
A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; 
Knights, C.; Lau, A.; Loh Jr, V. M.; Matthews, I. T. W.; Moore, S.; O'Connor, M. J.; 
Smith, G. C. M.; Martin, N. M. B. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-
4-fluorobenzyl]-2H- phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-
ribose) Polymerase-1. J. Med. Chem. 2008, 51, 6581-6591. 
117. Penning, T. D.; Zhu, G. D.; Gandhi, V. B.; Gong, J.; Thomas, S.; Lubisch, W.; 
Grandel, R.; Wernet, W.; Park, C. H.; Fry, E. H.; Liu, X.; Shi, Y.; Klinghofer, V.; 
Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Olson, 
A. M.; Marsh, K. C.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L. Discovery and SAR of 2-
(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of 
poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg. Med. Chem. 
2008, 16, 6965-6975. 
118. Plummer, R.; Jones, C.; Middleton, M.; Wilson, R.; Evans, J.; Olsen, A.; Curtin, 
N.; Boddy, A.; McHugh, P.; Newell, D.; Harris, A.; Johnson, P.; Steinfeldt, H.; Dewji, 
R.; Wang, D.; Robson, L.; Calvert, H. Phase I study of the poly(ADP-ribose) polymerase 
inhibitor, AG014699, in combination with temozolomide in patients with advanced solid 
tumors. Clin. Cancer Res. 2008, 14, 7917-7923. 
119. Rottenberg, S.; Jaspers, J. E.; Kersbergen, A.; van der Burg, E.; Nygren, A. O.; 
Zander, S. A.; Derksen, P. W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; 
Cranston, A.; O'Connor, M. J.; Martin, N. M.; Borst, P.; Jonkers, J. High sensitivity of 
BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in 
combination with platinum drugs. Proc. Natl. Acad. Sci. USA 2008, 105, 17079-17084. 
120. Evers, B.; Drost, R.; Schut, E.; de Bruin, M.; van der Burg, E.; Derksen, P. W.; 
Holstege, H.; Liu, X.; van Drunen, E.; Beverloo, H. B.; Smith, G. C.; Martin, N. M.; Lau, 
A.; O'Connor, M. J.; Jonkers, J. Selective inhibition of BRCA2-deficient mammary 
tumor cell growth by AZD2281 and cisplatin. Clin. Cancer. Res. 2008, 14, 3916-3925. 
121. Perkins, E.; Sun, D.; Nguyen, A.; Tulac, S.; Francesco, M.; Tavana, H.; Nguyen, 
H.; Tugendreich, S.; Barthmaier, P.; Couto, J.; Yeh, E.; Thode, S.; Jarnagin, K.; Jain, A.; 
Morgans, D.; Melese, T. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and 
PARP2 identified using a cell-based screen in yeast. Cancer Res. 2001, 61, 4175-4183. 
122. Iwashita, A.; Mihara, K.; Yamazaki, S.; Matsuura, S.; Ishida, J.; Yamamoto, H.; 
Hattori, K.; Matsuoka, N.; Mutoh, S. A new poly(ADP-ribose) polymerase inhibitor, 
FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates 
methamphetamine-induced dopaminergic neurotoxicity in mice. J. Pharmacol. Exp. 
Ther. 2004, 310, 1114-1124. 
123. Oliver, A. W.; Ame, J. C.; Roe, S. M.; Good, V.; de Murcia, G.; Pearl, L. H. 
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. 
Nucleic Acids Res. 2004, 32, 456-464. 
124. Ruf, A.; de Murcia, G.; Schulz, G. E. Inhibitor and NAD+ binding to poly(ADP-
ribose) polymerase as derived from crystal structures and homology modeling. 
Biochemistry 1998, 37, 3893-3900. 
125. Ishida, J.; Yamamoto, H.; Kido, Y.; Kamijo, K.; Murano, K.; Miyake, H.; 
Ohkubo, M.; Kinoshita, T.; Warizaya, M.; Iwashita, A.; Mihara, K.; Matsuoka, N.; 
Hattori, K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD 
analysis via a combination of X-ray structural study and homology modeling. Bioorg. 
Med. Chem. 2006, 14, 1378-1390. 
126. Schraufstatter, I. U.; Hyslop, P. A.; Hinshaw, D. B.; Spragg, R. G.; Sklar, L. A.; 
Cochrane, C. G. Hydrogen peroxide-induced injury of cells and its prevention by 
inhibitors of poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. USA 1986, 83, 4908-
4912. 
127. Cheung, A.; Zhang, J. A scintillation proximity assay for poly(ADP-ribose) 
polymerase. Anal. Biochem. 2000, 282, 24-28. 
128. Lee, S.; Koo, H. N.; Lee, B. H. Development of a miniaturized assay for the high-
throughput screening program for poly(ADP-ribose) polymerase-1. Methods Find. Exp. 
Clin. Pharmacol. 2005, 27, 617-622. 
129. Dillon, K. J.; Smith, G. C.; Martin, N. M. A FlashPlate assay for the identification 
of PARP-1 inhibitors. J. Biomol. Screen. 2003, 8, 347-352. 
130. Wenkert, E.; Wenkert. Derivatives of Hemimellitic Acid. A Synthesis of 
Erythrocentaurin1. J. Org. Chem. 1964, 29, 2534-2542. 
131. Watson, C. Y.; Whish, W. J.; Threadgill, M. D. Synthesis of 3-substituted 
benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as 
inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg. Med. Chem. 1998, 6, 721-
734. 
132. Woon, C. Y., Dhami, A., Sunderland, P. T., Threadgill, M. D. Reductive 
Cyclisation of 2-Cyanomethyl-3-Nitrobenzoates. Lett. Org. Chem. 2006, 3, 571-578. 
133. Heck. Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, 
benzyl, and styryl halides. J. Org. Chem. 1972, 37, 2320-2322. 
134. Mizoroki, T., Mori, K., Ozaki, A. Arylation of olefin with aryl iodide catalyzed 
by palladium. Bull. Chem. Soc. Jpn. 1971, 44, 581. 
135. Berry, J. M. W., C. Y.; Whish, W. J. D.; Threadgill, M. D. 5-Nitrofuran-2-
ylmethyl group as a potential bioreductively activated pro-drug system. J. Chem. Soc. 
Perkin Trans. 1 1997, 1147-1156. 
136. Plevyak. Selective palladium-catalyzed vinylic substitutions with bromoiodo 
aromatics. J. Org. Chem. 1979, 44, 4078-4080. 
137. Carda, M.; Gonzalez, F.; Sanchez, R.; Marco, J. A. Stereoselective synthesis of (-
)-cytoxazone. Tetrahedron: Asymmetry 2002, 13, 1005-1010. 
138. Kim, S.; Ko, H.; Kim, E.; Kim, D. Stereocontrolled Total Synthesis of 
Pancratistatin. Org. Lett. 2002, 4, 1343-1345. 
139. Ponticello. Useful synthesis of 4-substituted indoles. J. Org. Chem. 1979, 44, 
4003-4005. 
140. March, J. In Advanced Organic Chemistry, 2nd ed.; McGraw-Hill.: London, 1977, 
816-817. 
141. Banwell, M., G.  Cowden, C, J. Convergent Routes to the <1,3>Dioxolo<4,5-
j>phenanthridin-6(5H)-one and 2,3,4,4a-Tetrahydro<1,3>dioxolo<4,5-j>phenanthridin-
6(5H)-one Nuclei. Application to Syntheses of the Amaryllidaceae Alkaloids 
Crinasiadine, N-Methylcrinasiadine and Trisphaeridine. Aust. J. Chem. 1994, 47, 2235-
2254. 
142. Bisagni, E.; Landras, C.; Thirot, S.; Huel, C. A convenient way to dibenzo[c,h]-
1,5-naphthyridines (11-aza-benzo[c] phenanthridines). Tetrahedron 1996, 52, 10427-
10440. 
143. Iley, J., Carvalho, E., Norberto, F., Rosa, E. . Reaction of N-Aryl- and N-Alkyl-
benzimidoyl Chlorides with Silver Nitrate. J. Chem. Soc., Perkin Trans. 2. 1992, 2, 281-
290. 
144. Gordon. The Swamping Catalyst Effect. VI. The Halogenation of Isoquinoline 
and Quinoline1. J. Org. Chem. 1964, 29, 329-332. 
145. Braye. Eur. J. Med. Chem. 1977, 9, 197-200. 
146. Palucki, M.; Buchwald, S. L. Palladium-Catalyzed Î±-Arylation of Ketones. J. 
Am. Chem. Soc. 1997, 119, 11108-11109. 
147. Moradi, W. A.; Buchwald, S. L. Palladium-Catalyzed Î±-Arylation of Esters. J. 
Am. Chem. Soc. 2001, 123, 7996-8002. 
148. Zeevaart, J. G.; Parkinson, C. J.; de Koning, C. B. Palladium-catalysed arylation 
of acetoacetate esters to yield 2-arylacetic acid esters. Tetrahedron Lett. 2004, 45, 4261-
4264. 
149. Zeevaart, J. G.; Parkinson, C. J.; de Koning, C. B. Copper(I) iodide-catalysed 
arylation of acetoacetate to yield 2-arylacetic acid esters. Tetrahedron Lett. 2007, 48, 
3289-3293. 
150. Ozdemir, I.; Yigit, M.; Cetinkaya, E.; Cetinkaya, B. Synthesis of arylacetic acid 
derivatives from diethyl malonate using in situ formed palladium(1,3-
dialkylimidazolidin-2-ylidene) catalysts. Tetrahedron Lett. 2004, 45, 5823-5825. 
151. Culkin, D. A.; Hartwig, J. F. Palladium-Catalyzed Î±-Arylation of Carbonyl 
Compounds and Nitriles. Acc.Chem. Res. 2003, 36, 234-245. 
152. Milstein. A general, selective, and facile method for ketone synthesis from acid 
chlorides and organotin compounds catalyzed by palladium. J. Am. Chem. Soc. 1978, 
100, 3636-3638. 
153. Milstein. Palladium-catalyzed coupling of tetraorganotin compounds with aryl 
and benzyl halides. Synthetic utility and mechanism. J. Am. Chem. Soc. 1979, 101, 4992-
4998. 
154. Milstein. Mechanism of reductive elimination. Reaction of alkylpalladium(II) 
complexes with tetraorganotin, organolithium, and Grignard reagents. Evidence for 
palladium(IV) intermediacy. J Am. Chem. Soc. 1979, 101, 4981-4991. 
155. Woon, E. C.; Threadgill, M. D. Poly(ADP-ribose)polymerase inhibition - where 
now? Curr. Med. Chem. 2005, 12, 2373-2392. 
156. Eltze, T.; Boer, R.; Wagner, T.; Weinbrenner, S.; McDonald, M. C.; 
Thiemermann, C.; Burkle, A.; Klein, T. Imidazoquinolinone, imidazopyridine, and 
isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) 
polymerase (PARP): a comparison with standard PARP inhibitors. Mol. Pharmacol. 
2008, 74, 1587-1598. 
157. Pellicciari, R.; Camaioni, E.; Costantino, G.; Formentini, L.; Sabbatini, P.; 
Venturoni, F.; Eren, G.; Bellocchi, D.; Chiarugi, A.; Moroni, F. On the way to selective 
PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of 
isoquinolinone derivatives. Chem.Med. Chem. 2008, 3, 914-23. 
158. Woon, C. Y., Dhami, A., Mahon, F., Threadgill, M. D. 5-Nitroisocoumarins from 
tandem Castro-Stephens coupling-6-endo-dig cyclisation of 2-iodo-3-nitrobenzoic acid 
and arylethynes and ring-closure of methyl 2-alkynyl-3-nitrobenzoates with electrophiles. 
Tetrahedron 2006, 62, 4829-4837. 
159. Hurtley, W., R., H. Replacement of halogen in orthobromo-benzoic acid. J. Chem. 
Soc. 1929, 1870-1873. 
160. Cirigottis, K., A., Ritchie, E., Taylor, W., C. Studies on the Hurtley reaction. Aust. 
J. Chem. 1974, 27, 2209-2228. 
161. Ames, D., R., Ribeiro., O. Heterocyclic synthesis from o-halogeno-acids. Part III. 
Synthesis of 2-methylindole-4-carboxylic acid and related compounds and of some 
derivatives of 3-phenylisoquinolin-1(2H)-one. J. Chem. Soc. Perkin Trans. 1 1976, 1, 
1073-1078. 
162. Woon, E. C. Y. PhD Thesis, University of Bath, 2004. 
163. Kim. Synthesis of 4-Acetylisocoumarin: First Total Syntheses of AGI-7 and 
Sescandelin. J. Org. Chem. 2002, 67, 3127-3130. 
164. Kama, A., Robertson, A., Tittensor, R. Hydroxy-carbonyl compounds. Part XIV. 
The syntheses of some isocoumarins. J. Chem. Soc. 1950, 3375-3380. 
165. Chatterjee, J., N., Mukherjee, S., K., Bhakta, C., Jha, H., C., Zilliken, F. Eine neue 
Synthese von Tetrahydrocapillarin, O-Methylglomellin und Oospolacton Chem. Ber. 
1980, 113, 3927-3931. 
166. Ford, A.; Sinn, E.; Woodward, S. Exploitation of differential reactivity of the 
carbon-chlorine bonds in 1,3-dichloroisoquinoline. Routes to new N,N-chelate ligands 
and 1,3-disubstituted isoquinolines. J. Chem. Soc., Perkin Trans. 1. 1997, 927 - 934. 
167. Gamage, S. A.; Spicer, J. A.; Rewcastle, G. W.; Milton, J.; Sohal, S.; Dangerfield, 
W.; Mistry, P.; Vicker, N.; Charlton, P. A.; Denny, W. A. Structure-Activity 
Relationships for Pyrido-, Imidazo-, Pyrazolo-, Pyrazino-, and 
Pyrrolophenazinecarboxamides as Topoisomerase-Targeted Anticancer. J. Med. Chem. 
2002, 45, 740 - 743. 
168. Elpern; Hamilton. J. Am. Chem. Soc. 1946, 68, 1436. 
169. Secel, A., D. Sanchez., J., P. Hollis Showalter, H., D.,. Simple Synthesis of 4-
Substituted 1(2H)-Isoquinolinones via Electrophilic Trapping of Lithiated Mono- and 
Dianion Precursors  Synth. Commun 2007, 37, 4199-4208. 
170. Mao. Syntheses of dihydropyrenes with functionality in the cavity of the pi.-
electron cloud. J. Org. Chem. 1980, 45, 2746-2749. 
171. Horning, D., E., Lacasse, G., Muckowski, J., M. Isocarbostrils. I. Electrophilic 
Substitution Reactions. Can. J. Chem. 1971, 49, 2785-2796. 
172. Barder. Catalysts for SuzukiMiyaura Coupling Processes: Scope and Studies of 
the Effect of Ligand Structure. J. Am. Chem. Soc. 2005, 127, 4685-4696. 
173. Wong, M. S.; Zhang, X. L. Ligand promoted palladium-catalyzed homo-coupling 
of arylboronic acids. Tetrahedron Lett. 2001, 42, 4087-4089. 
174. Smith, J. A.; Jones, R. K.; Booker, G. W.; Pyke, S. M. Sequential and selective 
Buchwald-Hartwig amination reactions for the controlled functionalization of 6-bromo-2-
chloroquinoline: synthesis of ligands for the Tec Src homology 3 domain. J. Org. Chem. 
2008, 73, 8880-8892. 
175. Dhami, A. PhD Thesis, University of Bath, 2008. 
176. Parveen, I.; Naughton, D. P.; Whish, W. J. D.; Threadgill, M. D. 2-nitroimidazol-
5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered 
release of the PARP inhibitor 5-bromoisoquinolinone. Bioorg. Med. Chem. Lett. 1999, 9, 
2031-2036. 
177. Ferrer, S. N., D., Parveen, I., Threadgill, M.D. N- and O-Alkylation of 
isoquinolin-1-ones in the Mitsunobu reaction: development of potential drug delivery 
systems. J. Chem. Soc., Perkin Trans. 1. 2002, 335-340. 
178. Nair, M. D.; Mehta, S. R. Ind. J. Chem. 1967, 5, 403-408. 
179. Gamage, S. A.; Spicer, J. A.; Rewcastle, G. W.; Milton, J.; Sohal, S.; Dangerfield, 
W.; Mistry, P.; Vicker, N.; Charlton, P. A.; Denny, W. A. Structure Activity 
Relationships for Pyrido-, Imidazo-, Pyrazolo-, Pyrazino-, and 
Pyrrolophenazinecarboxamides as Topoisomerase-Targeted Anticancer Agents. J. Med. 
Chem. 2002, 45, 740-743. 
 
 
 
 
 
 
 
 
 
 
 
  
 
